CN1926132B - Pyrazole compounds useful as protein kinase inhibitors - Google Patents
Pyrazole compounds useful as protein kinase inhibitors Download PDFInfo
- Publication number
- CN1926132B CN1926132B CN018174345A CN01817434A CN1926132B CN 1926132 B CN1926132 B CN 1926132B CN 018174345 A CN018174345 A CN 018174345A CN 01817434 A CN01817434 A CN 01817434A CN 1926132 B CN1926132 B CN 1926132B
- Authority
- CN
- China
- Prior art keywords
- ring
- aliphatic group
- halogen
- compound
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
This invention describes novel pyrazole compounds of formula II:wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2, 4-triazinyl ring, and R<2>, R<2>, R<x>, and R<y> are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R<2> and R<2> are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and R<x> and R<y> are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.
Description
The cross reference of relevant application
The application requires the U.S. Provisional Patent Application 60/232 of submission on September 15th, 2000,795, the U.S. Provisional Patent Application of submitting on December 21st, 2,000 60/257,887 and the U.S. Provisional Patent Application 60/286 submitted to April 27 calendar year 2001,949 right of priority, these content quotations at this as a reference.
Technical field
The invention belongs to the medical chemistry field, relate to the compound as kinases inhibitor, the composition that contains this compounds and using method.More particularly, the present invention relates to such compound, they are inhibitor of GSK-3 and Aurora-2 protein kinase.The invention still further relates to the method for treatment and these protein kinase diseases associated, for example diabetes, cancer and Alzheimer.
Background technology
In recent years the deep understanding of enzyme and other biomolecular structure relevant with the target disease has been gone far towards the research of novel treatment.The important enzyme of a class that has become the broad research theme is a protein kinase.
Protein kinase mediated intracellular signal transduction.They accomplish this point by influencing phosphoryl from the protein acceptor that nucleoside triphosphate is transferred to the participation signal pathway.By a large amount of kinases and approach, extracellular and other stimulations cause various cell responses to occur in cell interior.The example that this class stimulates comprises environment and chemical stress reaction signal (for example osmotic shock, heat shock, uv-radiation, bacterial endotoxin, H
2O
2), cytokine (for example il-1 (IL-1) and tumor necrosis factor alpha (TNF-α)) and somatomedin (for example rHuGM-CSF (GM-CSF) and fibroblast growth factor (FGF)).Extracellular stimulus can influence one or more cell responses, relates to that cell is grown, divided a word with a hyphen at the end of a line, differentiation, hormone secretion, transcription factor activation, Muscle contraction, carbohydrate metabolism, protein synthesis control and Cycle Regulation.
A lot of diseases are replied relevant with the abnormal cells that is excited by protein kinase mediated incident.These diseases comprise autoimmune disorders, inflammatory diseases, neurological and neurodegenerative disease, cancer, cardiovascular disorder, transformation reactions and asthma, Alzheimer or relate to the disease of hormone.Therefore, medical chemistry circle makes great efforts to find kinases inhibitor always, and they are effective therapeutical agents.
Aurora-2 is a kind of serine/threonine protein kitase, it and people's cancer implication, for example colon, mammary gland and other noumenal tumours.This kinases it is believed that the protein phosphorylation incident that participates in regulating the cell cycle.Particularly, Aurora-2 may control during mitotic division in the chromosomal correct separation and play a role.The mistuning of cell cycle is energy-conservation to cause that enough cell proliferation and other are unusual.In the human colon carcinoma tissue, have been found that Aurora-2 albumen is by overexpression.Referring to Bischoff etc., EMBO J., 1998,17,3052-3065; Schumacher etc., J.Cell Biol., 1998,143,1635-1646; Kimura etc., J.Biol.Chem., 1997,272,13766-13771.
It is a kind of serine/threonine protein kitase that glycogen synthesizes kinases-3 (GSK-3), is made of α and β isotype, separately by different coded by said gene (Coghlan etc., Chemi stry ﹠amp; Biology, 7,793-803 (2000); Kim and Kimmel, Curr.OpinionGenetics Dev., 10,508-514 (2000)).GSK-3 and various diseases implication, (WO 99/65897 to comprise diabetes, Alzheimer, CNS obstacle (for example manic depressibility mental disorder and neurodegenerative disease) and myocardial hypertrophy; WO 00/38675; Haq etc., J.Cell Biol. (2000) 151, and 117).The abnormal operation of some cell signal approach that these diseases can be played a role therein by GSK-3 is caused or is caused these abnormal operation.Have been found that the GSK-3 phosphorylation and regulate a large amount of modulability activity of proteins.These protein comprise that glycogen synthesizes that necessary rate-limiting enzyme glycogen synthetase, microtubule Rapsyn τ, gene transcription factor beta-catenin are white, translation initiation factor elF2B and ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB and CEPB α.These different protein targets make all implications of a lot of aspects of GSK-3 and cellular metabolism, propagation, differentiation and growth.
In type ii diabetes treatment dependency GSK-3 mediated pathways, insulin-induced signalling causes that grape cell Sugar intake and glycogen synthesize.Along this approach, GSK-3 is the down regulator of insulin-induced signal.Under the normal circumstances, the existence of Regular Insulin causes the glycogen synthetase phosphorylation of GSK-3 mediation and the inhibition of inactivation.The inhibition of GSK-3 causes that glycogen synthesizes and increase (Klein etc., PNAS, 93, the 8455-9 (1996) of glucose uptake; Cross etc., Biochem.J., 303,21-26 (1994); Cohen, Biochem.Soc.Trans., 21,555-567 (1993); Massillon etc., Biochem.J., 299,123-128 (1994)).But, in the weakened diabetic subject of insulin replies, although there is the Regular Insulin of quite high blood levels, glycogen is synthetic can not to be increased with glucose uptake.This causes the glucose of unusual high blood levels, and acute and long-term consequence can finally cause cardiovascular disorder, renal failure and blind.In this class patient, normal insulin-induced GSK-3 suppresses and can not take place.According to another report, in the type ii diabetes patient, GSK-3 is by overexpression (WO 00/38675).Therefore the therapeutic inhibitor of GSK-3 can be used for treating the weakened diabetic subject of insulin replies potentially.
The GSK-3 activity is also relevant with Alzheimer.This disease is the feature that forms with neurofibrillary tangles in beta amyloid peptide of knowing and the cell.Neurofibrillary tangles contains the tau protein of excessive phosphorylation, wherein τ on unusual site by phosphorylation.GSK-3 these unusual sites of phosphorylation in cell and animal model have been shown.And then, shown that being suppressed at of GSK-3 prevents excessive phosphorylation (Lovestone etc., Current Biology 4, the 1077-86 (1994) of τ in the cell; Brownlees etc., Neuroreport 8,3251-55 (1997)).Therefore, it is believed that the GSK-3 activity can promote the generation of neurofibrillary tangles and the progress of Alzheimer.
Another kind of GSK-3 substrate is that beta-catenin is white, and it is degraded after by the GSK-3 phosphorylation.The beta-catenin white level reduces the report that has seen the schizophreniac, also relates to dead disease relevant (Zhong etc., Nature, 395, the 698-702 (1998) that increases of neuronal cell with other; Takashima etc., PNAS, 90,7789-93 (1993); Pei etc., J.Neuropathol.Exp., 56,70-78 (1997)).
As the result of the biology importance of GSK-3, current interest is on the therapeutics effectively GSK-3 inhibitor.The existing recently report (WO 99/65897 (Chiron) of small molecules that suppresses GSK-3; WO 00/38675 (SmithKline Beecham)).
For the active relevant above-mentioned disease of a lot of and unusual GSK-3, other protein kinases also have been oriented to the identical disease of treatment.But, various protein kinases often play a role by different biological pathways.For example, to be in the news recently be that (WO 00/12497, Scios) for the kinase whose inhibitor of p38 to some quinazoline derivant.These compounds it is reported that can be used for treating with enhancing of p38-alpha active and/or the enhancing of TGF-'beta ' activity is the illness of feature.Although p38 active with multiple disease implication, comprise diabetes, but do not report that the p38 kinases is the component part of regulating the insulin signaling approach of the synthetic or glucose uptake of glycogen.Therefore, different with GSK-3, p38 suppresses not strengthened the synthetic and/or glucose uptake of glycogen by expection.
Still need to find the therapeutical agent of new treatment human diseases.The target that is used to find novel treatment that protein kinase A urora-2 and GSK-3 especially receive publicity is because they play an important role in cancer, diabetes, Alzheimer and other diseases.
Summary of the invention
Have now found that The compounds of this invention and pharmaceutical composition thereof are the effective protein proteins kinase inhibitor, specifically the inhibitor of Aurora-2 and GSK-3.These compounds have general formula I:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Z
1To Z
4Be as described below;
Ring A is selected from down group:
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 0-3 is selected from the ring hetero atom of oxygen, sulphur or nitrogen, wherein by R with intervenient atom
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace, by R
xAnd R
yAny commutable nitrogen is by R on the described ring that constitutes
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted group, and described group is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6) 2
SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R
9Be selected from-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
As used herein, should be suitable for following definition, except as otherwise noted.Wording " optionally substituted " is used interchangeably with wording " replacement or unsubstituted " or term " (not) replaces ".Except as otherwise noted, optionally substituted group can have substituting group in each commutable position of this group, and each the replacement is independent of each other.
Term used herein " aliphatic series " expression straight chain, side chain or ring-type C
1-C
12Hydrocarbon, it is fully saturated or contains one or more degrees of unsaturation, but aromatics whether.For example, the aliphatic group of Shi Heing comprises replacement or unsubstituted straight chain, side chain or cyclic alkyl, thiazolinyl, alkynyl and mixing thereof, for example (cycloalkyl) alkyl, (cycloalkenyl group) alkyl or (cycloalkyl) thiazolinyl.Comprise straight chain and the side chain that contains one to 12 carbon atom separately or as term " alkyl ", " alkoxyl group ", " hydroxyalkyl ", " alkoxyalkyl " and " alkoxy carbonyl " that the part of macoradical is more used.Should comprise straight chain and the side chain that contains two to 12 carbon atoms separately or as term " thiazolinyl " and " alkynyl " that the part of macoradical is more used.Should comprise ring-type C separately or as the term " cycloalkyl " that the part of macoradical is more used
3-C
12Hydrocarbon, it is fully saturated or contains one or more unsaturated groups, but aromatics whether.
Term " haloalkyl ", " haloalkenyl group " and " halogenated alkoxy " expression are depended on the circumstances by alkyl, thiazolinyl or alkoxyl group that one or more halogen atoms replace.Term " halogen " expression F, Cl, Br or I.
Term " heteroatoms " expression nitrogen, oxygen or sulphur comprise any oxidized form of nitrogen and sulphur and the quaternary ammonium form of any basic nitrogen.And term " nitrogen " comprises the commutable nitrogen of heterocyclic.As an example, be selected from the unsaturated ring of saturated or part of oxygen, sulphur or nitrogen having 0-3, nitrogen can be N (3, in the 4-dihydro-2 h-pyrrole base), NH (in pyrrolidyl) or NR
+(in the pyrrolidyl that N-replaces).
Term used herein " carbocyclic ring ", " carbocylic radical ", " carbocyclic ring also " or " isocyclic " expression have the aliphatic ring system of three to 14 annular atomses.Term " carbocyclic ring ", " carbocylic radical ", " carbocyclic ring also " or " isocyclic " no matter be saturated or part undersaturated, also the expression optionally substituted ring.Term " carbocyclic ring ", " carbocylic radical ", " carbocyclic ring also " or " isocyclic " comprise also and one or more aromatics or non-aromatic ring condensed aliphatic series ring that for example in decahydro naphthyl or tetralyl, wherein atomic group of Lian Jieing or point are positioned on this aliphatic series ring.
Have the aromatics cyclic group of five to 14 annular atomses, for example phenyl, benzyl, styroyl, 1-naphthyl, 2-naphthyl, 1-anthryl and 2-anthryl separately or as term " aryl " expression that macoradical more uses as the part of " aralkyl ", " aralkoxy " or " aryloxy alkyl ".Optionally substituted ring also represented in term " aryl ".Term " aryl " can exchange with term " aryl rings " and use." aryl " also comprises condensed polycyclic aromatic ring system, and wherein aromatic ring and one or more ring condense.Example comprises 1-naphthyl, 2-naphthyl, 1-anthryl and 2-anthryl.Also comprise such group in term used herein " aryl " scope, wherein aromatic ring and one or more non-aromatic ring condense, and for example in dihydro indenyl, phenanthridinyl or tetralyl, wherein atomic group of Lian Jieing or point are positioned on this aromatic ring.
Term used herein " heterocycle ", " heterocyclic radical " or " heterocyclic " comprise have five to 14, the non-aromatics ring system of preferred five to ten annular atomses, wherein one or more, preferred one to four ring carbon replaces for example N, O or S separately by heteroatoms.The heterocyclic example comprises 3-1H-benzimidazolyl-2 radicals-ketone, (1-replaces)-2-oxo-benzoglyoxaline-3-base, the 2-tetrahydrofuran base, the 3-tetrahydrofuran base, the 2-THP trtrahydropyranyl, the 3-THP trtrahydropyranyl, the 4-THP trtrahydropyranyl, [1,3]-the dioxane amyl group, [1,3]-the dithia cyclopentyl, [1,3]-alkyl dioxins, the 2-tetrahydro-thienyl, the 3-tetrahydro-thienyl, the 2-morpholinyl, morpholinyl, the 4-morpholinyl, the 2-thio-morpholinyl, the 3-thio-morpholinyl, the 4-thio-morpholinyl, the 1-pyrrolidyl, the 2-pyrrolidyl, the 3-pyrrolidyl, the 1-piperazinyl, the 2-piperazinyl, piperidino, the 2-piperidyl, the 3-piperidyl, the 4-piperidyl, the 4-thiazolidyl, diazole ketone group (diazolonyl), the diazole ketone group that N-replaces, 1-benzopyrrole ketone group, benzo oxa-cyclopropyl (benzoxanyl), the benzopyrrole alkyl, the benzo piperidyl, benzo oxa-cyclopentyl, benzimidazole thiophanate heterocycle amyl group and benzimidazole thiophanate piperidyl.In term used herein " heterocyclic radical " or " heterocyclic " scope, also comprise such group, wherein non-aromatics contains heteroatomic ring and one or more aromatics or non-aromatic ring and condenses, for example in indolinyl, chromanyl, phenanthridinyl or tetrahydric quinoline group, wherein atomic group of Lian Jieing or point are positioned at this non-aromatics and contain on the heteroatomic ring.Term " heterocycle ", " heterocyclic radical " or " heterocyclic " no matter be saturated or part undersaturated, also the expression optionally substituted ring.
Separately or have a heteroaromatic cyclic group of five to 14 annular atomses as term " heteroaryl " expression that the part of macoradical " heteroaralkyl " or " assorted aralkoxy " is more used.The example of heteroaryl comprises the 2-furyl, the 3-furyl, the TMSIM N imidazole base, the 2-imidazolyl, the 4-imidazolyl, the 5-imidazolyl, the 3-isoxazolyl, the 4-isoxazolyl, the 5-isoxazolyl, 2-oxadiazole base, 5-oxadiazole base, the 2-oxazolyl, the 4-oxazolyl, the 5-oxazolyl, the 1-pyrryl, the 2-pyrryl, the 3-pyrryl, the 2-pyridyl, the 3-pyridyl, the 4-pyridyl, the 2-pyrimidyl, the 4-pyrimidyl, the 5-pyrimidyl, the 3-pyridazinyl, the 2-thiazolyl, the 4-thiazolyl, the 5-thiazolyl, the 5-tetrazyl, the 2-triazolyl, the 5-triazolyl, the 2-thienyl, the 3-thienyl, carbazyl, benzimidazolyl-, benzothienyl, benzofuryl, indyl, quinolyl, the benzotriazole base, benzothiazolyl benzoxazolyl, benzimidazolyl-, isoquinolyl, indyl, pseudoindoyl, acridyl or benzoisoxazole base.Also comprise such group in term used herein " heteroaryl " scope, wherein heteroaromatic rings and one or more aromatics or non-aromatic ring condense, and wherein atomic group of Lian Jieing or point are positioned on this heteroaromatic rings.Example comprises tetrahydric quinoline group, tetrahydro isoquinolyl and pyrido [3,4-d] pyrimidyl.Optionally substituted ring also represented in term " heteroaryl ".Term " heteroaryl " can exchange with term " heteroaryl ring " or term " heteroaromatic group " and use.
Aryl (comprising aralkyl, aralkoxy, aryloxy alkyl etc.) or heteroaryl (comprising heteroaralkyl and assorted aralkoxy etc.) can contain one or more substituting groups.The substituting group example that is fit on the unsaturated carbon atom of aryl, heteroaryl, aralkyl or heteroaralkyl comprise halogen ,-R ° ,-OR ° ,-SR °, 1; 2-methylene-dioxy, ethylenedioxy, protected OH (for example acyloxy), phenyl (Ph), the Ph that replaces ,-O (Ph), replace-O (Ph) ,-CH
2(Ph), replace-CH
2(Ph) ,-CH
2CH
2(Ph), replace-CH
2CH
2(Ph) ,-NO
2,-CN ,-N (R °)
2R ° of ,-NR ° C (O) ,-NR ° C (O) N (R °)
2,-NR ° CO
2R ° ,-R ° of NR ° NR ° C (O) ,-NR ° NR ° C (O) N (R °)
2,-NR ° NR ° CO
2R ° ,-R ° of C (O) C (O) ,-C (O) CH
2R ° of C (O) ,-CO
2R ° ,-R ° of C (O) ,-C (O) N (R °)
2,-OC (O) N (R °)
2,-S (O)
2R ° ,-SO
2N (R °)
2R ° of ,-S (O) ,-NR ° SO
2N (R °)
2,-NR ° SO
2R ° ,-C (=S) N (R °)
2,-C (=NH)-N (R °)
2,-(CH
2)
yR ° of NHC (O) ,-(CH
2)
yNHC (O) CH (V-R °) (R °); Wherein R ° be hydrogen, replacement or unsubstituted aliphatic group, unsubstituted heteroaryl or heterocycle, phenyl (Ph), the Ph that replaces ,-O (Ph), replacement-O (Ph) ,-CH
2(Ph) or replace-CH
2(Ph); Y is 0-6; V is a linking group.Substituting group example on R ° of aliphatic group or the benzyl ring comprises amino, alkylamino, dialkyl amido, aminocarboxyl, halogen, alkyl, alkyl amino-carbonyl, dialkyl amino carbonyl, alkylamino carbon acyloxy, dialkyl amido carbon acyloxy, alkoxyl group, nitro, cyano group, carboxyl, alkoxy carbonyl, alkyl-carbonyl, hydroxyl, halogenated alkoxy or haloalkyl.
Aliphatic group or non-aromatic heterocyclic can contain one or more substituting groups.The substituting group example that is fit on the saturated carbon of aliphatic group or non-aromatic heterocyclic comprise above about cited those of the unsaturated carbon of aryl or heteroaryl and following groups :=O ,=S ,=NNHR
*,=NN (R
*)
2,=N-,=NNHC (O) R
*=NNHCO
2(alkyl) ,=NNHSO
2(alkyl) or=NR
*, each R wherein
*Be independently selected from the aliphatic group of hydrogen, unsubstituted aliphatic group or replacement.Substituent example comprises amino, alkylamino, dialkyl amido, aminocarboxyl, halogen, alkyl, alkyl amino-carbonyl, dialkyl amino carbonyl, alkylamino carbon acyloxy, dialkyl amido carbon acyloxy, alkoxyl group, nitro, cyano group, carboxyl, alkoxy carbonyl, alkyl-carbonyl, hydroxyl, halogenated alkoxy or haloalkyl on the aliphatic group.
The substituting group that is fit on the nitrogen of non-aromatic heterocyclic comprises-R
+,-N (R
+)
2,-C (O) R
+,-CO
2R
+,-C (O) C (O) R
+,-C (O) CH
2C (O) R
+,-SO
2R
+,-SO
2N (R
+)
2,-C (=S) N (R
+)
2,-C (=NH)-N (R
+)
2With-NR
+SO
2R
+R wherein
+Be the aliphatic group, phenyl (Ph) of hydrogen, aliphatic group, replacement, the Ph that replaces ,-O (Ph), replacement-O (Ph) ,-CH
2(Ph), replace-CH
2(Ph) or unsubstituted heteroaryl or heterocycle.Substituent example comprises amino, alkylamino, dialkyl amido, aminocarboxyl, halogen, alkyl, alkyl amino-carbonyl, dialkyl amino carbonyl, alkylamino carbon acyloxy, dialkyl amido carbon acyloxy, alkoxyl group, nitro, cyano group, carboxyl, alkoxy carbonyl, alkyl-carbonyl, hydroxyl, halogenated alkoxy or haloalkyl on aliphatic group or the benzyl ring.
Term " linking group " or " connecting base " expression connect the organic group of two parts of compound.Connect base usually by atoms such as oxygen or sulphur ,-NH-,-CH
2-,-C (O)-,-atomchains such as unit such as C (O) NH-or alkylidene chain constitute.The molecular mass that connects base usually in about 14 to 200 scopes, preferably in 14 to 96 scopes, about at the most six atoms of length.The example that connects base comprises saturated or undersaturated C
1-6Alkylidene chain, it optionally is substituted, wherein one or two saturated carbon of this chain optionally by-C (O)-,-C (O) C (O)-,-CONH-,-CONHNH-,-CO
2-,-OC (O)-,-NHCO
2-,-O-,-NHCONH-,-OC (O) NH-,-NHNH-,-NHCO-,-S-,-SO-,-SO
2-,-NH-,-SO
2NH-or-NHSO
2-replace.
The optionally substituted straight or branched carbochain of term " alkylidene chain " expression, it can be saturated fully or have one or more unsaturated units.Optionally substituting group is as above described about aliphatic group.
The combination of substituting group or variable is only just to be allowed to when a kind of like this combination causes stable or chemically feasible compound.Stable compound or chemically feasible compound are such, wherein do not have moisture or other chemical reaction conditions in the presence of, when keeping at least one week under 40 ℃ or following temperature, chemical structure does not have change in essence.
Unless otherwise prescribed, the structure that this paper described also represents to comprise all stereochemical forms of this structure; Just about the R and the S configuration of each asymmetric center.Therefore, the single three-dimensional chemical isomer of The compounds of this invention and enantiomorph and non-enantiomer mixture belong to scope of the present invention.Unless otherwise prescribed, the structure that this paper described is only also represented to comprise compound different in the existence of one or more isotopic enrichment atoms.For example, replaced or the carbon quilt by deuterium or tritium except hydrogen
13C-or
14The compound that has structure of the present invention beyond the carbon of C-enrichment replaces belongs to scope of the present invention.
Formula I compound or its salt can be formulated into composition, and in preferred embodiment, said composition is a pharmaceutical composition.In one embodiment, composition comprises protein kinase, the particularly kinases inhibitor of GSK-3 significant quantity that suppresses among biological specimen or the patient.In another embodiment, The compounds of this invention and pharmaceutical composition thereof can be in order to prepare patient's administration, and said composition comprises kinases inhibitor and pharmaceutically acceptable carrier, auxiliary agent or the vehicle of treatment or prevention GSK-3 mediation illness significant quantity.
Any disease or other harmful conditioned disjunction states that term used herein " illness of GSK-3 mediation " or the known GSK-3 of " disease " expression are played a role therein.This class disease or illness comprise diabetes, Alzheimer, Huntington's disease, Parkinson's disease, dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, myocardial hypertrophy, again perfusion/local asphyxia and the alopecia relevant with AIDS without limitation.
The patient that one aspect of the present invention relates to needs strengthens the method that glycogen synthesizes and/or reduce the glucose blood levels, and this method comprises formula I compound or its pharmaceutical composition of the patient being given to treat significant quantity.This method especially can be used for the diabetic subject.Another kind method relates to the generation that suppresses excessive phosphorylation tau protein, and this can be used for stopping or delaying the progress of Alzheimer.Another kind method relates to and suppresses the white phosphorylation of beta-catenin, and this can be used for treating schizophrenia.
Another aspect of the present invention relates to the GSK-3 activity that suppresses in the biological specimen, and this method comprises makes biological specimen contact with the GSK-3 inhibitor of formula I.
Another aspect of the present invention relates to the active method of Aurora-2 that suppresses among the patient, and this method comprises gives formula I compound or comprise described compound compositions the patient.
Another aspect of the present invention relates to and utilizes Aurora-2 inhibitor for treating or prevention Aurora-2 disease mediated method, and this method comprises formula I compound or its pharmaceutical composition of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Any disease or other harmful symptoms that term used herein " illness of Aurora-2 mediation " or the known Aurora of " disease " expression are played a role therein.Term " Aurora-2 mediation illness " or " disease " are also represented those diseases or the illness that are alleviated by the Aurora-2 inhibitor for treating.This class illness comprises cancer without limitation.Term " cancer " includes but not limited to following cancer: colon and ovary.
Another aspect of the present invention relates to the Aurora-2 activity that suppresses in the biological specimen, and this method comprises makes biological specimen contact with Aurora-2 inhibitor or its composition of formula I.
Another aspect of the present invention relates to and utilizes CDK-2 inhibitor for treating or prevention CDK-2 disease mediated method, and this method comprises formula I compound or its pharmaceutical composition of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Any disease or other harmful conditions that term used herein " illness of CDK-2 mediation " or the known CDK-2 of " disease " expression are played a role therein.Term " CDK-2 mediation illness " or " disease " are also represented those diseases or the illness that are alleviated by the CDK-2 inhibitor for treating.This class illness comprises cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HIV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis without limitation.Referring to Fischer, P.M.andLane, D.P., Current Medicinal Chemistry, 7,1213-1245 (2000); Mani, S., Wang, C., Wu, K., Francis, R.and Pestell, R., Exp.Opin.Invest.Drugs, 9,1849 (2000); Fry, D.W.and Garrett, M.D., Current Opinion in Oncologic, Endocrine ﹠amp; MetabolicInvestigational Drugs, 2,40-59 (2000).
Another aspect of the present invention relates to the CDK-2 activity that suppresses among biological specimen or the patient, and this method comprises gives formula I compound or comprise described compound compositions the patient.
Another aspect of the present invention relates to and utilizes ERK-2 inhibitor for treating or prevention ERK-2 disease mediated method, and this method comprises formula I compound or its pharmaceutical composition of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Any disease or other harmful symptoms that term used herein " illness of ERK mediation " the known ERK of expression is played a role therein.Term " ERK-2 mediation illness " or " disease " are also represented those diseases or the illness that are alleviated by the ERK-2 inhibitor for treating.This class illness comprises cancer, apoplexy, diabetes, hepatomegaly, cardiovascular disorder (comprising megalocardia), Alzheimer, Cysticfibrosis, virus disease, autoimmune disorders, atherosclerosis, restenosis, psoriasis, allergy obstacle (comprising asthma), inflammation, neurological obstacle without limitation and relates to the disease of hormone.Term " cancer " includes but not limited to the cancer at following position: mammary gland, ovary, uterine neck, prostate gland, testis, urogenital tract, oesophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, adenocarcinoma of lung, bone, colon, adenoma, pancreas, gland cancer, Tiroidina, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, spermocytoma, melanoma, sarcoma, bladder cancer, liver cancer and biliary tract, kidney, marrow sample disease, lymph sample disease, He Jiejinshi, hair cell, the vestibule of mouth diease and pharynx (oral cavity), lip, tongue, mouthful, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia.The ERK-2 protein kinase and with involving of various diseases existing document description (Bokemeyer etc., 1996, Kidney Int.49,1187; Anderson etc., 1990, Nature 343,651; Crews etc., 1992, Science 258,478; Bjorbaek etc., 1995, J.Biol.Chem.270,18848; Rouse etc., 1994, Cell 78,1027; Raingeaud etc., 1996, Mol.Cell Biol.16,1247; Raingeaud etc., 1996; Chen etc., 1993, Proc.Natl.Acad.Sci.USA90,10952; Oliver etc., 1995, Proc.Soc.Exp.Biol.Med.210,162; Moodie etc., 1993, Science 260,1658; Frey and Mulder, 1997, Cancer Res.57,628; Sivaraman etc., 1997, J.Clin.Invest.99,1478; Whelchel etc., 1997, Am.J.Respir.Cell Mol.Biol.16,589).
Another aspect of the present invention relates to the ERK-2 activity that suppresses among biological specimen or the patient, and this method comprises gives formula I compound or comprise described compound compositions the patient.
Another aspect of the present invention relates to and utilizes AKT inhibitor for treating or prevention AKT disease mediated method, and this method comprises formula I compound or its pharmaceutical composition of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Any disease or other harmful symptoms that term used herein " illness of AKT mediation " the known AKT of expression is played a role therein.Term " AKT mediation illness " or " disease " are also represented those diseases or the illness that are alleviated by the AKT inhibitor for treating.The disease or the illness of AKT mediation include but not limited to proliferative disorder, cancer and neurodegeneration obstacle.AKT also is known as protein kinase B, the relation of it and various diseases existing document description (Khwaja, A., Nature, pp.33-34,1990; Zang, Q.Y. etc., Oncogene, 19,2000; Kazuhiko, N. etc., The Journal of Neuroscience, 20,2000).
Another aspect of the present invention relates to the AKT activity that suppresses among biological specimen or the patient, and this method comprises gives formula I compound or comprise described compound compositions the patient.
Another aspect of the present invention relates to and utilizes Src inhibitor for treating or prevention Src disease mediated method, and this method comprises formula I compound or its pharmaceutical composition of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Any disease or other harmful symptoms that term used herein " illness of Src mediation " the known Src of expression is played a role therein.Term " Src mediation illness " or " disease " are also represented those diseases or the illness that are alleviated by the Src inhibitor for treating.This class illness comprises the symptomatic treatment and the osteitis deformans of hypercalcemia, osteoporosis, osteoarthritis, cancer, metastatic tumor of bone without limitation.The Src protein kinase and with involving of various diseases existing document description (Soriano, Cell, 69,551 (1992); Soriano etc., Cell, 64,693 (1991); Takayanagi, J.Clin.Invest., 104,137 (1999); Boschelli, Drugs of the Future, 2000,25 (7), 717 (2000); Talamonti, J.Cl in.Invest., 91,53 (1993); Lutz, Biochem.Biophys.Res., 243,503 (1998); Rosen, J.Biol.Chem., 261,13754 (1986); Bolen, Proc.Natl.Acad.Sci.USA, 84,2251 (1987); Masaki, Hepatology, 27,1257 (1998); Biscardi, Adv.Cancer Res., 76,61 (1999); Lynch, Leukemia, 7,1416 (1993); Wiener, Clin.Cancer Res., 5,2164 (1999); Staley, Cell Growth Diff., 8,269 (1997)).
Another aspect of the present invention relates to the Src activity that suppresses among biological specimen or the patient, and this method comprises gives formula I compound or comprise described compound compositions the patient.
Carrier, auxiliary agent or vehicle that term " pharmaceutically acceptable carrier, auxiliary agent or vehicle " expression is nontoxic, they can be with compound of the present invention to patient's administration, and does not destroy the latter's pharmacologically active.
Term " patient " comprises people and beasts curee.
Term used herein " biological specimen " comprises cell culture or its extract without limitation; The enzyme prepared product that is suitable for external test; The biopsy material or its extract that obtain from Mammals; With blood, saliva, urine, excrement, seminal fluid, tear or other body fluid or its extract.
Effectively the amount of arrestin kinases, for example GSK-3 and Aurora-2 is that enzymic activity when not having inhibitor to exist is compared the amount that suppresses kinase activity on measurable degree.Any method may be used to measure restraining effect, for example biological test example hereinafter described.
The pharmaceutically acceptable carrier that can be used in these pharmaceutical compositions includes but not limited to ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein (for example human serum albumin), buffer substance (for example phosphoric acid salt), glycine, Sorbic Acid, potassium sorbate, the partial glyceride mixture of saturated vegetable fatty acid, water, salt or ionogen (protamine sulfate for example, Sodium phosphate dibasic, potassium hydrogen phosphate, sodium-chlor, zinc salt), colloid silica, Magnesium Trisilicate, polyvinylpyrrolidone, cellulose substances, polyoxyethylene glycol, Xylo-Mucine, polyacrylic ester, wax, polyethylene-polyoxypropylene block polymer, polyoxyethylene glycol and lanolin.
The administration of the present composition can be oral, parenteral, suction spraying, part, rectum, nose, cheek, vagina or via implanting the Drug Storage administration.That term used herein " parenteral " comprises is subcutaneous, in the intravenously, intramuscular, intraarticular, synovial membrane, in the breastbone, in the sheath, in the liver, in the damage location and intracranial injection or infusion techniques.Preferably, composition is oral, intraperitoneal or intravenous administration.
The sterile injectable formulation of the present composition can be water-based or oiliness suspension.These suspensions can use suitable dispersion or wetting agent and suspension agent to be prepared according to technology known in the art.Sterile injectable preparation can also be at nontoxic parenteral acceptable diluent or sterile injectable solution or the suspension in the solvent, for example solution in 1,3 butylene glycol.Acceptable carrier that can adopt and solvent are water, Ringer's solution and isotonic sodium chlorrde solution.In addition, aseptic fixed oil is conventionally used as solvent or suspension medium.For this reason, can adopt the fixed oil of any brand, comprise synthetic list-or two-glyceryl ester.Lipid acid is oleic acid and glyceride derivative thereof for example, can be used for preparing injection, because they are natural pharmaceutically acceptable oil, and for example sweet oil or Viscotrol C, especially their polyoxy ethylization form.These oil solutions or suspension can also contain long-chain alcohol thinner or dispersion agent, for example carboxymethyl cellulose or similar dispersion agent, and they are usually used in preparing pharmaceutically acceptable formulation, comprise emulsion and suspension.For the purpose of preparation, can also use other tensio-active agents commonly used, for example Tweens, spans and other emulsifying agents or bioavailability toughener, they are usually used in making pharmaceutically acceptable solid, liquid or other formulations.
Pharmaceutical composition of the present invention can be taken orally, and any oral acceptable forms includes but not limited to capsule, tablet, aqueous suspensions or solution.Under the situation of oral tablet, carrier commonly used comprises lactose and W-Gum.Also add lubricant, for example Magnesium Stearate usually.About the oral capsule administration, useful thinner comprises lactose and exsiccant W-Gum., activeconstituents is mixed with emulsifying and suspending agent when needing aqueous suspensions when oral.If necessary, can also add some sweeting agent, correctives or tinting material.
Select as an alternative, pharmaceutical composition of the present invention can be the form of suppository, is used for rectal administration.They can prepare like this, and medicine is mixed with the nonirritant excipient that is fit to, and the latter at room temperature is a solid, but is liquid under rectal temperature, therefore will melt at internal rectum, discharges medicine.This class material comprises theobroma oil, beeswax and polyoxyethylene glycol.
The all right topical of pharmaceutical composition of the present invention especially when therapeutic goal comprises local application easy to reach position or organ, comprises the disease of eye, skin or lower intestinal tract.The topical formulations that is fit to is prepared according to each these position or organ easily.
Lower intestinal tract local application can utilize rectal suppository (on seeing) or suitable enema to carry out.Can also use the topical transdermal patch.
About local application, pharmaceutical composition can be formulated in the suitable ointment, wherein contains to suspend or be dissolved in active ingredient in one or more carriers.The topical carrier of The compounds of this invention includes but not limited to mineral oil, Albolene, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.Select as an alternative, pharmaceutical composition can be mixed with suitable lotion or creme, wherein contains to suspend or be dissolved in active ingredient in one or more pharmaceutically acceptable carriers.The carrier that is fit to includes but not limited to mineral oil, Arlacel-60, polysorbate60, spermaceti ester type waxes, cetostearyl alcohol, 2-Standamul G, phenylcarbinol and water.
About eye usefulness, pharmaceutical composition can be mixed with micronization suspension or the solution in the Sterile Saline of isoosmotic pH regulator preferably in the Sterile Saline of isoosmotic pH regulator, and the two all contains or does not have sanitas, for example a benzalkonium chloride.Select as an alternative, about eye usefulness, pharmaceutical composition can be formulated in the ointment, for example Vaseline.
Pharmaceutical composition of the present invention can also pass through nose aerosol or inhalation administration.This based composition is to prepare according to the technology that field of pharmaceutical preparations is known, can make salt brine solution, adopt absorption enhancer, fluorocarbon and/or other the conventional solubilizing agent or the dispersion agent of phenylcarbinol or other sanitass that is fit to, raising bioavailability.
Except compound of the present invention, can also in composition, adopt the pharmaceutically acceptable derivates or the prodrug of The compounds of this invention, to treat or to prevent above-mentioned disease or obstacle.
Salt or other derivatives of any pharmacy acceptable salt of " pharmaceutically acceptable derivates or prodrug " expression The compounds of this invention, ester, ester, they can directly or indirectly provide The compounds of this invention or its inhibitory activity meta-bolites or residue after to recipient's administration.Particularly advantageous derivative or prodrug are those (for example making easier being absorbed of compound of oral administration enter blood) that increase the The compounds of this invention bioavailability after such compound is to patient's administration, perhaps strengthen the release of parent compound to body cavity of organism (for example brain or lymphsystem), this is relative parent kind.
The pharmaceutically acceptable prodrug of The compounds of this invention comprises ester, amino acid ester, phosphoric acid ester, metal-salt and sulphonate without limitation.
The pharmacy acceptable salt of The compounds of this invention comprise from pharmaceutically acceptable inorganic and organic acid and alkali deutero-those.The example of the hydrochlorate that is fit to comprises acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, hydrosulfate, butyrates, Citrate trianion, camphorate, camsilate, cyclopentane propionate, digluconate, dodecyl sulfate, esilate, formate, fumarate, gluceptate, glycerophosphate, oxyacetate, Hemisulphate, enanthate, hexanoate, hydrochloride, hydrobromate, hydriodate, the 2-isethionate, lactic acid salt, maleate, malonate, mesylate, the 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectate, persulphate, 3-phenylpropionic acid salt, phosphoric acid salt, picrate, Pivalate, propionic salt, salicylate, succinate, vitriol, tartrate, thiocyanate-, tosylate and undecane hydrochlorate.Other acid are oxalic acid for example, although itself be not pharmaceutically acceptable, but can be used for preparing in obtaining The compounds of this invention and their pharmaceutically-acceptable acid addition salt as intermediate.
Comprise basic metal (for example sodium and potassium), alkaline-earth metal (for example magnesium), ammonium and N from suitable alkali deutero-salt
+(C
1-4Alkyl)
4Salt.The present invention also envisions any alkaline nitrogen-containing group quaternized of compound disclosed herein.Quaternizedly can obtain water or oily solubility or dispersibility product by this.
Can be mixed with the amount of the kinases inhibitor of single formulation with solid support material will be different because of the patient that treated and specific administering mode.Preferably, composition should be preparation like this, so that can give the inhibitor of dosage in the 0.01-100mg/kg body weight/day to the patient who accepts these compositions.
Also should self-evidently be that concrete dosage and treatment plan about particular patient will depend on various factors, comprise activity, age, body weight, general health situation, sex, diet, administration time, discharge rate, drug regimen, attending doctor's judgement and the seriousness of the specified disease for the treatment of of the particular compound that is adopted.The amount of inhibitor also will depend on the specific compound in the composition.
According to the kinase mediated illness of specific protein that will treat or prevent, can give under normal circumstances in order to treat or to prevent the other therapeutical agent of this illness with inhibitor of the present invention.For example, in treatment of diabetes, other antidiabetics can with GSK-3 inhibitor combination therapy diabetes of the present invention.These medicines comprise Regular Insulin or insulin analog, glitazone, α glycosidase inhibitor, biguanides, insulin sensitizers and the sulfonylurea of the injectable or the form of suction without limitation.
Other can comprise chemotherapeutics or other antiproliferatives, for example Zorubicin, dexamethasone, vincristine(VCR), endoxan, Fluracil, Hycamtin, taxol, Interferon, rabbit and platinum derivatives without limitation with the example of the medicine of inhibitor of the present invention associating; Anti-inflammatory agent, for example reflunomide, tnf blockers, IL-1RA, azathioprine, endoxan and sulfasalazine; Immunomodulatory and immunosuppressor, for example S-Neoral, tacrolimus, rapamycin, Mycophenolic Acid mofetil, Interferon, rabbit, reflunomide, endoxan, azathioprine and sulfasalazine; Neurotrophic factor, for example acetylcholinesterase depressant, MAO inhibitor, Interferon, rabbit, anticonvulsive agent, ionic channel retarding agent, Riluzole and anti-parkinson agent; The medicine that is used for the treatment of cardiovascular disorder, for example beta-Blocking agent, ACE inhibitor, diuretic(s), nitric ether, calcium channel blocker and Statins; The medicine that is used for the treatment of hepatopathy, for example reflunomide, Colestyramine, Interferon, rabbit and antiviral agent; The medicine that is used for the treatment of hematologic disease, for example reflunomide, leukemia agent and somatomedin; With the medicine that is used for the treatment of the immune deficiency sexual dysfunction, for example gamma Globulin.
These other therapeutical agents can with the composition separate administration that contains kinases inhibitor, as the part of multiple doses scheme.Select as an alternative, these medicines can be the parts of single formulation, are mixed together in the single composition with kinases inhibitor of the present invention.
Can there be the alternative tautomerism type in The compounds of this invention, shown in the following tautomer 1 and 2.Except as otherwise noted, the representation of one of two kinds of tautomers means and comprises another kind.
R
xAnd R
y(respectively at position Z
3And Z
4) can constitute the condensed ring together, obtain containing the bicyclic ring system that encircles A.Preferred R
x/ R
yRing comprises having 0-2 the first unsaturated or undersaturated ring of part of heteroatomic 5-, 6-, 7-or 8-, wherein said R
x/ R
yRing optionally is substituted.Shown in the following Compound I of the example-A to I-DD of ring A system, Z wherein
1Be nitrogen or C (R
9), Z2 is nitrogen or C (H).
Preferred two ring A systems comprise I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L and I-M, more preferably I-A, I-B, I-C, I-F and I-H, most preferably I-A, I-B and I-H.
In monocycle A system, preferred R
xGroup comprises hydrogen, alkyl-or dialkyl-7-amino, kharophen or C when existing
1-4Aliphatic group, for example methyl, ethyl, cyclopropyl, sec.-propyl or the tertiary butyl.Preferred R
yGroup comprises T-R when existing
3, wherein T is valency bond or methylene radical, R
3Be-R ,-N (R
4)
2Or-OR.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or dialkyl-7-amino, kharophen, optionally substituted phenyl (for example phenyl or halogenophenyl) and methoxymethyl.
In two ring A systems, by R
xAnd R
yThe ring of Gou Chenging can be substituted or unsubstituted together.The substituting group that is fit to comprises-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, wherein R and R
4Be as defined above.Preferred R
x/ R
yRing substituents comprises-halogen ,-R ,-OR ,-COR ,-CO
2R ,-CON (R
4)
2,-CN or-N (R
4)
2, wherein R is hydrogen or optionally substituted C
1-6Aliphatic group.
R
2And R
2' can constitute the condensed ring together, thus obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring, and wherein said fused rings optionally is substituted.They are the following formula I compound for example, has the bicyclic ring system of containing pyrazoles:
R
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-3Alkyl ,-C
1-3Haloalkyl ,-NO
2,-O (C
1-3Alkyl) ,-CO
2(C
1-3Alkyl) ,-CN ,-SO
2(C
1-3Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-3Alkyl) ,-NHC (O) (C
1-3Alkyl) ,-C (O) NH
2With-CO (C
1-3Alkyl), (C wherein
1-3Alkyl) most preferably is methyl.
When the pyrazoles ring system is monocycle, preferred R
2Group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-or two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).Preferred R
2' group is hydrogen.
Be particularly useful for treating the disease mediated embodiment of GSK-3 and relate to formula II compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 0-3 is selected from the ring hetero atom of oxygen, sulphur or nitrogen, wherein by R with intervenient atom
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace, by R
xAnd R
yAny commutable nitrogen is by R on the described ring that constitutes
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted group, and described group is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R as formula II
xAnd R
yWhen constituting the condensed ring together, preferred R
x/ R
yRing comprises having O-2 the first unsaturated or undersaturated ring of part of heteroatomic 5-, 6-, 7-or 8-, wherein said R
x/ R
yRing optionally is substituted.This obtains containing the bicyclic ring system of pyrimidine ring.The example of preferred formula II pyrimidine ring system be show down single-with two-encircle ring system.
Preferred formula II pyrimidine ring system comprises II-A, II-B, II-C, II-F and II-H, most preferably II-A, II-B and II-H.
In the monocycle pyrimidine ring system of formula II, preferred R
xGroup comprises hydrogen, alkyl-or dialkyl-7-amino, kharophen or C
1-4Aliphatic group, for example methyl, ethyl, cyclopropyl, sec.-propyl or the tertiary butyl.Preferred R
yGroup comprises T-R
3, wherein T is valency bond or methylene radical, R
3Be-R ,-N (R
4)
2Or-OR.Work as R
3Be-R or-during OR, preferred R is optionally substituted group, is selected from C
1-6Aliphatic group, phenyl or 5-6 unit's heteroaryl or heterocyclic ring.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or dialkyl-7-amino, kharophen, optionally substituted phenyl (for example phenyl or halogenophenyl) and methoxymethyl.
In the bicyclic pyrimidine ring system of formula II, by R
xAnd R
yThe ring of Gou Chenging can be substituted or unsubstituted together.The substituting group that is fit to comprises-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, wherein R and R
4Be as defined above.Preferred R
x/ R
yRing substituents comprises-halogen ,-R ,-OR ,-COR ,-CO
2R ,-CON (R
4)
2,-CN or-N (R
4)
2, wherein R is optionally substituted C
1-6Aliphatic group.
The R of formula II
2And R
2' can constitute the condensed ring together, thus obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They for example are the Formula Il compounds, and it has the bicyclic ring system of containing pyrazoles:
The R of formula II
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When the pyrazoles ring system of formula II is monocycle, preferred R
2Group comprises hydrogen or replacement or unsubstituted aryl, heteroaryl or the C of being selected from
1-6The group of aliphatic group.The preferred R of this class
2Examples of groups comprise methyl, the tertiary butyl ,-CH
2OCH
3, cyclopropyl, furyl, thienyl and phenyl.Preferred R
2' group is hydrogen.
Preferred formula II ring system is as follows, and they can be substituted as mentioned above, wherein R
2And R
2' constitute the indazole ring with the pyrazoles ring; R
xAnd R
yEach is methyl, perhaps R naturally
xAnd R
yConstitute quinazoline or tetrahydro quinazoline ring with pyrimidine ring:
Particularly preferably be formula II-Aa, II-Ba or II-Ha compound, wherein encircling C is benzyl ring, R
1Be halogen, methyl or trifluoromethyl.
Preferred formula II ring C group is phenyl and pyridyl.When last two the adjacent substituting groups of ring C constituted the condensed ring together, ring C was comprised in the bicyclic ring system.Preferred fused rings comprises benzo or pyrido ring.This class ring preferably condenses an ortho position and the position at ring C.The example of preferred bicyclic ring C system comprises naphthyl, quinolyl and isoquinolyl.
The key character of formula II compound is the R on the ring C
1Ortho-substituent.Ring C or the ortho position of ring on the D position during with respect to shack A defines.Preferred R
1Group comprises-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Work as R
1Be optionally substituted C
1-6During aliphatic group, most preferred optional substituting group is a halogen.Preferred R
1Examples of groups comprises-CF
3,-Cl ,-F ,-CN ,-COCH
3,-OCH
3,-OH ,-CH
2CH
3,-OCH
2CH
3,-CH
3,-CF
2CH
3, cyclohexyl, the tertiary butyl, sec.-propyl, cyclopropyl ,-C ≡ CH ,-C ≡ C-CH
3,-SO
2CH
3,-SO
2NH
2,-N (CH
3)
2,-CO
2CH
3,-CONH
2,-NHCOCH
3,-OC (O) NH
2,-NHSO
2CH
3With-OCF
3
On the ring C of formula II, preferred R
5Substituting group comprises when existing-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2With-N (R
4) SO
2R.Preferred R
5Substituting group comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).The preferred R of this class
5Substituent example comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NHMe ,-NMe
2,-OEt, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl and-CO
2Et.
That preferred formula II compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, R
yBe T-R
3, perhaps R
xAnd R
yConstitute the optionally substituted 0-2 of having the unsaturated or undersaturated ring of part of 5-7 unit that encircles nitrogen with intervenient atom;
(c) R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6
(d) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula II compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring;
(b) R
xBe hydrogen or methyl, R
yBe-R ,-N (R
4)
2Or-OR, perhaps R
xAnd R
yConstitute 5-7 unit unsaturated or undersaturated carbocyclic ring of part and ring with intervenient atom, optionally by-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN;
(d) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom;
(e) each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula II compound has one or more, the more preferably feature of group under whole being selected from:
(a) ring C is a benzyl ring, optionally by-R
5Replace;
(b) R
xBe hydrogen or methyl, R
yBe methyl, methoxymethyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or the optionally substituted 2-of being selected from pyridyl, 4-pyridyl, piperidyl or phenyl groups, perhaps R
xAnd R
yConstitute optionally substituted benzo ring or undersaturated 6-unit's carbocyclic ring of part and ring with intervenient atom;
(c) R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN;
(d) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(e) each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).
Representative formula II compound is as shown in table 1 below.
Table 1
In another embodiment, the invention provides composition, comprise formula II compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, and this method comprises and comprises formula II compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula II compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula II compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula II compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula II compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula II compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula II compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise formula II compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises formula II compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HIV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
Another kind method relates to GSK-3, Aurora or the CDK-2 activity that suppresses in the biological specimen, and this method comprises the formula IIGSK-3 that makes biological specimen and inhibition GSK-3, Aurora or CDK-2 significant quantity or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora or CDK-2 or the treatment of diseases that alleviates thus preferably utilizes aforesaid preferred formula II compound to carry out.
Another embodiment of the invention relates to the formula III compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
xAnd R
yConstitute condensed benzo ring or 5-8 unit's carbocyclic ring and ring with intervenient atom, wherein by R
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3Be selected from-R ,-halogen ,=O ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
Each R is independently selected from hydrogen or optionally substituted group, and described group is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(the C that selectivity replaces
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen.
Preferred formula III ring D monocycle comprises and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.When last two the adjacent substituting groups of ring D constituted the condensed ring together, this ring d system was a bicyclic.Preferred formula III ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.The example of preferred two ring d systems comprises naphthyl and isoquinolyl.
Formula III ring D goes up preferred R
5Substituting group comprise halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted 5-6 unit heterocyclic radical, the C of being selected from
6-10Aryl or C
1-6The group of aliphatic group.Preferred R
5Substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted 5-6 unit heterocyclic radical, the C of being selected from
6-10Aryl or C
1-6The group of aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
R when formula III
xAnd R
yWhen group constituted the condensed ring together, the preferred ring that is constituted comprises 5-, 6-or 7-unit is unsaturated or undersaturated carbocyclic ring of part and ring, and any commutable carbon is by oxo or T-R on the wherein said fused rings
3Replace.The example that preferred bicyclic ring is is as follows.
The R of formula III
x/ R
yOn the fused rings preferred substituted comprise-R, oxo, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, wherein R and R
4Be as defined above.R
x/ R
yMore preferred substituents comprises halogen, CN, oxo, C on the fused rings
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl.The example of this class preferred substituted comprises methoxyl group, methyl, sec.-propyl, methylsulfonyl, cyano group, chlorine, pyrryl, methoxyl group, oxyethyl group, ethylamino, ethanoyl and kharophen.
The preferred R of formula III
2Substituting group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-and two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).
R when formula III
2And R
2' when group constitutes a ring together, preferably contain the R of pyrazoles ring
2/ R
2' ring system comprises benzo, pyrido, Mi Dingbing, 3-oxo-2H-pyridazine and and undersaturated 6-unit's carbocyclic ring of part and ring.This class preferably contains the R of pyrazoles ring
2/ R
2' ring system comprises as follows:
The R of formula III
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
That preferred formula III compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring D is optionally substituted following ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xAnd R
yConstitute optionally substituted benzo ring or 5-7 unit's carbocyclic ring and ring with intervenient atom;
(c) R
2' be hydrogen or methyl, R
2Be T-W-R
6Or R, wherein W is-C (R
6)
2O-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-or-CON (R
6)-, R be optionally substituted, be selected from C
1-6Aliphatic group or phenyl groups, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula III compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring D is optionally substituted following ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xAnd R
yConstitute benzo ring or 5-7 unit's carbocyclic ring and ring with intervenient atom, optionally by-R, oxo, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) each R
5Be independently selected from halogen, oxo, CN, NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted 5-6 unit heterocyclic radical, the C of being selected from
6-10Aryl or C
1-6The group of aliphatic group.
And then preferred formula III compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
xAnd R
yConstitute benzo ring or 6 yuan of undersaturated carbocyclic rings of part and ring with intervenient atom, optionally by halogen, CN, oxo, C
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl replace;
(b) each R
5Be independently selected from-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R or replacement or unsubstituted 5-6 unit heterocyclic radical, the C of being selected from
6-10Aryl or C
1-6The group of aliphatic group;
(c) R
2' be hydrogen or methyl, R
2Be T-W-R
6Or R, wherein W is-C (R
6)
2O-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6)
2N (R
6) C (O)-or-CON (R
6)-, R is optionally substituted group, is selected from C
1-6Aliphatic group or phenyl, perhaps R
2And R
2' constitute the undersaturated 6-of benzo, pyrido or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl.
Representative formula III compound is as shown in table 2 below.
Table 2
In another embodiment, the invention provides composition, comprise formula III compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, and this method comprises and comprises the formula III compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises the formula III compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise the formula III compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise the formula III compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise the formula III compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise the formula III compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises the formula III compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise the formula III compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises the formula III compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HIV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
One aspect of the present invention relates to the active method of Src that suppresses among the patient, comprises to comprise the formula III compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Src inhibitor for treating on the other hand, described method comprises the step that comprises the formula III compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating the symptomatic treatment and the osteitis deformans of hypercalcemia, osteoporosis, osteoarthritis, cancer, metastatic tumor of bone.
Another kind method relates to GSK-3, Aurora, CDK-2 or the Src activity that suppresses in the biological specimen, and this method comprises makes biological specimen contact with formula III GSK-3, Aurora, CDK-2 or the Src inhibitor or its pharmaceutical composition that suppress GSK-3, Aurora, CDK-2 or Src significant quantity.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora, CDK-2 or Src or the treatment of diseases that alleviates thus preferably utilizes aforesaid preferred formula III compound to carry out.
R wherein
2' be hydrogen and R
xAnd R
yThe formula III compound that constitutes optionally substituted quinazoline ring system with pyrimidine ring still is the inhibitor of ERK-2 and AKT protein kinase.
Therefore, another kind of method of the present invention relates to ERK-2 or the active method of AKT that suppresses among the patient, comprises the wherein R that comprises that the patient is given to treat significant quantity
2' be hydrogen and R
xAnd R
yConstitute the formula III compound compositions of optionally substituted quinazoline ring system with pyrimidine ring.
Relate on the other hand and treating by ERK-2 or AKT inhibitor for treating and the method for the disease that alleviates, described method comprises the wherein R that comprises that the patient of a kind of like this treatment of needs is given to treat significant quantity
2' be hydrogen and R
xAnd R
yConstitute the step of the formula III compound compositions of optionally substituted quinazoline ring system with pyrimidine ring.This method especially can be used for treating cancer, apoplexy, hepatomegaly, cardiovascular disorder, Alzheimer, Cysticfibrosis, virus disease, autoimmune disorders, restenosis, psoriasis, allergy obstacle (comprising asthma), inflammation and neurological obstacle.
Another embodiment of the invention relates to formula IV compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen independently
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yConstitute the 5-8 unit ring that condensed, the unsaturated or undersaturated 1-3 of having of part are selected from the ring hetero atom of oxygen, sulphur or nitrogen with intervenient atom, any commutable carbon is optionally and independently by-R on the wherein said fused rings
3Replace, any commutable nitrogen is by R on the described ring
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or the undersaturated 0-3 of containing of part ring that is selected from the ring hetero atom of nitrogen, oxygen or sulphur with intervenient atom, wherein said fused rings is optionally replaced by three groups at the most, substituting group be independently selected from halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6
R
3Be selected from-R ,-halogen ,=O ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
Each R is independently selected from hydrogen or optionally substituted group, and described group is selected from C
1-6 aliphatic groups, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(the C that selectivity replaces
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (
R6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen.
Preferred formula IV ring D monocycle comprises and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.Preferred formula IV ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.Preferred ring D bicyclic example comprises naphthyl and isoquinolyl.
Formula IV ring D go up preferred substituted comprise halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R, replacement or unsubstituted group, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Preferred R
5Substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted group are selected from 5-6 unit heterocyclic radical, C
6-10Virtue or C
1-6Aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
R as formula IV
xAnd R
yWhen group constitutes the condensed ring together, preferred R
x/ R
yRing comprises having 1-2 the first unsaturated or undersaturated ring of part of heteroatomic 5-, 6-, 7-or 8-.This obtains containing the bicyclic ring system of pyrimidine ring.The example of preferred formula IV pyrimidine ring system be show down singly-with two-loop systems.
Preferred formula IV pyrimidine ring system comprises IV-E, IV-G, IV-H, IV-J, IV-K, IV-L, IV-M, IV-T and IV-U.
In the monocycle pyrimidine ring system of formula IV, preferred R
xGroup comprises hydrogen, amino, nitro, alkyl-or dialkyl-7-amino, kharophen or C
1-4Aliphatic group, for example methyl, ethyl, cyclopropyl, sec.-propyl or the tertiary butyl.Preferred R
yGroup comprises T-R
3, wherein T is valency bond or methylene radical, R
3Be-R ,-N (R
4)
2Or-OR.Work as R
3Be-R or-during OR, preferred R is optionally substituted group, is selected from C
1-6Aliphatic group, phenyl or 5-6 unit's heteroaryl or heterocyclic ring.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or dialkyl-7-amino, kharophen, optionally substituted phenyl (for example phenyl, p-methoxy-phenyl, trimethoxyphenyl or halogenophenyl) and methoxymethyl.
In the bicyclic pyrimidine ring system of formula IV, by R
xAnd R
yThe ring of Gou Chenging can be substituted or unsubstituted together.The substituting group that is fit to comprises-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, wherein R and R
4Be as above defined about formula IV compound.Preferred R
x/ R
yRing substituents comprises-halogen ,-R ,-OR ,-COR ,-CO
2R ,-CON (R
4)
2,-CN or-N (R
4)
2, wherein R replaces or unsubstituted C
1-6Aliphatic group.
The R of formula IV
2And R
2' group can constitute the condensed ring together, thereby obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They are following formula I V compound for example, and it has the bicyclic ring system of containing pyrazoles:
The R of formula IV
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When the pyrazoles ring system of formula IV is monocycle, preferred R
2Group comprises hydrogen or replacement or unsubstituted group, is selected from aryl, heteroaryl or C
1-6Aliphatic group.The preferred R of this class
2Examples of groups comprise methyl, the tertiary butyl ,-CH
2OCH
3, cyclopropyl, furyl, thienyl and phenyl.Preferred R
2' group is hydrogen.
That preferred formula IV compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, R
yBe T-R
3, perhaps R
xAnd R
yConstitute the ring of the unsaturated or undersaturated 1-2 of having of the part ring hetero atom of optionally substituted 5-7 unit with intervenient atom;
(c) R
2' be hydrogen or methyl, R
2Be T-W-R
6Or R, wherein W is-C (R
6)
2O-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-or-CON (R
6)-, R is optionally substituted group, is selected from C
1-6Aliphatic group or phenyl, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula IV compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring D is optionally substituted following ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xBe hydrogen or methyl, R
yBe-R ,-N (R
4)
2Or-OR, perhaps R
xAnd R
yConstitute the unsaturated or undersaturated ring of part of 5-7 unit with intervenient atom, have 1-2 and encircle nitrogen, wherein said ring optionally by-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) each R
5Be independently selected from halogen, oxo, CN, NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted 5-6 unit heterocyclic radical, the C of being selected from
6-10Aryl or C
1-6The group of aliphatic group.
And then preferred formula IV compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
xAnd R
yIt is unsaturated or part is undersaturated, have 1-2 ring that encircles nitrogen, optionally by halogen, CN, oxo, C to constitute 6-unit with intervenient atom
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl replace;
(b) each R
5Be independently selected from-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R or replacement or unsubstituted 5-6 unit heterocyclic radical, the C of being selected from
6-10Aryl or C
1-6The group of aliphatic group;
(c) R
2' be hydrogen, R
2Be T-W-R
6Or R, wherein W is-C (R
6)
2O-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6)
2N (R
6) C (O)-or-CON (R
6)-, R is optionally substituted group, is selected from C
1-6Aliphatic group or phenyl, perhaps R
2And R
2' constitute the undersaturated 6-of benzo, pyrido or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl.
Representative formula IV compound is as shown in table 3 below.
Table 3
In another embodiment, the invention provides composition, comprise formula IV compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, comprises to comprise formula IV compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula IV compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula IV compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula IV compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula IV compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula IV compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula IV compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise formula IV compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises formula IV compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HIV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
Another kind method relates to GSK-3, Aurora or the CDK-2 activity that suppresses in the biological specimen, and this method comprises the formula IVGSK-3 that makes biological specimen and inhibition GSK-3, Aurora or CDK-2 significant quantity or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora or CDK-2 or the treatment of diseases that alleviates thus preferably utilizes aforesaid preferred formula IV compound to carry out.
Another embodiment of the invention relates to formula V compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Z
1Be N, CR
aOr CH, Z
2Be N or CH, its condition is Z
1And Z
2One of be nitrogen;
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yWith intervenient atom constitute condensed, unsaturated or part is undersaturated, have 0-3 be selected from oxygen, sulphur or nitrogen ring hetero atom, 5-8 unit ring, wherein by R
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace, by R
xAnd R
yAny commutable nitrogen is by R on the described ring that constitutes
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted group, and described group is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6(OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R
aBe selected from halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R ,-OC (=O) N (R
4)
2, or optionally substituted following groups: be selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms.
Formula V compound can be by specifying Z
1And Z
2The following formula representative:
R as formula V
xAnd R
yWhen group constitutes the condensed ring together, preferred R
x/ R
yRing comprises having 0-2 heteroatomic 5-, 6-, 7-or 8-first unsaturated or the undersaturated ring of part, wherein R
x/ R
yOptionally be substituted.This obtains containing the bicyclic ring system of pyridine ring.The example that preferred formula V bicyclic ring is is as follows.
Preferred formula V bicyclic ring is to comprise Va-A, Vb-A, Vc-A, Va-B, Vb-B, Vc-B, Va-D, Vb-D, Vc-D, Va-E, Vb-E, Vc-E, Va-J, Vb-J, Vc-J, Va-K, Vb-K, Vc-K, Va-L, Vb-L, Vc-L, Va-M, Vb-M and Vc-M, most preferably Va-A, Vb-A, Vc-A, Va-B, Vb-B and Vc-B.
In the monocycle pyridine ring system of formula V, preferred R
xGroup comprises hydrogen, alkyl-or dialkyl-7-amino, kharophen or C
1-4Aliphatic group, for example methyl, ethyl, cyclopropyl, sec.-propyl or the tertiary butyl.Preferred R
yGroup comprises T-R
3, wherein T is valency bond or methylene radical, R
3Be-R ,-N (R
4)
2Or-OR.Work as R
3Be-R or-during OR, preferred R is optionally substituted following groups, is selected from C
1-6Aliphatic group, phenyl or 5-6 unit's heteroaryl or heterocyclic ring.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or dialkyl-7-amino, kharophen, optionally substituted phenyl (for example phenyl or halogenophenyl) and methoxymethyl.
In the bicyclic ring system of formula V, by R
xAnd R
yThe ring of Gou Chenging can be substituted or unsubstituted together.The substituting group that is fit to comprises-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, wherein R and R
4Be as defined above.Preferred R
x/ R
yRing substituents comprises-halogen ,-R ,-OR ,-COR ,-CO
2R ,-CON (R
4)
2,-CN or-N (R
4)
2, wherein R replaces or unsubstituted C
1-6Aliphatic group.
The R of formula V
2And R
2' group can constitute the condensed ring together, thereby obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They are following formula V compound for example, has the bicyclic ring system of containing pyrazoles:
The R of formula V
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When the pyrazoles ring system is monocycle, preferred R
2Group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-and two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).Preferred R
2' group is hydrogen.
Preferred formula V ring system is as follows, and it can be substituted as mentioned above, wherein R
2And R
2' constitute optionally substituted indazole ring with the pyrazoles ring; R
xAnd R
yEach is methyl, perhaps R naturally
xAnd R
yConstitute optionally substituted quinoline, isoquinoline 99.9, tetrahydroquinoline or tetrahydroisoquinoline ring with pyridine ring:
When G was ring C, preferred formula V ring C group was phenyl and pyridyl.When last two the adjacent substituting groups of ring C constituted the condensed ring together, ring C was comprised in the bicyclic ring system.Preferred fused rings comprises benzo or pyrido ring.This class ring preferably condenses an ortho position and the position at ring C.The example of preferred two ring C systems comprises naphthyl and isoquinolyl.Preferred R
1Group comprises-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Work as R
1Be optionally substituted C
1-6During aliphatic group, most preferred optional substituting group is a halogen.Preferred R
1Examples of groups comprises-CF
3,-Cl ,-F ,-CN ,-COCH
3,-OCH
3,-OH ,-CH
2CH
3,-OCH
2CH
3,-CH
3,-CF
2CH
3, cyclohexyl, the tertiary butyl, sec.-propyl, cyclopropyl ,-C ≡ CH ,-C ≡ C-CH
3,-SO
2CH
3,-SO
2NH
2,-N (CH
3)
3,-CO
2CH
3,-CONH
2,-NHCOCH
3,-OC (O) NH
2,-NHSO
2CH
3With-OCF
3
Ring C goes up preferred R
5Substituting group comprises when existing-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2With-N (R
4) SO
2R.Preferred R
5Substituting group comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).The preferred R of this class
5Substituent example comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NHMe ,-NMe
2,-OEt, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl and-CO
2Et.
When G was ring D, preferred formula V ring D monocycle comprised and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.When last two the adjacent substituting groups of ring D constituted the condensed ring together, the ring d system was a bicyclic.Preferred formula V ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.The example of preferred two ring d systems comprises naphthyl and isoquinolyl.
Formula V ring D go up preferred substituted comprise following one or more: halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R, replacement or unsubstituted group, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Preferred R
5Substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted group are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
That preferred formula V compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring, R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, R
yBe T-R
3, perhaps R
xAnd R
yConstitute the unsaturated or undersaturated 0-2 of having of part the ring that encircles nitrogen of optionally substituted 5-7 unit with intervenient atom;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula V compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN; Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xBe hydrogen or methyl, R
yBe-R ,-N (R
4)
2Or-OR, perhaps R
xAnd R
yConstitute benzo ring or 5-7 undersaturated carbocyclic ring of unit's part and ring with intervenient atom, described benzo or carbocyclic ring and ring optionally by-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted group, be selected from aryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom;
(d) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula V compound has one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN; Perhaps encircling D is optionally substituted ring, is selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, isoquinolyl, quinolyl or naphthyl;
(b) R
xBe hydrogen or methyl, R
yBe methyl, methoxymethyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or optionally substituted group, be selected from 2-pyridyl, 4-pyridyl, piperidyl or phenyl, perhaps R
xAnd R
yConstitute optionally substituted benzo ring or 6-undersaturated carbocyclic ring of unit's part and ring with intervenient atom, optionally by halogen, CN, oxo, C
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl replace;
(c) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(d) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).
Representative formula V compound is as shown in table 4 below.
Table 4
In another embodiment, the invention provides composition, comprise formula V compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, comprises to comprise formula V compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula V compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula V compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula V compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula V compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula V compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula V compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise formula V compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises formula V compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
Another kind method relates to GSK-3, Aurora or the CDK-2 activity that suppresses in the biological specimen, and this method comprises the formula VGSK-3 that makes biological specimen and inhibition GSK-3, Aurora or CDK-2 significant quantity or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora or CDK-2 or the treatment of diseases that alleviates therefrom preferably utilizes aforesaid preferred formula V compound to carry out.
Another embodiment of the invention relates to formula VI compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-VI-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
yBe T-R
3';
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3' be optionally substituted group, be selected from C
1-6Aliphatic group, C
3-10Carbocylic radical, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R is independently selected from hydrogen or optionally substituted group, and described group is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
The preferred R of formula VI
yGroup comprises T-R
3', wherein T is valency bond or methylene radical, R
3' be optionally substituted group, be selected from C
1-6Aliphatic group, C
3-10Carbocylic radical, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms.Preferred R
3' group is optionally substituted group, is selected from C
3-6Carbocylic radical, phenyl or 5-6 unit's heteroaryl or heterocyclic ring.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, morpholinyl, cyclopropyl, cyclohexyl and optionally substituted phenyl, for example phenyl or halogenophenyl.
The R of formula VI
2And R
2' group can constitute the condensed ring together, thereby obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They are following formula VI compound for example, has the bicyclic ring system of containing pyrazoles:
R
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When the pyrazoles ring system is monocycle, the preferred R of formula VI
2Group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-and two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).Preferred R
2' group is hydrogen.
When G was ring C, preferred formula VI ring C group was phenyl and pyridyl.When last two the adjacent substituting groups of ring C constituted the condensed ring together, ring C was comprised in the bicyclic ring system.Preferred fused rings comprises benzo or pyrido ring.This class ring preferably condenses an ortho position and the position at ring C.The example of preferred two ring C systems comprises naphthyl and isoquinolyl.Preferred R
1Group comprises-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Work as R
1Be optionally substituted C
1-6During aliphatic group, most preferred optional substituting group is a halogen.Preferred R
1Examples of groups comprises-CF
3,-Cl ,-F ,-CN ,-COCH
3,-OCH
3,-OH ,-CH
2CH
3,-OCH
2CH
3,-CH
3,-CF
2CH
3, cyclohexyl, the tertiary butyl, sec.-propyl, cyclopropyl ,-C ≡ CH ,-C ≡ C-CH
3,-SO
2CH
3,-SO
2NH
2,-N (CH
3)
2,-CO
2CH
3,-CONH
2,-NHCOCH
3,-OC (O) NH
2,-NHSO
2CH
3With-OCF
3
Ring C goes up preferred R
5Substituting group comprises when existing-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2With-N (R
4) SO
2R.Preferred R
5Substituting group comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).The preferred R of this class
5Substituent example comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NHMe ,-NMe
2,-OEt, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl and-CO
2Et.
When G was ring D, preferred formula VI ring D monocycle comprised and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.When last two the adjacent substituting groups of ring D constituted the condensed ring together, the ring d system was a bicyclic.Preferred formula VI ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.The example of preferred two ring d systems comprises naphthyl and isoquinolyl.
Formula VI ring D go up preferred substituted comprise following one or more: halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted following groups, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Preferred ring D substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted group are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
That preferred formula VI compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is selected from phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring, R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
yBe T-R
3', wherein T is valency bond or methylene radical;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula VI compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN; Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
yBe T-R
3', wherein T is valency bond or methylene radical, R
3' be optionally substituted group, be selected from C
1-6Aliphatic group, C
3-6Carbocylic radical, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom;
(d) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula VI compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
yBe T-R
3', wherein T is valency bond or methylene radical, R
3' be optionally substituted group, be selected from C
1-4Aliphatic group, C
3-6Carbocylic radical, phenyl or 5-6 unit's heteroaryl or heterocyclic ring;
(b) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN; Perhaps encircling D is optionally substituted ring, is selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, isoquinolyl, quinolyl or naphthyl;
(c) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(d) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).
Another embodiment of the invention relates to formula VIa compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-VI-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R by formula VIa
2And R
2' the preferred ring that constitutes of group comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They are following formula VIa compound for example, has the bicyclic ring system of containing pyrazoles:
R
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When G was ring C, preferred formula VIa ring C group was phenyl and pyridyl.When last two the adjacent substituting groups of ring C constituted the condensed ring together, ring C was comprised in the bicyclic ring system.Preferred fused rings comprises benzo or pyrido ring.This class ring preferably condenses an ortho position and the position at ring C.The example of preferred two ring C systems comprises naphthyl and isoquinolyl.Preferred R
1Group comprises-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Work as R
1Be optionally substituted C
1-6During aliphatic group, most preferred optional substituting group is a halogen.Preferred R
1Examples of groups comprises-CF
3,-Cl ,-F ,-CN ,-COCH
3,-OCH
3,-OH ,-CH
2CH
3,-OCH
2CH
3,-CH
3,-CF
2CH
3, cyclohexyl, the tertiary butyl, sec.-propyl, cyclopropyl ,-C ≡ CH ,-C ≡ C-CH
3,-SO
2CH
3,-SO
2NH
2,-N (CH
3)
2,-CO
2CH
3,-CONH
2,-NHCOCH
3,-OC (O) NH
2,-NHSO
2CH
3With-OCF
3
Ring C goes up preferred R
5Substituting group comprises when existing-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2With-N (R
4) SO
2R.Preferred R
5Substituting group comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).The preferred R of this class
5Substituent example comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NHMe ,-NMe
2,-OEt, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl and-CO
2Et.
When G was ring D, preferred formula VIa ring D monocycle comprised and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.When last two the adjacent substituting groups of ring D constituted the condensed ring together, the ring d system was a bicyclic.Preferred formula VIa ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.The example of preferred two ring d systems comprises naphthyl and isoquinolyl.
Formula VIa ring D go up preferred substituted comprise following one or more: halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted following groups, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Preferred ring D substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted group are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
That preferred formula VIa compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring, R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
Preferred formula VIa compound has-individual or a plurality of, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN; Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
2And R
2' constitute with intervenient atom and to replace or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(c) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula VIa compound has one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN; Perhaps encircling D is optionally substituted ring, is selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, isoquinolyl, quinolyl or naphthyl;
(b) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(c) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).
Representative formula VI and VIa compound are described in table 5 below.
Table 5
In another embodiment, the invention provides composition, comprise formula VI or VIa compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, comprises to comprise formula VI or VIa compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula VI or VIa compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula VI or VIa compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula VI or VIa compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula VI or VIa compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula VI or VIa compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula VI or VIa compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise formula VI or VIa compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises formula VI or VIa compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HIV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
Another kind method relates to GSK-3, Aurora or the CDK-2 activity that suppresses in the biological specimen, and this method comprises the formula VI that makes biological specimen and inhibition GSK-3, Aurora or CDK-2 significant quantity or VIa GSK-3 or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora or CDK-2 or the treatment of diseases that alleviates therefrom preferably utilizes aforesaid preferred formula VI or VIa compound to carry out.
Another embodiment of the invention relates to formula VII compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
yBe hydrogen or T-R
3";
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3" be selected from optionally substituted group, be selected from C
3-10Carbocylic radical, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R
9Be selected from-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
The preferred R of formula VII
yGroup comprises T-R
3", wherein T is valency bond or methylene radical.Preferred R
3" group comprises optionally substituted following groups, is selected from C
3-6Carbocylic radical, phenyl or 5-6 unit's heteroaryl or heterocyclic ring.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, cyclopropyl and optionally substituted phenyl, for example phenyl or halogenophenyl.
The R of formula VII
2And R
2' group can constitute the condensed ring together, thereby obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They are following formula VII compound for example, has the bicyclic ring system of containing pyrazoles:
R
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When the pyrazoles ring system of formula VII is monocycle, preferred R
2Group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-and two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).Preferred R
2' group is hydrogen.
When G was ring C, preferred formula VII ring C group was phenyl and pyridyl.When last two the adjacent substituting groups of ring C constituted the condensed ring together, ring C was comprised in the bicyclic ring system.Preferred fused rings comprises benzo or pyrido ring.This class ring preferably condenses an ortho position and the position at ring C.The example of preferred two ring C systems comprises naphthyl and isoquinolyl.Preferred R
1Group comprises-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Work as R
1Be optionally substituted C
1-6During aliphatic group, most preferred optional substituting group is a halogen.Preferred R
1Examples of groups comprises-CF
3,-Cl ,-F ,-CN ,-COCH
3,-OCH
3,-OH ,-CH
2CH
3,-OCH
2CH
3,-CH
3,-CF
2CH
3, cyclohexyl, the tertiary butyl, sec.-propyl, cyclopropyl ,-C ≡ CH ,-C ≡ C-CH
3,-SO
2CH
3,-SO
2NH
2,-N (CH
3)
2,-CO
2CH
3,-CONH
2,-NHCOCH
3,-OC (O) NH
2,-NHSO
2CH
3With-OCF
3
Ring C goes up preferred R
5Substituting group comprises when existing-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2With-N (R
4) SO
2R.Preferred R
5Substituting group comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).The preferred R of this class
5Substituent example comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NHMe ,-NMe
2,-OEt, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl and-CO
2Et.
When G was ring D, preferred formula VII ring D monocycle comprised and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.When last two the adjacent substituting groups of ring D constituted the condensed ring together, the ring d system was a bicyclic.Preferred formula VII ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.The example of preferred two ring d systems comprises naphthyl and isoquinolyl.
Formula VII ring D go up preferred substituted comprise following one or more: halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted following groups, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Preferred ring D substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted following groups are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
That preferred formula VII compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring, R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Perhaps encircling D is optionally substituted following ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
yBe T-R
3", wherein T is valency bond or methylene radical;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula VII compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN; Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
yBe T-R
3", wherein T is valency bond or methylene radical, R
3" be optionally substituted following groups, be selected from C
3-6Carbocylic radical, C
6-10Aryl or 5-6 unit's heteroaryl or heterocyclic ring;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted group, be selected from aryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom;
(d) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula VII compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
yBe T-R
3", wherein T is valency bond or methylene radical, R
3" be optionally substituted group, be selected from phenyl or 5-6 unit's heteroaryl or heterocyclic ring;
(b) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN; Perhaps encircling D is optionally substituted ring, is selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, isoquinolyl, quinolyl or naphthyl;
(c) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(d) ring D is by oxo or R
5Replace, wherein each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).
Representative formula VII compound is described in table 6 below.
Table 6
In another embodiment, the invention provides composition, comprise formula VII compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, comprises to comprise formula VII compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula VII compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula VII compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula VII compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula VII compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula VII compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula VII compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise formula VII compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises formula VII compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HIV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
Another kind method relates to GSK-3, Aurora or the CDK-2 activity that suppresses in the biological specimen, and this method comprises the formula VIIGSK-3 that makes biological specimen and inhibition GSK-3, Aurora or CDK-2 significant quantity or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora or CDK-2 or the treatment of diseases that alleviates thus preferably utilizes aforesaid preferred formula VII compound to carry out.
Another embodiment of the invention relates to formula VIII compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Z
1Be N or CR
9, Z
2Be N or CH, Z
3Be N or CR
x, its condition is Z
1And Z
3One of be nitrogen;
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xBe T-R
3
T is valency bond or C
1-4Alkylidene chain;
R
2And R
2' be independently selected from-R ,-T-W-R
6, perhaps R
2And R
2' constitute condensed, 5-8 unit, unsaturated or part is undersaturated, have the ring that 0-3 is selected from the ring hetero atom of nitrogen, oxygen or sulphur, wherein by R with intervenient atom
2And R
2' on the described fused rings that constitutes each commutable carbon by halogen, oxo ,-CN ,-NO
2,-R
7Or-V-R
6Replace, by R
2And R
2' on the described ring that constitutes any commutable nitrogen by R
4Replace;
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R
9Be selected from-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
Therefore, the present invention relates to formula VIIIa as follows, VIIIb, VIIIc and VIIId compound:
The preferred R of formula VIII
xGroup comprises T-R
3, wherein T is valency bond or methylene radical, R
3Be CN ,-R or-OR.Work as R
3Be-during R, preferred R
3Group comprises optionally substituted group, is selected from C
1-6Aliphatic group, phenyl or 5-6 unit's heteroaryl or heterocyclic ring.Work as R
3Be-during OR, preferred R group comprises optionally substituted C
1-6Aliphatic group, for example alkyl-or dialkyl-7-amino alkyl and aminoalkyl group.Preferred R
xExample comprise kharophen, CN, piperidyl, piperazinyl, phenyl, pyridyl, imidazoles-1-base, imidazoles-2-base, cyclohexyl, cyclopropyl, methyl, ethyl, sec.-propyl, the tertiary butyl, NH
2CH
2CH
2NH and NH
2CH
2CH
2O.
The preferred R of formula VIII
9Group comprises R, OR and N (R when existing
4)
2Preferred R
9Example comprise methyl, ethyl, NH
2, NH
2CH
2CH
2NH, N (CH
3)
2CH
2CH
2NH, N (CH
3)
2CH
2CH
2O, (piperidines-1-yl) CH
2CH
2O and NH
2CH
2CH
2O.
The R of formula VIII
2And R
2' group can constitute the condensed ring together, thereby obtain containing the bicyclic ring system of pyrazoles ring.Preferred fused rings comprises undersaturated 6-unit's carbocyclic ring of benzo, pyrido, Mi Dingbing and part and ring.They are following formula VIII compound for example, has the bicyclic ring system of containing pyrazoles:
The R of formula VIII
2/ R
2' on the fused rings preferred substituted comprise following one or more :-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2With-CO (C
1-4Alkyl), (C wherein
1-4Alkyl) is straight chain, side chain or cyclic alkyl.Preferably, (C
1-4Alkyl) is methyl.
When the pyrazoles ring system of formula VIII is monocycle, preferred R
2Group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-and two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).Preferred R
2' group is hydrogen.
When G was ring C, preferred formula VIII ring C group was phenyl and pyridyl.When last two the adjacent substituting groups of ring C constituted the condensed ring together, ring C was comprised in the bicyclic ring system.Preferred fused rings comprises benzo or pyrido ring.This class ring preferably condenses an ortho position and the position at ring C.The example of preferred two ring C systems comprises naphthyl and isoquinolyl.Preferred R
1Group comprises-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Work as R
1Be optionally substituted C
1-6During aliphatic group, most preferred optional substituting group is a halogen.Preferred R
1Examples of groups comprises-CF
3,-Cl ,-F ,-CN ,-COCH
3,-OCH
3,-OH ,-CH
2CH
3,-OCH
2CH
3,-CH
3,-CF
2CH
3, cyclohexyl, the tertiary butyl, sec.-propyl, cyclopropyl ,-C ≡ CH ,-C ≡ C-CH
3,-SO
2CH
3,-SO
2NH
2,-N (CH
3)
2,-CO
2CH
3,-CONH
2,-NHCOCH
3,-OC (O) NH
2,-NHSO
2CH
3With-OCF
3
Ring C goes up preferred R
5Substituting group comprises when existing-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2With-N (R
4) SO
2R.Preferred R
5Substituting group comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).The preferred R of this class
5Substituent example comprises-Cl ,-F ,-CN ,-CF
3,-NH
2,-NHMe ,-NMe
2,-OEt, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl and-CO
2Et.
When G was ring D, preferred formula VIII ring D monocycle comprised and replacing and unsubstituted phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl and morpholine basic ring.When last two the adjacent substituting groups of ring D constituted the condensed ring together, the ring d system was a bicyclic.Preferred formula VIII ring D two rings comprise 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl and naphthyl.The example of preferred two ring d systems comprises naphthyl and isoquinolyl.
Formula VIII ring D goes up preferred R
5Substituting group comprise halogen, oxo, CN ,-NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted following groups, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Preferred R
5Substituting group comprises-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted group are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.Ring D substituent example comprises-OH, phenyl, methyl, CH
2OH, CH
2CH
2OH, pyrrolidyl, OPh, CF
3, C ≡ CH, Cl, Br, F, I, NH
2, C (O) CH
3, sec.-propyl, the tertiary butyl, SEt, OMe, N (Me)
2, methylene-dioxy and ethylenedioxy.
That preferred formula VIII compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring, R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xBe T-R
3, wherein T is valency bond or methylene radical;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
That preferred formula VIII compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN; Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xBe T-R
3, wherein T is valency bond or methylene radical, R
3Be CN ,-R or-OR;
(c) R
2' be hydrogen, R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl or C
1-6Aliphatic group, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom;
(d) each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula VIII compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
xBe T-R
3, wherein T is valency bond or methylene radical, R
3Be-R or-OR, wherein R is optionally substituted group, is selected from C
1-6Aliphatic alkyl, phenyl or 5-6 unit's heteroaryl or heterocyclic ring;
(b) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN; Perhaps encircling D is optionally substituted ring, is selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, isoquinolyl, quinolyl or naphthyl;
(c) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-N (R
4)
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2,-O (C
1-4Alkyl) ,-CO
2(C
1-4Alkyl) ,-CN ,-SO
2(C
1-4Alkyl) ,-SO
2NH
2,-OC (O) NH
2,-NH
2SO
2(C
1-4Alkyl) ,-NHC (O) (C
1-4Alkyl) ,-C (O) NH
2Or-CO (C
1-4Alkyl) replaces, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(d) each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group);
(e) R
9Be R, OR or N (R
4)
2
Representative formula VIII compound is as shown in table 7 below.
Table 7
In another embodiment, the invention provides composition, comprise formula VIII compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, comprises to comprise formula VIII compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula VIII compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula VIII compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula VIII compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula VIII compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula VIII compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula VIII compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
One aspect of the present invention relates to the active method of CDK-2 that suppresses among the patient, comprises to comprise formula VIII compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the CDK-2 inhibitor for treating on the other hand, described method comprises the step that comprises formula VIII compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, Alzheimer, restenosis, vasculogenesis, glomerulonephritis, cytomegalovirus, HV, bleb, psoriasis, atherosclerosis, alopecia and autoimmune disorders, for example rheumatoid arthritis.
Another kind method relates to GSK-3, Aurora or the CDK-2 activity that suppresses in the biological specimen, and this method comprises the formula VIII GSK-3 that makes biological specimen and inhibition GSK-3, Aurora or CDK-2 significant quantity or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3, Aurora or CDK-2 or the treatment of diseases that alleviates therefrom preferably utilizes aforesaid preferred formula VIII compound to carry out.
Above-mentioned formula I compound contains and carries R
2And R
2' substituent pyrazoles ring.When seeking the inhibitor of further protein kinase G SK and Aurora, the applicant seeks to replace with other heteroaromatic rings the pyrazoles part of formula I.Find that one of how effective pyrazoles ring surrogate is a triazole ring.Inhibitor with this triazole ring is structurally similar to formula I compound, is represented by general formula I X:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Z
1Be nitrogen or CR
9, Z
2Be nitrogen or CH, its condition is Z
1And Z
2Have at least one to be nitrogen;
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yWith intervenient atom constitute condensed, unsaturated or part is undersaturated, have 0-3 be selected from oxygen, sulphur or nitrogen ring hetero atom, 5-8 unit ring, wherein by R
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace, by R
xAnd R
yAny commutable nitrogen is by R on the described ring that constitutes
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2Be-R or-T-W-R
6
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(optionally substituted C
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R
9Be selected from-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
Can there be the alternative tautomerism type in formula IX compound, shown in the following tautomer 1-3.Except as otherwise noted, the representation of any of these tautomer all means and comprises other two kinds.
The R of formula IX
xAnd R
yGroup can constitute the condensed ring together, obtains containing the bicyclic ring system that encircles A.Preferred R
x/ R
yRing comprises having 0-2 the first unsaturated or undersaturated ring of part of heteroatomic 5-, 6-, 7-or 8-, wherein said R
x/ R
yRing optionally is substituted.Shown in the following Compound I of the example X-A to IX-DD of ring A system, Z wherein
1Be nitrogen or C (R
9), Z
2Be nitrogen or C (H).
Preferred formula IX two encircles the A systems and comprises IX-A, IX-B, IX-C, IX-D, IX-E, IX-F, IX-G, IX-H, IX-I, IX-J, IX-K, IX-L and IX-M, more preferably IX-A, IX-B, IX-C, IX-F and IX-H, most preferably IX-A, IX-B and IX-H.
In the monocycle A of formula IX system, preferred R
xGroup comprises hydrogen, alkyl-or dialkyl-7-amino, kharophen or C
1-4Aliphatic group, for example methyl, ethyl, cyclopropyl, sec.-propyl or the tertiary butyl.Preferred R
yGroup comprises T-R when existing
3, wherein T is valency bond or methylene radical, R
3Be-R ,-N (R
4)
2Or-OR.Preferred R
yExample comprise 2-pyridyl, 4-pyridyl, piperidyl, methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or dialkyl-7-amino, kharophen, optionally substituted phenyl (for example phenyl or halogenophenyl) and methoxymethyl.
In the two ring A systems of formula IX, by R
xAnd R
yThe ring of Gou Chenging can be substituted or unsubstituted together.The substituting group that is fit to comprises-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, wherein R and R
4Be as above defined about formula IX compound.Preferred R
x/ R
yRing substituents comprises-halogen ,-R ,-OR ,-COR ,-CO
2R ,-CON (R
4)
2,-CN or-N (R
4)
2, wherein R replaces or unsubstituted C
1-6Aliphatic group.
The preferred R of formula IX
2Group comprises hydrogen, C
1-4The phenyl that aliphatic group, alkoxy carbonyl, (not) replace, hydroxyalkyl, alkoxyalkyl, aminocarboxyl, list-and two-alkyl amino-carbonyl, aminoalkyl group, alkylamino alkyl, dialkyl aminoalkyl, phenyl amino carbonyl and (N-heterocyclic radical) carbonyl.The preferred R of this class
2Substituent example comprises methyl, cyclopropyl, ethyl, sec.-propyl, propyl group, the tertiary butyl, cyclopentyl, phenyl, CO
2H, CO
2CH
3, CH
2OH, CH
2OCH
3, CH
2CH
2CH
2OH, CH
2CH
2CH
2OCH
3, CH
2CH
2CH
2OCH
2Ph, CH
2CH
2CH
2NH
2, CH
2CH
2CH
2NHCOOC (CH
3)
3, CONHCH (CH
3)
2, CONHCH
2CH=CH
2, CONHCH
2CH
2OCH
3, CONHCH
2Ph, CONH (cyclohexyl), CON (Et)
2, CON (CH
3) CH
2Ph, CONH (n-C
3H
7), CON (Et) CH
2CH
2CH
3, CONHCH
2CH (CH
3)
2, CON (n-C
3H
7)
2, CO (3-methoxymethyl tetramethyleneimine-1-yl), CONH (3-tolyl), CONH (4-tolyl), CONHCH
3, CO (morpholine-1-yl), CO (4-methylpiperazine-1-yl), CONHCH
2CH
2OH, CONH
2And CO (piperidines-1-yl).About the preferred R of formula IX compound
2Group is a hydrogen.
Be particularly useful for treating the disease mediated embodiment of GSK-3 and relate to formula X compound, wherein A is a pyrimidine ring:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 0-3 is selected from the ring hetero atom of oxygen, sulphur or nitrogen, wherein by R with intervenient atom
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace, by R
xAnd R
yAny commutable nitrogen is by R on the described ring that constitutes
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2Be-R or-T-W-R
6
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(the C that selectivity replaces
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
Formula X compound is structurally similar to formula II compound, but the pyrazoles loop section is partly replaced by triazole ring.The preferred R of formula X
2, R
x, R
yWith encircling the C group is as above described about formula II compound.That preferred formula X compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, R
yBe T-R
3, perhaps R
xAnd R
yWith intervenient atom constitute the optionally substituted 0-2 of having ring nitrogen, the unsaturated or undersaturated ring of part of 5-7 unit;
(c) R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6
(d) R
2Be hydrogen or replacement or unsubstituted group, be selected from aryl, heteroaryl or C
1-6Aliphatic group.
That preferred formula X compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring;
(b) R
xBe hydrogen or methyl, R
yBe-R ,-N (R
4)
2Or-OR, perhaps R
xAnd R
yConstitute 5-7 unit unsaturated or undersaturated carbocyclic ring of part and ring with intervenient atom, optionally by-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN;
(d) R
2Be hydrogen or replacement or unsubstituted group, be selected from aryl or C
1-6Aliphatic group;
(e) each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R.
And then preferred formula X compound has one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring;
(b) R
xBe hydrogen or methyl, R
yBe methyl, methoxymethyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or optionally substituted following groups, be selected from 2-pyridyl, 4-pyridyl, piperidyl or phenyl, perhaps R
xAnd R
yConstitute optionally substituted benzo ring or undersaturated 6-unit's carbocyclic ring of part and ring with intervenient atom;
(c) R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN;
(d) R
2Be hydrogen or C
1-6Aliphatic group;
(e) each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group).
Another embodiment of the invention relates to formula XI compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
xAnd R
yConstitute condensed benzo ring or 5-8 unit's carbocyclic ring and ring with intervenient atom, wherein by R
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2Be-R or-T-W-R
6
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(the C that selectivity replaces
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen.
Formula XI compound is structurally similar to the formula III compound, but the pyrazoles loop section is partly replaced by triazole ring.The preferred R of formula XI
2, R
x, R
yWith encircling the D group is as above described about the formula III compound.That preferred formula XI compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring D is optionally substituted following ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xAnd R
yConstitute optionally substituted benzo ring or 5-7 unit's carbocyclic ring and ring with intervenient atom;
(c) R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group.
That preferred formula XI compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring D is optionally substituted following ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xAnd R
yConstitute benzo ring or 5-7 unit's carbocyclic ring and ring with intervenient atom, optionally by-R, oxo, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl or C
1-6Aliphatic group;
(d) each R
5Be independently selected from halogen, oxo, CN, NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R, replacement or unsubstituted following groups, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.
And then preferred formula XII compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
xAnd R
yConstitute benzo ring or 6 yuan of undersaturated carbocyclic rings of part and ring with intervenient atom, optionally by halogen, CN, oxo, C
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl replace;
(b) each R
5Be independently selected from-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R, replacement or unsubstituted group are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group;
(c) R
2Be hydrogen or C
1-6Aliphatic group.
Another embodiment of the invention relates to formula XII compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 1-3 is selected from the ring hetero atom of oxygen, sulphur or nitrogen with intervenient atom, any commutable carbon is by oxo or T-R on the wherein said fused rings
3Replace, any commutable nitrogen is by R on the described ring
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2Be-R or-T-W-R
6
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(the C that selectivity replaces
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen.
Formula XII compound is structurally similar to formula IV compound, but the pyrazoles loop section is partly replaced by triazole ring.The preferred R of formula XII
2, R
x, R
yWith encircling the D group is as above described about formula IV compound.That preferred formula XII compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, R
yBe T-R
3, perhaps R
xAnd R
yIt is unsaturated or part is undersaturated, have the ring of 1-2 ring hetero atom to constitute optionally substituted 5-7 unit with intervenient atom;
(c) R
2Be hydrogen or replacement or unsubstituted group, be selected from aryl, heteroaryl or C
1-6Aliphatic group.
That preferred formula XII compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xBe hydrogen or methyl, R
yBe-R ,-N (R
4)
2Or-OR, perhaps R
xAnd R
yConstitute the unsaturated or undersaturated ring of part of 5-7 unit with intervenient atom, have 1-2 and encircle nitrogen, wherein said ring optionally by-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl or C
1-6Aliphatic group;
(d) each R
5Be independently selected from halogen, oxo, CN, NO
2,-N (R
4)
2,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2,-N (R
4) SO
2R ,-SR ,-OR ,-C (O) R or replacement or unsubstituted following groups, be selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group.
And then preferred formula XII compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
xAnd R
yIt is unsaturated or part is undersaturated, have 1-2 ring that encircles nitrogen, optionally by halogen, CN, oxo, C to constitute 6-unit with intervenient atom
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl replace;
(b) each R
5Be independently selected from-halogen ,-CN ,-oxo ,-SR ,-OR ,-N (R
4)
2,-C (O) R or replacement or unsubstituted following groups are selected from 5-6 unit heterocyclic radical, C
6-10Aryl or C
1-6Aliphatic group;
(c) R
2Be hydrogen or C
1-6Aliphatic group.
Another embodiment of the invention relates to formula XIII compound:
Or its pharmaceutically acceptable derivates or prodrug, wherein:
Z
1Be nitrogen, CR
aOr CH, Z
2Be nitrogen or CH, its condition is Z
1And Z
2One of be nitrogen;
G is ring C or ring D;
Ring C is selected from phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl or 1,2, and 4-triazine basic ring, wherein said ring C have one or two and independently be selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently by-R
5Replace, ring C last two adjacent substituting groups constitute condensed, unsaturated or part is undersaturated, have 0-3 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively, described fused rings optionally by halogen, oxo or-R
8Replace;
Ring D is 5-7 unit monocycle or 8-10 unit two rings, is selected from aryl, heteroaryl, heterocyclic radical or carbocylic radical, and described heteroaryl or heterocyclic ring have 1-4 ring hetero atom that is selected from nitrogen, oxygen or sulphur, wherein encircle D on any commutable ring carbon by oxo or-R
5Replace quilt-R on any commutable ring nitrogen
4Replace, its condition is when ring D is hexa-atomic aryl or heteroaryl ring ,-R
5On each ortho position carbon of ring D is hydrogen;
R
1Be selected from-halogen ,-CN ,-NO
2, T-V-R
6, phenyl, 5-6 unit heteroaryl ring, 5-6 unit's heterocyclic ring or C
1-6Aliphatic group, described phenyl, heteroaryl and heterocyclic ring are optionally replaced by three groups at the most separately, substituting group be independently selected from halogen, oxo or-R
8, described C
1-6Aliphatic group is optionally replaced by halogen, cyano group, nitro or oxygen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xAnd R
yBe independently selected from T-R
3, perhaps R
xAnd R
yWith intervenient atom constitute condensed, unsaturated or part is undersaturated, have 0-3 be selected from oxygen, sulphur or nitrogen ring hetero atom, 5-8 unit ring, wherein by R
xAnd R
yAny commutable carbon is by oxo or T-R on the described fused rings that constitutes
3Replace, by R
xAnd R
yAny commutable nitrogen is by R on the described ring that constitutes
4Replace;
T is valency bond or C
1-4Alkylidene chain;
R
2Be-R or-T-W-R
6
R
3Be selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-COCH
2COR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
7)
2,-SO
2N (R
7)
2,-OC (=O) R ,-N (R
7) COR ,-N (R
7) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
7) CON (R
7)
2,-N (R
7) SO
2N (R
7)
2,-N (R
4) SO
2R or-OC (=O) N (R
7)
2
Each R is independently selected from hydrogen or optionally substituted following groups, is selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms;
Each R
4Be independently selected from-R
7,-COR
7,-CO
2(the C that selectivity replaces
1-6Aliphatic group) ,-CON (R
7)
2Or-SO
2R
7, two R on the perhaps same nitrogen
4Constitute 5-8 unit's heterocyclic radical or heteroaryl ring together;
Each R
5Be independently selected from-R ,-halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-S (O)
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
V is-O-,-S-,-SO-,-SO
2-,-N (R
6) SO
2-,-SO
2N (R
6)-,-N (R
6)-,-CO-,-CO
2-,-N (R
6) CO-,-N (R
6) C (O) O-,-N (R
6) CON (R
6)-,-N (R
6) SO
2N (R
6)-,-N (R
6) N (R
6)-,-C (O) N (R
6)-,-OC (O) N (R
6)-,-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-or-C (R
6)
2N (R
6) CON (R
6)-;
W is-C (R
6)
2O-,-C (R
6)
2S-,-C (R
6)
2SO-,-C (R
6)
2SO
2-,-C (R
6)
2SO
2N (R
6)-,-C (R
6)
2N (R
6)-,-CO-,-CO
2-,-C (R
6) OC (O)-,-C (R
6) OC (O) N (R
6)-,-C (R
6)
2N (R
6) C (O)-,-C (R
6)
2N (R
6) C (O) O-,-C (R
6)=NN (R
6)-,-C (R
6)=N-O-,-C (R
6)
2N (R
6) N (R
6)-,-C (R
6)
2N (R
6) SO
2N (R
6)-,-C (R
6)
2N (R
6) CON (R
6)-or-CON (R
6)-;
Each R
6Be independently selected from hydrogen or optionally substituted C
1-4Aliphatic group, two R on the perhaps same nitrogen-atoms
6Constitute 5-6 unit's heterocyclic radical or heteroaryl ring with this nitrogen-atoms;
Each R
7Be independently selected from hydrogen or optionally substituted C
1-6Aliphatic group, two R on the perhaps same nitrogen
7Constitute 5-8 unit's heterocyclic radical or heteroaryl ring with this nitrogen;
Each R
8Be independently selected from optionally substituted C
1-4Aliphatic group ,-OR
6,-SR
6,-COR
6,-SO
2R
6,-N (R
6)
2,-N (R
6) N (R
6)
2,-CN ,-NO
2,-CON (R
6)
2Or-CO
2R
6
R
aBe selected from halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R ,-OC (=O) N (R
4)
2, or optionally substituted following groups, be selected from C
1-6Aliphatic group, C
6-10Aryl, have the heteroaryl ring of 5-10 annular atoms or have the heterocyclic ring of 5-10 annular atoms.
Formula XIII compound can be by specifying Z
1And Z
2The following formula representative:
Formula XIII compound is structurally similar to formula V compound, but the pyrazoles loop section is partly replaced by triazole ring.The preferred R of formula XIII
2, R
x, R
y, R
aWith encircling the G group is as above described about formula V compound.That preferred formula XIII compound has is one or more, the more preferably feature organized down of whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring, R
1Be-halogen, substituted C optionally
1-6Aliphatic group, phenyl ,-COR
6,-OR
6,-CN ,-SO
2R
6,-SO
2NH
2,-N (R
6)
2,-CO
2R
6,-CONH
2,-NHCOR
6,-OC (O) NH
2Or-NHSO
2R
6Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, thienyl, nitrogen heterocyclic heptyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, R
yBe T-R
3, perhaps R
xAnd R
yIt is unsaturated or part is undersaturated, have 0-2 ring that encircles nitrogen to constitute optionally substituted 5-7 unit with intervenient atom;
(c) R
2Be hydrogen or replacement or unsubstituted following groups, be selected from aryl, heteroaryl or C
1-6Aliphatic group.
That preferred formula XIII compound has is one or more, the more preferably feature of group under whole being selected from:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, C
1-6Halogenated aliphatic group, C
1-6Aliphatic group, phenyl or-CN; Perhaps encircling D is optionally substituted ring, be selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, 2,3-dihydro-1H-pseudoindoyl, 2,3-dihydro-1H-indyl, isoquinolyl, quinolyl or naphthyl;
(b) R
xBe hydrogen or methyl, R
yBe-R ,-N (R
4)
2Or-OR, perhaps R
xAnd R
yConstitute benzo ring or 5-7 undersaturated carbocyclic ring of unit's part and ring with intervenient atom, described benzo or carbocyclic ring and ring optionally by-R, halogen ,-OR ,-C (=O) R ,-CO
2R ,-COCOR ,-NO
2,-CN ,-S (O) R ,-SO
2R ,-SR ,-N (R
4)
2,-CON (R
4)
2,-SO
2N (R
4)
2,-OC (=O) R ,-N (R
4) COR ,-N (R
4) CO
2(optionally substituted C
1-6Aliphatic group) ,-N (R
4) N (R
4)
2,-C=NN (R
4)
2,-C=N-OR ,-N (R
4) CON (R
4)
2,-N (R
4) SO
2N (R
4)
2,-N (R
4) SO
2R or-OC (=O) N (R
4)
2Replace;
(c) R
2Be hydrogen or replacement or unsubstituted group, be selected from aryl or C
1-6Aliphatic group;
(d) each R
5Be independently selected from-halogen ,-CN ,-NO
2,-N (R
4)
2, substituted C optionally
1-6Aliphatic group ,-OR ,-C (O) R ,-CO
2R ,-CONH (R
4) ,-N (R
4) COR ,-SO
2N (R
4)
2Or-N (R
4) SO
2R, when ring G was ring D, ring D was by oxo or R
5Replace.
And then preferred formula XIII compound has one or more, the more preferably feature of group under whole being selected from:
(a) R
xBe hydrogen or methyl, R
yBe methyl, methoxymethyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl, alkyl-or optionally substituted group, be selected from 2-pyridyl, 4-pyridyl, piperidyl or phenyl, perhaps R
xAnd R
yConstitute optionally substituted benzo ring or 6-undersaturated carbocyclic ring of unit's part and ring with intervenient atom, optionally by halogen, CN, oxo, C
1-6Alkyl, C
1-6Alkoxyl group, (C
1-6Alkyl) carbonyl, (C
1-6Alkyl) alkylsulfonyl, list-or two-alkylamino, list-or two-alkyl amino-carbonyl, list-or two-alkylamino carbon acyloxy or 5-6 unit heteroaryl replace;
(b) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was the naphthyl ring, R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN; Perhaps encircling D is optionally substituted ring, is selected from phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidyl, morpholinyl, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydric quinoline group, isoquinolyl, quinolyl or naphthyl;
(c) R
2Be hydrogen or C
1-6Aliphatic group;
(d) each R
5Be independently selected from-Cl ,-F ,-CN ,-CF
3,-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2,-O (C
1-4Aliphatic group), C
1-4Aliphatic group and-CO
2(C
1-4Aliphatic group), when ring G was ring D, ring D was by oxo or R
5Replace.
Representative formula IX compound is as shown in table 8 below.
In another embodiment, the invention provides composition, comprise formula IX compound and pharmaceutically acceptable carrier.
One aspect of the present invention relates to and suppresses the active method of patient GSK-3, comprises to comprise formula IX compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the GSK-3 inhibitor for treating on the other hand, described method comprises the step that comprises formula IX compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.
Relating to patient to needs on the other hand, to strengthen glycogen synthetic and/or reduce the method for glucose blood levels, comprises to comprise formula IX compound compositions to what described patient gave to treat significant quantity.This method especially can be used for the diabetic subject.
The patient who relates on the other hand needs suppresses the method that excessive phosphorylation tau protein produces, and comprises to comprise formula IX compound compositions to what described patient gave to treat significant quantity.This method especially can be used for stopping or delaying the progress of Alzheimer.
The patient who relates on the other hand needs suppresses beta-catenin white phosphorus acidifying method, comprises to comprise formula IX compound compositions to what described patient gave to treat significant quantity.This method especially can be used for treating schizophrenia.
One aspect of the present invention relates to the active method of Aurora that suppresses among the patient, comprises to comprise formula IX compound compositions to what the patient gave to treat significant quantity.
Relate to the method for the treatment of the disease that is alleviated by the Aurora inhibitor for treating on the other hand, described method comprises the step that comprises formula IX compound compositions of the patient of a kind of like this treatment of needs being given to treat significant quantity.This method especially can be used for treating cancer, for example colon, ovary and mammary cancer.
Another kind method relates to GSK-3 or the Aurora activity that suppresses in the biological specimen, and this method comprises the formula IX GSK-3 that makes biological specimen and inhibition GSK-3 or Aurora significant quantity or Aurora inhibitor or its pharmaceutical composition and contacts.
Every kind of aforesaid method at the inhibition of GSK-3 or Aurora or the treatment of diseases that alleviates therefrom preferably utilizes aforesaid preferred formula IX compound to carry out.
Compound of the present invention can be prepared as following synthetic method, synthetic embodiment described herein and general method well known by persons skilled in the art.
General synthetic method
Following general synthetic method provides a series of general reaction paths that are used to prepare The compounds of this invention.Following method A-F is particularly useful for preparation formula II compound.In most of the cases, ring C is depicted as and carries ortho position R
1Substituent benzyl ring.But, will can obtain having the compound of other rings C group for those skilled in the art's it is evident that by similar manner.The method that is similar to method A-F also can be used for preparing other The compounds of this invention.Following method F-I is particularly useful for preparing formula III or IV compound.
Method A
Method A wherein encircles the general preparation approach that C is the compound of aryl or heteroaryl ring.According to Chem.Pharm.Bull., 30,9,1982, the described similar mode of 3121-3124 can realize the preparation of raw material dichloro pyrimidine 1.According to J.Med.Chem., 38, the described similar mode of 3547-3557 (1995), intermediate
14 chlorine can be replaced by amino-pyrazol or Aminoindazole, obtain intermediate
2Then under the palladium katalysis, use for boric acid ester (boronic ester) introduce ring C (referring to Tetrahedron, 48,37,1992,8117-8126).This method is as described in the following technology.
With 1H-quinazoline-2, (10.0g is 61.7mmol) at POCl for the 4-diketone
3(60ml, 644mmol) and N, accelerine (8ml, 63.1mmol) suspension under refluxing, heat 2h (hour).The POCl that vaporising under vacuum is excessive
3, resistates is poured in the ice, filter collecting precipitation.Thick solid 2,4-two chloro-quinazoline products need not to be further purified and can use.
To 2,4-two chloro-quinazolines (3.3g, and dehydrated alcohol 16.6mmol) (150ml) solution adding 5-methyl isophthalic acid H-pyrazole-3-yl amine (3.2g, 32.9mmol).Mixture is at room temperature stirred 4h, filter and collect the gained precipitation, use washing with alcohol, dry under vacuum, obtain (2-chloro-quinazoline-4-yl)-(5-methyl isophthalic acid H-pyrazole-3-yl)-amine.
(50mg, DMF 0.19mmol) (1.0ml) solution add required aryl for boric acid (0.38mmol), 2M Na to (2-chloro-quinazoline-4-yl)-(5-methyl isophthalic acid H-pyrazole-3-yl)-amine
2CO
3(0.96mmol) and tri-butyl phosphine (0.19mmol).Under nitrogen, disposable adding PdCl
2(dppf) (0.011mmol).Then reaction mixture is heated 5 to 10h down at 80 ℃, be cooled to room temperature, pour in the water (2ml).Filter and collect the gained precipitation, wash with water, through the HPLC purifying.
Method B
Method B to F is described in and at first constructs the approach that ring C and pyrimidine ring part is introduced the pyrazoles ring afterwards.General intermediate is the 4-chloropyrimide
4, it is easily from pyrimidone
3Obtain, shown in method B (i).This reaction sequence generally is applicable to various ring C groups, comprises aliphatic group, aryl, heteroaryl or heterocyclic radical.Referring to J.Med.Chem., 38,3547-3557 (1995).
About quinazoline ring system (R wherein
xAnd R
yConstitute the benzo ring together), useful as intermediates
6Can obtain like this, condensation anthranilic acid or derivatives thereof and benzamidine, as method B (ii) shown in, perhaps condensation Benzoyl chloride and anthranilamide, as method B (iii) shown in.A lot of anthranilic acid, anthranilamide, benzamidine and Benzoyl chloride raw materials that replace can obtain by currently known methods.Referring to Aust.J.Chem., 38,467-474 and J.Med.Chem., 38,3547-3557 (1995).Method B is (iii) as described in the following technology.
At room temperature, to the THF and the CH of anthranilamide (33mmol)
2Cl
2(1: 1,70ml) solution added required Benzoyl chloride (33mmol) and triethylamine (99mmol).With mixture stir about 14h.Filter and collect the gained precipitation, use CH
2Cl
2And water washing, dry under vacuum.Thick 2-benzene carbon amide yl-benzamide can be directly used in next step, need not to be further purified.
At room temperature, ethanol (50ml) solution to above-mentioned crude product (13mmol) adds NaOEt (26mmol).Mixture is heated 48 to 96h under refluxing.Evaporating solvent, resistates is neutralized to pH7 with dense HCl.Filter then and collect product, dry under vacuum, obtain 2-phenyl-3H-quinazoline-4-one, need not to be further purified and can use.
POCl to above-mentioned product (12mmol)
3(120mmol) suspension adds three n-propyl amine (24mmol).Mixture is heated 1h under refluxing.Excessive POCl is removed in evaporation
3After, resistates is dissolved in ethyl acetate, with 1N NaOH (twice) and water (twice) washing.Organic layer is through MgSO
4Drying, the vaporising under vacuum solvent, crude product obtains 4-chloro-2-aryl-quinazoline through purification by flash chromatography (with the hexane wash-out that contains 10% ethyl acetate).
To the DMF of 4-chloro-2-aryl-quinazoline (0.16mmol) (or THF, ethanol) (1ml) solution add required amino-pyrazol or Aminoindazole (0.32mmol).With mixture heating 16h (perhaps in 130-160 ℃ ethanol, heating 16h) in 100 to 110 ℃ DMF (or the THF that refluxes), pour into then in the water (2ml).Filter collecting precipitation, through the HPLC purifying.
Method C
Method D (i)
Aforesaid method C and D (i) adopt 'beta '-ketoester respectively
8With
10As the pyrimidone precursor.If chlorocrotonic acid ester
11---rather than corresponding 'beta '-ketoester
10---with required benzamidine condensation, R on the pyrimidone ring
xAnd R
yThe replacement mode of group will be reversed (Synth.Comm. (1986), 997-1002).The following general technology of these methods is described.
Add sodium ethylate (7.8mmol) to 'beta '-ketoester (5.2mmol) and chlorination amidine (amidinium) ethanol (5ml) solution (5.7mmol).Mixture is heated 7-14h under refluxing.After the evaporation, the gained resistates is water-soluble, be acidified to pH6 with dense HCl, filter then, obtain solid product 2-aryl-3H-pyrimidin-4-one (yield 75-87%), can pass through the flash column chromatography purifying if necessary.Add POCl to this pyrimidone (3.7mmol)
3(4ml) and n-Pr
3N (1.4ml).Mixture is heated 1h under refluxing.Evaporate excessive POCl
3After, resistates is dissolved in ethyl acetate, with 1N NaOH solution (three times) and NaHCO
3(once) washing is through MgSO
4Dry.Go out to desolvate under vacuum, resistates is through the flash column chromatography purifying, and the hexane wash-out with containing 10% ethyl acetate obtains 2-aryl-4-chloro-pyrimidine, is faint yellow soup compound.This crude product can be handled with 3-amino-pyrazol or 3-Aminoindazole, as mentioned above.
Method D (ii)
Aforesaid method D (ii) shows the general way of The compounds of this invention preparation, and for example compound 40, wherein R
yBe N (R
4)
2Referring to Il Farmaco, 52 (1) 61-65 (1997).The displacement of 6-cl radical here is example with the morpholine.This method is as described in the following technology.
Add ethanol (10ml) solution of suitable amidine salt (5mmol) to the solution of 2-methyl-malonic ester (5mmol) and sodium ethylate (15mmol), reactant is heated 2-24h under refluxing.Resistates is water-soluble, with 2N HCl acidifying.Leach the gained precipitation, further pass through purification by flash chromatography (yield 5-35%), obtain pyrimidine dione
37To
37(1.6mmol) add POCl
3(32mmol), make reactant backflow 1h with three n-propyl amine (6.4mmol).Evaporate excessive POCl
3After, resistates is dissolved in ethyl acetate, with 1N NaOH alkalization, separate and contain water, use twice of ethyl acetate extraction.Merge organic phase, dry (sodium sulfate), evaporation.Through purification by flash chromatography, obtain dichloro pyrimidine (
38), be xanchromatic oil, yield 23%.
Will
38Methyl alcohol (0.33mmol) (5ml) solution is handled with amine, is example with morpholine (0.64mmol) here, backflow 1h.Behind the evaporating solvent, resistates obtains the monochloro pyrimidine through purification by flash chromatography
39, be colourless oil, yield 75%.
According to similar to aforesaid method A basically mode with B, can be with the monochloro pyrimidine
39(0.19mmol) with 3-amino-pyrazol or 3-Aminoindazole compound treatment.
Method E
As above shown in the method E, acyl isocyanate
12Can with enamine (enamine) condensation, obtain pyrimidone
9(J.Org.Chem. (1993), 58,414-418; J.Med.Chem. (1992), 35,1515-1520; J.Org.Chem. (1967), 32,213-214).The following general technology of this method is described.
Enamine is according to W.White etc., J.Org.Chem. (1967), 32, the 213-214 preparation.Acyl isocyanate is according to G Bradley etc., J.Med.Chem. (1992), 35, the 1515-1520 preparation.Thereafter linked reaction is deferred to Kawamura etc., J.Org.Chem. (1993), 58, the technology of 414-418.Under 0 ℃ of nitrogen, to tetrahydrofuran (THF) (30ml) solution of enamine (10mmol) go through 5min (minute) drip tetrahydrofuran (THF) (5ml) solution of acyl isocyanate (10mmol).After stirring 0.5h, add acetate (30ml), add ammonium acetate (50mmol) then.Make mixture backflow 2h, remove tetrahydrofuran (THF) continuously.Reactant is cooled to room temperature, pours in the water (100ml).Filtering-depositing, water and ether washing, drying obtains 2-aryl-3H-pyrimidin-4-one.
Method F
Method F shows the general way of The compounds of this invention preparation, wherein R
xAnd R
yConstitute together and have 1-3 unsaturated, the saturated or undersaturated ring of heteroatomic 5-8 unit's part.2-aminocarboxylic acid, for example 2-amino-nicotinic acid
13With acyl chlorides 7 condensations, De is Dao oxazinone
14Will
14Handle with ammonium hydroxide, obtain benzamide
15, the latter can cyclisation be 2-(replacement)-pyrido [2,3-d] [1,3] pyrimidin-4-one
16The following technology of this method is described.
To the 2-amino-nicotinic acid (2.04g, 14.76mmol) 20ml pyridine solution drip 2-(trifluoromethyl) Benzoyl chloride (4.2ml, 29.2mmol).Reaction mixture is heated 30min down at 158 ℃, be cooled to room temperature then.Pour reactant into 200ml water, have oil to generate, stir after fixing.Solid is collected in vacuum filtration, water and diethyl ether washing.With the product drying, obtain 2-(2-trifluoromethyl-phenyl)-pyrido [2,3-d] [1,3] oxazine-4-ketone (2.56g, 60% productive rate), need not to be further purified and promptly can be used for next step.
At room temperature, [1,3] oxazine-4-ketone (2.51g) stirs in 30% ammonium hydroxide (25ml) and spends the night with 2-(2-trifluoromethyl-phenyl)-pyrido [2,3-d].Filtration gained precipitation, water and diethyl ether flushing.To be deposited in dried overnight under 50 ℃ of vacuum, obtain 2-(2-trifluoromethyl-benzamido)-niacinamide (850mg, 33%).
(800mg 2.6mmol) is dissolved in 10ml ethanol with 2-(2-trifluoromethyl-benzamido)-niacinamide.(435mg 5.2mmol), is heated to backflow 16h to add potassium ethylate to this solution.Evaporation reaction mixture obtains gummy residue in a vacuum, and it is water-soluble, is acidified to pH7 with 10% sodium pyrosulfate.Filtration gained precipitation, dry under 50 ℃ of vacuum, obtain 2-(2-trifluoromethyl-phenyl)-3H-pyrido [2,3-d] pyrimidin-4-one.
Method G
Method G is similar to aforesaid method B (i).The following general technology of this method is described.
(1g 3.43mmol) is suspended in the phosphoryl chloride (4ml), and reaction mixture is stirred 3h down at 110 ℃ with 2-(3,4-two chloro-phenyl)-3H-quinazoline-4-one.Evaporating solvent is used ice-cold NaHCO carefully with resistates then
3Saturated aqueous solution is handled.Solid collected by filtration with the ether washing, obtains 4-chloro-2-(3,5-two chloro-phenyl)-quinazoline, is white solid (993mg, 93%).
To 4-chloro-2-(3,5-two chloro-phenyl)-quinazoline (400mg, THF 1.29mmol) (30ml) solution add the 3-amino-5-methylpyrazole (396mg, 2.58mmol), with reaction mixture 65 ℃ of following heated overnight.Evaporating solvent is developed resistates with ethyl acetate then, filters, and with the small amount of ethanol washing, obtains [2-(3, the 4-dichlorophenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine, is white solid (311mg, 65%):
mp?274℃；
1H?NMR(DMSO)δ2.34(3H，s)，6.69(1H，s)，7.60(1H，m)，7.84(1H，d)，7.96(2H，d)，8.39(1H，dd)，8.60(1H，d)，8.65(1H，d)，10.51(1H，s)，12.30(1H，s)；IR(solid)1619，1600，1559，1528，1476，1449，1376，1352，797，764，738；MS?370.5.(M+H)
+.
The THF solvent that is used in the step can be with the replacement of other organic solvents, for example ethanol, N, dinethylformamide Huo diox.
Method H
Method H shows that the ring D aryl that wherein carries halogen (X is Br or I) can be converted into the approach of other formula III compounds.Method H (i) shows that phenyl for boric acid and ring D coupling, obtains compound
18, method H (ii) shows the acetylene coupling, obtains compound
19Compound
17In substituent X can be bromine or iodine.The following technology of these methods is described.
Method H (i): (196mg, 0.51mmol) (75mg, 0.62mmol) (1/1,4ml) mixture in adds Na at THF/ water for boric acid with phenyl to [2-(4-bromo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine
2CO
3(219mg, 2.06mmol), triphenyl phosphine (9mg, 1/15mol%) and acid chloride (1mg, 1/135mol%).With mixture 80 ℃ of following heated overnight, evaporating solvent, resistates is through purification by flash chromatography (CH
2Cl
2/ MeOH gradient), obtain in (2-biphenyl-4-base-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine, be yellow solid (99mg, 51%):
1H?NMR(DMSO)δ2.37(3H，s)，6.82(1H，s)，7.39-7.57(4H，m)，7.73-7.87(6H，m)，8.57(2H，d)，8.67(1H，d)，10.42(1H，s)，12.27(1H，s)；MS?378.2(M+H)
Method H is (ii): to [2-(4-bromo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (114mg, 0.3mmol) and trimethylsilyl acetylene (147mg, 1.5mmol) mixture in DMF (2ml) add CuI (1.1mg, 1/50mol%), Pd (PPh
3)
2Cl
2(4.2mg, 1/50mol%) and triethylamine (121mg, 0.36mmol).With mixture at 120 ℃ of following heated overnight, evaporating solvent.In ethyl acetate, develop resistates, filter collecting precipitation.
Above-mentioned precipitation is suspended among the THF (3ml), to wherein add tetrabutylammonium (1M THF solution, 1.1eq).Reaction mixture is at room temperature stirred 2h, evaporating solvent.Resistates is through purification by flash chromatography (CH
2Cl
2/ MeOH gradient), obtain [2-(4-ethynyl phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine, be white solid (68mg, 70%):
1H?NMR(DMSO)δ2.34(3H，s)，4.36(1H，s)，6.74(1H，s)，7.55(1H，m)，7.65(2H，d)，7.84(2H，m)，8.47(2H，d)，8.65(1H，d)，10.43(1H，s)，12.24(1H，s)；MS326.1(M+H)
+
Method I
Aforesaid method I shows the general way of The compounds of this invention preparation, and wherein encircling D is heteroaryl or the heterocyclic ring that directly is connected with pyrimidine 2-position via nitrogen-atoms.Can according to J.Med.Chem., 38,2763-2773 (1995) and J.Chem.Soc., the similar mode of 1766-1771 (1948) is carried out the displacement of 2-cl radical, is example here with the piperidines.The following technology of this method is described.
(1eq (equivalent), N,N-dimethylacetamide 0.1-0.2mmol) (1ml) solution adds required amine (3eq) to (2-chloro-quinazoline-4-yl)-(1H-indazole-3-yl)-amine.Make the gained mixture keep 6h down, pass through the reversed-phase HPLC purifying then at 100 ℃.
Method J
Aforesaid method J shows from the pyridyl ring of the suitable replacement metathesis preparation formula V compound via the chloro group.Method J (i) be the approach that is used for preparation formula Va compound (referring to IndianJ.Chem.Sect.B, 35,8,1996,871-873).Method J (ii) be the approach that is used for preparation formula Vb compound (referring to Bioorg.Med.Chem., 6,12,1998,2449-2458).For convenience's sake, chloropyridine shown in 21 and 23 has the phenyl substituent that is equivalent to formula V ring D.Those skilled in the art will wherein encircle the formula V compound that D is heteroaryl, heterocyclic radical, carbocylic radical or other aryl rings for it is evident that method J also can be used for preparing.The following technology of method J is described.
Method J (i): (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-quinolyl-4)-amine.To 4-chloro-2-phenylquinoline (J.Het.Chem., 20,1983,121-128) (0.53g, phenyl ether 2.21mmol) (5ml) solution add the 3-amino-5-methylpyrazole, and (0.43g 4.42mmol), 200 ℃ of following heated overnight, stirs mixture simultaneously.Add sherwood oil (20ml) to chilled mixture, filter gained and slightly precipitate, further use petroleum ether.Thick solid is through purification by flash chromatography (SiO
2, gradient DCM-MeOH), obtain title compound, be white solid: mp 242-244 ℃;
1H NMR (DMSO) δ 2.27 (3H, s), 6.02 (1H, s), 7.47 (2H, d), 7.53-7.40 (2H, br m), 7.67 (1H, m), 7.92 (1H, m), 8.09 (2H, d), 8.48 (2H, m), 9.20 (1H, s), 12.17 (1H, br s); IR (solid) 1584,1559,1554,1483,1447,1430,1389; MS301.2 (M+H)
+
Method J is (ii): (5-methyl-2H-pyrazole-3-yl)-(3-phenyl-isoquinolyl-1)-amine.To 1-chloro-3-phenyl isoquinolin quinoline (J.Het.Chem., 20,1983,121-128) (0.33g, dry DMF 1.37mmol) (5ml) solution add the 3-amino-5-methylpyrazole (0.27g, 2.74mmol) and salt of wormwood (0.57g, 4.13mmol), mixture is heated 6h under refluxing.Cooling mixture evaporates a large amount of DMF.Resistates merges organic layer with ethyl acetate extraction twice, uses the salt water washing, dry (MgSO
4), filter, concentrate.Crude product is through purification by flash chromatography (SiO
2, gradient DCM-MeOH), obtain title compound, be colourless oil:
1H?NMR(MeOD)δ2.23(3H，s)，5.61(1H，s)，7.41(1H，m)，7.52(2H，m)，7.62(1H，m)，7.81(1H，m)，8.07(1H，d)，8.19(2H，m)，8.29(1H，s)，8.54(1H，d)；MS?301.2(M+H)
+
Method K
The preparation approach of method K display type VI compound.General raw material is 2,4,6-three chloro-[1,3,5] triazine
25, wherein chlorine substituent can be by first rear substitution.One of chlorine is described in PCT patent application WO 01/25220 and Helv.Chim.Acta by aryl Grignard reagent or aryl for the boric acid displacement, in 33,1365 (1950).One of chlorine is described in WO01/25220 by the heteroaryl ring displacement; J.Het.Chem., 11,417 (1974) and Tetrahedron 31,1879 (1975) in.These reactions obtain 2,4-two chloro-(6-replaces) [1,3,5] triazine
26, it is the intermediate that can be used for preparation formula VI compound.Select as an alternative,, also can obtain intermediate by currently known methods structure triazine ring
26Referring to United States Patent (USP) 2,832,779 and United States Patent (USP) 2,691,020 and J.Am.Chem.Soc., 60,1656 (1938).And then,
26One of chlorine can be replaced as mentioned above, obtain 2-chloro-(4,6-is dibasic) [1,3,5] triazine
27Will
27Handle with suitable amino-pyrazol, obtain required formula VI compound.
Method L
Method L shows the approach that is used for preparation formula VII compound.For the purpose of illustration, use trifluoromethyl phenyl styryl ketone (chalcone)
28As raw material; But, will can use other rings to replace compound by those skilled in the art be it is evident that
28Trifluoromethyl and benzyl ring.The phenyl styryl ketone that replaces can prepare by currently known methods, Indian J.Chemistry for example, and 32B, 449 (1993) is described.Phenyl styryl ketone and urea condensation obtain pyrimidone
29, it can be used POCl
3Handle, obtain chloropyrimide
30Referring to J.Chem.Eng.Data, 30 (4) 512 (1985) and Egypt.J.Chem., 37 (3), 283 (1994).At compound
30Another kind of preparation method in, one of aryl rings that is connected with pyrimidine is to introduce like this, in the presence of alkali, for example yellow soda ash uses palladium catalyst, for example (Ph
3P)
4Pd, with 2, the 4-cl radical of 4-two chloro-(6-aryl)-pyrimidine is replaced for boric acid with aryl, as Bioorg.Med.Lett., 9 (7), 1057 (1999) is described.The chlorine of compound 30 is obtained compound of the present invention, for example by suitable amino-pyrazol displacement
31The following technology of the final step of this method is described.
[4-(4-methyl piperidine-1-yl)-pyrimidine-2-base]-(5-methyl-2H-pyrazole-3-yl)-amine.(utilize and Eur.J.Med.Chem. to 2-chloro-4-(4-methyl piperidine-1-yl)-pyrimidine, the prepared that 26 (7) 729 (1991) report is similar) (222mg, 1.05mmol) BuOH (5ml) solution add 3-amino-5-methyl-2H-pyrazoles (305mg, 3.15mmol), then with reaction mixture heated overnight under refluxing.Evaporating solvent, with resistates be dissolved in ethanol/water mixture (1/3,4ml).(57mg 0.41mmol), at room temperature stirs 2h with mixture to add salt of wormwood.Filter the gained suspension, wash twice with water,, obtain title compound, be white solid (143mg, 50%): mp 193-195 ℃ with ether flushing twice;
1HNMR (DMSO) δ 0.91 (3H, d), 1.04 (2H, m), 1.67 (3H, m), 2.16 (3H, s), 2.83 (2H, t), 4.31 (2H, m), 6.19 (2H, m), 7.87 (1H, d), 8.80 (1H, br s), 11.71 (1H, s); IR (solid) 1627,1579,1541,1498,1417,1388,1322,1246; MS273.3 (M+H)
+.
Method M
Method M provides acquisition formula VIII the approach of compound.Be used for 4-chloro-6-replace-pyrazoles that pyridazine 32 usefulness suitably replace replaces the general way that obtains VIIIa and is described in J.Het.Chem., in 20,1473 (1983).Similarly reaction can followingly be carried out: (a) with 3-chloro-5-replace-pyridazine
33Reaction obtains VIIIb, referring to J.Med.Chem., and 41 (3), 311 (1998); (b) with 5-chloro-3-replace-[1,2,4] triazine
34Reaction obtains VIIIc, referring to Heterocycles, and 26 (12), 3259 (1987); (c) with 3-chloro-5-replace-reaction of [1,2,4] triazine obtains VIIId, referring to Pol.J.Chem., 57,7, (1983); Indian J.Chem.Sect.B, 26,496 (1987); Agric.Biol.Chem., 54 (12), 3367 (1990).The alternative preparation technology of formula VIIIc compound is described in IndianJ.Chem.Sect.B, in 29 (5), 435 (1990).
The preparation method of formula IX compound is basically to top described those are similar about the formula I compound that contains pyrazoles.Replace amino-pyrazole compound with amino-triazole compounds, method A-J can be used to prepare the formula IX compound that contains triazole.This class methods concrete example such as following synthetic embodiment 415-422.Amino-triazole intermediate can pass through J.Org.Chem.USSR, and 27, the described method of 952-957 (1991) obtains.
Some synthetic intermediate that can be used for preparing kinases inhibitor of the present invention is new.Therefore, another aspect of the present invention relates to the 3-Aminoindazole compound of formula A:
R wherein
10Be one to three substituting group, be selected from fluorine, bromine, C1-6 haloalkyl, nitro or 1-pyrryl independently of one another.The example of this compounds comprises as follows:
Another aspect of the present invention relates to the 4-chloropyrimidine compound of formula B:
R wherein
xAnd R
yBe as defined above; R
1Be selected from Cl, F, CF
3, CN or NO
2R
5Be one to three substituting group, be selected from H, Cl, F, CF independently of one another
3, NO
2Or CN; Its condition is R
1And R
5Not Cl simultaneously.Formula B examples for compounds is as follows:
Another aspect of the present invention relates to formula C compound:
R wherein
x, R
y, R
2And R
2' be as defined above.Formula C examples for compounds is as follows:
Another aspect of the present invention relates to formula D compound:
R wherein
5, R
xAnd R
yBe as defined above.The example of formula D compound and other useful pyrimidone intermediates is as follows:
Embodiment
In order to understand invention described herein more fully, the following example is described.Should self-evidently be that these embodiment only supply explanation, never be interpreted as limiting the present invention.
Synthetic embodiment
In the analysis of compound, use as the specified following HPLC method of following synthetic embodiment.Term " R used herein
t" expression utilizes the retention time of the specified viewed compound of HPLC method.In an embodiment, HPLC-Method represents the HPLC method, and h represents hour, and min represents minute that solid represents solid, and impurity represents impurity, and eq represents equivalent.
HPLC method A:
Pillar: C18,3 μ m, 2.1 * 50mm, " Lighting " of Jones Chromatography
Gradient: wash-out: 100% water (contain 1% acetonitrile, 0.1%TFA), go through 4.0min, under 100% acetonitrile, keep 1.4min, return to initial conditions again to 100% acetonitrile (containing 0.1%TFA). total run time 7.0min
Flow velocity: 0.8ml/min
HPLC method B:
Pillar: C18,5 μ m, 4.6 * 150mm, " Dynamax " of Rainin
Gradient: wash-out: 100% water (contain 1% acetonitrile, 0.1%TFA), go through 20min, under 100% acetonitrile, keep 7.0min, return to initial conditions again to 100% acetonitrile (containing 0.1%TFA). total run time 31.5min
Flow velocity: 1.0ml/min
HPLC method C:
Pillar: Cyano, 5 μ m, 4.6 * 150mm, " Microsorb " of Varian
Gradient: wash-out: " 99% water (0.1%TFA), 1% acetonitrile (containing 0.1%TFA) are to 50% water (0.1%TFA), and 50% acetonitrile (containing 0.1%TFA) is gone through 20min, keep 8.0min, return to initial conditions again. total run time 30min
Flow velocity: 1.0ml/min
HPLC method D:
Pillar: Waters (YMC) ODS-AQ, 2.0 * 50mm, S5,120A
Gradient: wash-out: 90% water (0.2% formic acid), 10% acetonitrile (containing 0.1% formic acid) are to 10% water (0.1% formic acid), and 90% acetonitrile (containing 0.1% formic acid) is gone through 5.0min, keep 0.8min, return to initial conditions again. total run time 7.0min
Flow velocity: 1.0ml/min
HPLC method E:
Pillar: 50 * 2.0mm, Hypersil C18 BDS, 5 μ m
Gradient: wash-out: 100% water (0.1%TFA) is to 5% water (0.1%TFA), and 95% acetonitrile (containing 0.1%TFA) is gone through 2.1min, returns to initial conditions behind the 2.3min again
Flow velocity: 1ml/min
Embodiment 1[2-(2-chloro-phenyl-)-5,6-dimethyl pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-1):
1HNMR(500MHz，DMSO-d6)δ10.4(s，br，1H)，7.74(m，2H)，7.68(m，1H)，7.60(m，1H)，6.39(s，1H)，2.52(s，3H)，2.30(s，3H)，2.22(s，3H)；MS?314.1(M+H).
Embodiment 2[2-(2-chloro-phenyl-)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-(1H-indazole-3-yl)-amine (II-2): yield 30%.
1HNMR(500MHz，DMSO-d6)δ1.72(m，4H)，1.91(m，2H)，3.02(m，4H)，7.05(t，1H)，7.33(t，1H)，7.39(m，1H)，7.47(d，1H)，7.55(m，3H)，7.59(d，1H)，10.4(m，1H)，13.11(br.s，1H)；EI-MS?390.2(M+H)；HPLC-Method?A，R
t?2.99min.
Embodiment 3 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydrochysene-pyrido [3,4-d] pyrimidine-4-yl]-amine (II-3): at room temperature, in MeOH, (90mg 0.17mmol) 4.4% formic acid solution of weight Pd/C (10%) such as uses to handle 14h with Compound I I-18.By C salt filtering mixt, evaporated filtrate, crude product obtains the required product of 18mg (24%) through the HPLC purifying, is faint yellow solid.
1HNMR(500MHz，DMSO-d6)δ12.9(s，1H)，9.51(s，1H)，9.26(s，2H)，7.72(d，1H)，7.63(t，1H)，7.58(t，1H)，7.49(m，2H)，7.21(td，1H)，7.15(dd，1H)，4.24(s，2H)，3.56(m，2H)，2.95(m，2H)ppm.MS(ES+)：m/e＝429.22(M+H)；HPLC-Method?A，R
t?2.88min.
Embodiment 4[2-(2-chloro-phenyl-)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-(7-fluoro-1H-indazole-3-yl)-amine (II-4): yield 52% obtains white solid.
1HNMR(500MHz，DMSO-d6)δ1.72(m，4H)，1.92(m，2H)；3.00(m，4H)，7.02(td，1H)，7.20(dd，1H)，7.40(m，1H)，7.42(d，1H)，7.52(m，3H)，10.5(m，1H)，13.50(br.s，1H)；EI-MS?408.2(M+H)；HPLC-Method?A，R
t?3.00min.
Embodiment 5[2-(2-chloro-phenyl-)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-(5-fluoro-1H-indazole-3-yl)-amine (II-5): yield 51%.
1HNMR(500MHz，DMSO-d6)δ1.71(m，4H)，1.91(m，2H)，3.01(m，4H)，7.24(td，1H)，7.41(m，2H)，7.54(m，4H)，10.5(m，1H)，13.1(br.s，1H)；EI-MS?408.2(M+H)；HPLC-Method?A，R
t?3.05min.
Embodiment 6[2-(2-chloro-phenyl-)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-6): according to method C preparation, yield 72%.
1HNMR(500MHz，DMSO-d6)δ1.72(m，4H)，1.91(m，2H)，3.01(m，4H)，7.31(m，2H)，7.41(m，1H)，7.54(m，3H)，10.5(m，1H)，13.6(br.s，1H)；EI-MS?426.2(M+H)；HPLC-Method?A，R
t?3.21min.
Embodiment 7 (7-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydro quinazoline-4-yl]-amine (II-7): yield 62%.
1HNMR(500MHz，DMSO-d6)δ13.5(s，br，1H)，10.1(s，br，1H)，7.75(m，4H)，7.33(d，1H)，7.17(dd，1H)，7.00(td，1H)，2.80(m，2H)，2.71(m，2H)，1.89(br，4H)ppm；LC-MS(ES+)428.44(M+H)，(ES-)426.43(M-H)；HPLC-Method?A，R
t?3.02min.
Embodiment 8 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydro quinazoline-4-yl]-amine (II-8): yield 53%.
1HNMR(500MHz，DMSO-d6)δ13.1(s，1H)，10.2(s，br，1H)，7.75(m，4H)，7.50(dd，1H)，7.27(dd，1H)，7.21(td，1H)，2.80(m，2H)，2.72(m，2H)，1.88(m，4H)ppm；MS(ES+)428.43(M+H)，(ES-)426.43(M-H)；HPLC-Method?A，R
t?3.01min.
Embodiment 9 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydro quinazoline-4-yl]-amine (II-9): yield 37%.
1HNMR(500MHz，DMSO-d6)δ13.7(s，1H)，10.2(s，br，1H)，7.80(d，1H)，7.76(t，1H)，7.69(m，2H)，7.31(t，1H)，7.18(d，1H)，2.81(t，br，2H)，2.72(t，br，2H)，1.90(m，4H)ppm；MS(ES+)446.42(M+H)，(ES-)444.37(M-H)；HPLC-Method?A，R
t3.09min.
Embodiment 10 (5-Trifluoromethyl-1 H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydro quinazoline-4-yl]-amine (II-10): C prepares in ethanol according to method, yield 35%.
1HNMR(500MHz，DMSO-d6)δ13.2(s，1H)，10.1(s，br，1H)，8.01(s，1H)，7.76(d，1H)，7.66(m，4H)，7.57(d，1H)，2.79(m，2H)，2.73(m，2H)，1.89(m，4H)ppm.MS(ES+)478.45(M+H)，(ES-)476.42(M-H)；HPLC-Method?A，R
t?3.21min.
Embodiment 11 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-amine (II-11): yield 60%.White solid.
1HNMR(500MHz，DMSO-d6)δ1.72(m，4H)，1.91(m，2H)，3.01(m，4H)，7.15(dd，1H)，7.30(td，1H)，7.66(m，2H)，7.72(t，1H)，7.78(d，1H)，10.2(m，1H)，13.5(br.s，1H)；EI-MS?460.2(M+H)；HPLC-Method?A，R
t?3.13min.
Embodiment 12 (6-benzyl-2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydrochysene-pyrido [4,3-d] pyrimidine-4-yl)-(5-fluoro-1H-indazole-3-yl)-amine (II-12): yield 49%.
1HNMR(500MHz，DMSO-d6)δ12.8(s，1H)，9.11(s，1H)，7.68(d，1H)，7.58(t，1H)，7.53(t，1H)，7.44(m，4H)，7.37(t，2H)，7.29(t，1H)，7.19(m，2H)，3.78(s，2H)，3.61(s，2H)，2.81(s，br，4H)ppm；LC-MS(ES+)519.24(M+H)；HPLC-Method?A，R
t?3.11min.
Embodiment 13 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-amine (II-13): yield 40%.
1HNMR(500MHz，DMSO-d6)δ1.70(m，4H)，1.90(m，2H)，3.00(m，4H)，7.01(t，1H)，7.30(td，1H)，7.44(d，1H)，7.49(d，1H)，7.68(m，3H)，7.77(d，1H)，10.01(m，1H)，12.83(s，1H)；EI-MS?424.2(M+H)；HPLC-Method?A，R
t?3.17min.
Embodiment 14 (7-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan]-amine (II-14): yield 78%.
1HNMR(500MHz，DMSO-d6)δ1.71(m，4H)，1.91(m，2H)，3.00(m，4H)，6.98(td，1H)，7.16(dd，1H)，7.31(d，1H)，7.68(m，3H)，7.77(d，1H)，10.25(m，1H)，13.40(br.s，1H)；EI-MS?442.2(M+H)；HPLC-Method?A，R
t?3.12min.
Embodiment 15 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-6,7,8,9-tetrahydrochysene-5H-penta ring and pyrimidine-4-yl]-amine (II-15): yield 63%.
1HNMR(500MHz，DMSO-d6)δ1.71(m，4H)，1.91(m，2H)，3.00(m，4H)，7.20(td，1H)，7.25(dd，1H)，7.49(dd，1H)，7.69(br.t，2H)，7.74(m，1H)，7.79(d，1H)，10.35(m，1H)，13.00(br.s，1H)；EI-MS?442.2(M+H)；HPLC-Method?A，R
t?3.21min.
Embodiment 16 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydrochysene-pyrido [4,3-d] pyrimidine-4-yl]-amine (II-16): at room temperature, (45mg, methyl alcohol 0.087mmol) (4.4%HCOOH) solution such as use to handle 14h at weight Pd/C (10%) with Compound I I-12.By C salt filtering mixt, evaporated filtrate, crude product obtains the required product of 15mg (41%) through the preparation HPLC purifying, is yellow solid.
1HNMR(500MHz，DMSO-d6)δ12.9(s，1H)，9.52(s，1H)，9.32(s，2H，TFA-OH)，7.72(d，1H)，7.59(m，2H)，7.49(m，2H)，7.21(m，1H)，7.15(m，1H)，4.31(s，2H)，3.55(s，2H)，3.00(m，2H)ppm；LC-MS(ES+)429.20(M+H)；HPLC-Method?A，R
t?2.79min.
Embodiment 17 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydro quinazoline-4-yl]-amine (II-17): yield 58%.
1HNMR(500MHz，DMSO-d6)δ13.0(s，1H)，10.3(s，br，1H)，7.74(m，4H)，7.51(d，1H)，7.47(d，1H)，7.32(t，1H)，7.03(t，1H)，2.82(m，2H)，2.73(m，2H)，1.90(m，4H)ppm；LC-MS (ES+)410.21(M+H)；HPLC-Method?A，R
t?2.99min.
Embodiment 18 (7-benzyl-2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydrochysene-pyrido [4,3-d] pyrimidine-4-yl)-(5-fluoro-1H-indazole-3-yl)-amine (II-18): from compound B-11 1 preparation, yield 92%.
1HNMR(500MHz，DMSO-d6)δ12.9(s，1H)，10.5(s，br，1H)，9.58(s，1H，TFA-OH)，7.71(d，1H)，7.52(m，9H)，7.19(m，2H)，4.57(s，2H)，4.20(m，2H)，3.70(m，2H)，3.00(m，2H)ppm；LC-MS(ES+)519.23(M+H)；HPLC-Method?A，R
t?3.23min.
Embodiment 19 (1H-indazole-3-yl)-[6-methyl-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (II-19): yield 42%.Fusing point 235-237 ℃;
1HNMR (500MHz, DMSO) δ 2.44 (3H, s), 7.09 (1H, J=7.5Hz, t), 7.40 (1H, J=7.1Hz, t), 7.49 (1H, J=8.3Hz, d), 7.70 (3H, m), 7.79 (1H, J=7.3Hz, t), 7.87 (1H, J=8.3Hz, d), 8.03 (1H, J=7.7Hz, d), 10.3 (1H, s), 12.6 (1H, s) ppm; HPLC-Method A, R
t2.958min; MS (FIA) 370.2 (M+H)
+.
Embodiment 20 (1H-indazole-3-yl)-[6-phenyl-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (II-20): yield 32%.
1HNMR(500MHz，DMSO)δ6.94(1H，J＝7.4Hz，t)，7.24(1H，J＝7.4Hz，t)，7.33(1H，J＝8.4Hz，d)，7.42(3H，m)，7.57(1H，J＝7.3Hz，t)，7.68(2H，m)，7.75(1H，J＝7.9Hz，d)，7.93(3H，m)，8.18(1H，br?s)，10.45(1H，br?s)，12.5(1H，br?s)ppm；HPLC-Method?A，R
t4.0min；MS(FIA)432.2(M+H)
+.
Embodiment 21 (1H-indazole-3-yl)-[6-(pyridin-4-yl)-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (II-21): yield 12%.
1HNMR(500MHz，DMSO)δ7.16(1H，J＝7.4Hz，t)，7.46(1H，J＝7.6Hz，t)，7.56(1H，J＝8.3Hz，d)，7.80(1H，J＝7.2Hz，t)，7.90(2H，m)，7.97(1H，J＝7.8Hz，d)，8.09(1H，br)，8.22(2H，J＝4.9Hz，d)，8.45(1H，br?s)，8.93(2H，J＝4.8Hz，d)，10.9(1H，br?s)，12.8(1H，br?s)ppm；HPLC-Method?A，R
t?3.307min；MS(FIA)433.2(M+H)
+
Embodiment 22 (1H-indazole-3-yl)-[6-(pyridine-2-yl)-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (II-22): yield 42%.
1HNMR(500MHz，DMSO)δ7.07(1H，J＝7.4Hz，t)，7.36(1H，J＝7.4Hz，t)，7.46(1H，J＝7.4Hz，d)，7.53(1H，J＝5.0Hz，t)，7.70(1H，J＝7.4Hz，t)，7.79(1H，J＝7.1Hz，t)，7.83(1H，J＝7.4Hz，d)，7.88(1H，J＝7.8Hz，d)，7.97(1H，J＝7.7Hz，t)，8.02(1H，J＝5.5Hz，br?d)，8.36(1H，J＝7.8Hz，d)，8.75(2H，J＝4.1Hz，d)，10.5(1H，br?s)，12.7(1H，br?s)ppm；HPLC-Method?A，R
t3.677min；MS(FIA)433.2(M+H)
+.
Embodiment 23[6-(2-chloro-phenyl)-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-23): yield 44%.
1HMNR(500MHz，DMSO)δ7.08(1H，J＝7.5Hz，t)，7.37(1H，J＝7.5Hz，t)，7.45(1H，J＝8.4Hz，d)，7.51(2H，m)，7.61(1H，J＝7.4，1.9Hz，dd)，7.69(2H，m)，7.79(2H，J＝4.0Hz，d)，7.86(3H，J＝7.8Hz，d)，8.04(2H，J＝6.2Hz，br?d)，10.7(1H，br?s)，12.6(1H，br?s)ppm；HPLC-Method?A，R
t?3.552min；MS(FIA)466.2(M+H)
+.
Embodiment 24[5,6-dimethyl-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-24): yield 35%;
mp?183-186℃；
1HNMR(500MHz，DMSO)δ2.14(3H，s)，2.27(3H，s)，6.85(1H，J＝7.5Hz，t)，7.15(1H，J＝7.6Hz，t)，7.32(3H，m)，7.38(1H，J＝7.5Hz，t)，7.42(1H，J＝7.4Hz，t)，7.53(1H，J＝7.6Hz，d)，8.88(1H，s)，12.5(1H，s)ppm；HPLC-Method?A，R
t?2.889min.；MS(FIA)384.2(M+H).
Embodiment 25[5,6-dimethyl-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-25): yield 44%.Fusing point 160-163 ℃;
1HNMR (500MHz, DMSO) δ 2.27 (3H, s), 2.40 (3H, s), 7.16 (2H, m), 7.44 (2H, m), 7.52 (1H, J=7.4Hz, t), 7.57 (1H, J=7.4Hz, t), 7.67 (1H, J=7.8Hz, d), 9.03 (1H, s), 12.75 (1H, s) ppm; HPLC-Method A, R
t2.790min; MS (FIA) 402.2 (M+H)
+.
Embodiment 26[2-(2-chloro-phenyl)-5,6-dimethyl-pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-26): yield 30%.
1HNMR?(500MHz，DMSO)δ2.14(3H，s)，2.33(3H，s)，6.84(1H，J＝7.4Hz，t)，7.13(1H，J＝7.4Hz，t)，7.19(1H，J＝6.9Hz，br?t)，7.27(1H，J＝7.4Hz，d)，7.32(3H，br?m)，7.37(1H，J＝7.1Hz，d)，10.0(1H，br)，12.8(1H，br?s)ppm；δ2.919min；MS(FIA)350.1(M+H)
+.
Embodiment 27[5,6-dimethyl-2-(2-trifluoromethyl-phenyl) pyrimidine-4-yl]-(7-fluoro-1H-indazole-3-yl)-amine (II-27): yield 92%.
1HNMR?(500MHz，DMSO)δ2.33.(3H，s)，2.50(3H，s)，6.97(1H，m)，7.15(1H，m)，7.30(1H，J＝8.1Hz，d)，7.65(3H，m)，7.76(1H，J＝7.5Hz，d)，10.0(1H，s)，13.4(1H，s)ppm；HPLC-Method?A，R
t?3.053min；MS(FIA)402.2(M+H)
+.
Embodiment 28 (5,7-two fluoro-1H-indazole-3-yls)-[5,6-dimethyl-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (II-28): yield 50%.
1HNMR?(500MHz，DMSO)δ2.42(3H，s)，2.63(3H，s)，7.22(1H，J＝7.6Hz，d)，7.38(1H，J＝9.3，1.7Hz，dt)，7.71(1H，m)，7.75(1H，J＝7.0Hz，d)，7.79(1H，J＝6.7Hz，d)，7.86(1H，J＝8.0Hz，d)，10.0(1H，s)，13.2(1H，s)ppm?；HPLC-Method?A，R
t?3.111?min?；MS(FIA)420.2(M+H)
+.
Embodiment 29[2-(2-chloro-phenyl)-5,6-dimethyl-pyrimidine-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-29): yield 58%.
1HNMR?(500MHz，DMSO)δ2.47(3H，s)，2.66(3H，s)，7.44(2H，m)，7.53(1H，m)，7.64(3H，m)，10.4(1H，br)，13.8(1H，br?s)ppm；HPLC-Method?A，R
t2.921min；MS?(FIA)386.1(M+H)
+.
Embodiment 30[2-(2-chloro-phenyl)-5,6-dimethyl-pyrimidine-4-yl]-(7-fluoro-1H-indazole-3-yl)-amine (II-30): yield 70%.
1HNMR?(500MHz，DMSO)δ2.35(3H，s)，2.51(3H，s)，7.03(1H，J＝7.8，4.4Hz，dt)，7.22(1H，m)，7.33(1H，J＝7.4Hz，t)，7.42(1H，m)，9.19(1H，s)，13.3(1H，s)ppm；HPLC-Method?A，R
t?2.859min；MS(FIA)368.2(M+H)
+.
Embodiment 31[2-(2-chloro-phenyl)-5,6-dimethyl-pyrimidine-4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-31): yield 86%.
1HNMR(500MHz，DMSO)δ2.49(3H，s)，2.68(3H，s)，7.38(1H，J＝9.0Hz，t)，7.54(2H，m)，7.67(4H，m)，10.5(1H，br)，13.2(1H，br?s)ppm?；HPLC-Method?A，R
t2.850min；MS(FIA)368.1(M+H)
+.
Embodiment 32[2-(2,4-two chloro-phenyl)-5,6-dimethyl pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-32): yield 52%.
1HNMR(500MHz，DMSO)δ2.46(3H，s)，2.64(3H，s)，7.16(1H，J＝7.5Hz，t)，7.46(1H，J＝7.6Hz，t)，7.61(2H，m)，7.68(2H，J＝8.2Hz，d)，7.82(1H，m)，10.2(1H，br)，13.0(1H，br?s)ppm；HPLC-Method?A，R
t?2.983min；MS(FIA)384.1(M+H).
Embodiment 33 (5-methyl-2H-pyrazole-3-yl)-[2-(2-methyl-phenyl)-quinazoline-4-yl]-amine (II-33):
1HNMR (DMSO) δ 1.21 (3H, s), 2.25 (3H, s), 6.53 (1H, s), 7.38 (4H, m), 7.62 (1H, d), 7.73 (1H, d), 7.81 (1H, d), 7.89 (1H, t), 8.70 (1H, s), 12.20 (1H, s); MS316.3 (M+H)
+.
Embodiment 34[2-(2,4-two fluoro-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-34):
1HNMR (500MHz, DMSO-d6) δ 12.4 (br s, 1H), 10.8 (br s, 1H), 8.58 (d, 1H), 7.97 (m, 1H), 8.36 (m, 1H), 7.85 (m, 1H), 7.60 (m, 1H), 6.62 (s, 1H), 2.30 (s, 3H); MS 338.07 (M+H).
Embodiment 35[2-(2,5-dimethoxy-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-35):
1HNMR?(500MHz，DMSO-d6)δ12.5(br?s，1H)，8.68(br，1H)，7.92(t，J＝7.5Hz，1H)，7.86(d，J＝8.2Hz，1H)，7.65(t，J＝7.5Hz，1H)，7.45(s，1H)，7.14(m，2H)，6.51(s，1H)，3.79(s，3H)，3.67(s，3H)，2.14(s，3H)；MS?362.2(M+H).
Embodiment 36[2-(2-chloro-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-36):
1HNMR (500MHz, DMSO-d6) δ 11.8 (br, 1H), 8.80 (d, J=8.3Hz, 1H), 8.00 (t, J=7.Hz, 1H), 7.82 (d, J=8.3Hz, 1H), 7.78 (m, 2H), 7.67 (d, J=7.8Hz, 1H), 7.61 (t, J=7.0Hz, 1H), 7.55 (t, J=7.4Hz, 1H), 6.56 (s, 1H), 2.18 (s, 3H); MS336.1 (M+H).
Embodiment 37[2-(2-methoxyl group-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-37):
1HNMR (500MHz, DMSO-d6) δ 8.78 (s, br, 1H), 8.00 (t, J.=7.4Hz, 1H), 7.90 (m, 2H), 7.74 (t, J=7.5Hz, 1H), 7.63 (t, J=7.3Hz, 1H), 7.30 (d, J=8.4Hz, 1H), 7.18 (t, J=7.5Hz, 1H), 6.58 (s, br, 1H), 3.90 (s.3H), 2.21 (s, 3H); MS332.1 (M+H).
Embodiment 38[2-(2,6-dimethyl-phenyl)-quinazoline 4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-38):
1HNMR (500MHz, DMSO-d6) δ 12.2 (s, br, 2H), 8.88 (d, J=7.7Hz, 1H), 8.05 (t, J=7.7Hz, 1H), 7.80 (m, 2H), 7.37 (t, J=7.6Hz, 1H), 7.21 (d, J=7.7Hz, 2H), 6.36 (s, 1H), 2.16 (s, 3H), 2.15 (s, 6H); MS 330.1 (M+H).
Embodiment 39[2-(2-ethanoyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-39):
1HNMR (500MHz, DMSO-d6) δ 12.35 (s, br, 1H), 8.93 (d, J=8.4Hz, 1H), 8.37 (d, J=8.6Hz, 1H), 8.20 (d, J=7.6Hz, 1H), 8.11 (t, J=8.0Hz, 2H), 7.89 (m, 2H), 7.77 (m, 2H), 6.93 (s, 1H), 2.33 (s, 3H), 2.04 (s, 3H) MS 344.1 (M+H).
Embodiment 40[2-(2,3-dimethyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-40):
1HNMR (500MHz, DMSO-d6) δ 12.6 (s, br, 1H), 12.1 (s, br, 1H), 8.91 (d, J=7.7Hz, 1H), 8.14 (t, J=7.2Hz, 1H), 7.95 (d, J=8.4Hz, 1H), 7.89 (t, J=7.7Hz, 1H), 7.58 (d, J=7.6Hz, 1H), 7.53 (d, J=7.0Hz, 1H), 7.42 (t, J=7.6Hz, 1H), 6.60 (s, 1H), 2.43 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H); MS 330.1 (M+H).
Embodiment 41 (5-methyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-41):
1HNMR?(500MHz，DMSO-d6)δ12.3(s，1H)，10.5(s，1H)，8.77(d，J＝8.2Hz，1H)，7.92(m，2H)，7.85(m，3H)，7.56(t，J＝8.1Hz，1H)，7.67(t，J＝7.4Hz，1H)，6.63(s，1H)，2.27(s，3H)；MS?370.1(M+H).
Embodiment 42[2-(2-ethyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-42):
1HNMR (500MHz, DMSO-d6) δ 8.80 (m, 1H), 8.02 (s, br, 1H), 7.82 (d, J=8.4Hz, 1H), 7.77 (m, 1H), 7.62 (d, J=7.6Hz, 1H), 7.54 (m, 1H), 7.41 (m, 2H), 6.40 (s, 1H), 2.75 (q, J=7.1Hz, 2H), 2.17 (s, 3H), 0.99 (t, J=7.5Hz, 3H); MS 330.1 (M+H).
Embodiment 43 (2-biphenyl-2-base-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (II-43):
1HNMR (500MHz, DMSO-d6) δ 8.76 (d, J=7.6Hz, 1H), 8.04 (m, 1H), 7.75 (m, 6H), 7.30 (m, 5H), 5.34 (s, 1H), 2.14 (s, 3H); MS 378.2 (M+H).
Embodiment 44[2-(2-hydroxyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-44):
1HNMR?(500MHz，DMSO-d6)δ10.9(s，br，1H)，8.62(d，J＝8.2Hz，1H)，8.28(d，J＝7.9Hz，1H)，7.87(m，2H)，7.60(t，J＝7.9Hz，1H)，7.37(t，J＝7.8Hz，1H)，6.92(m，2H)，6.45(s，1H)，2.27(s，3H)；MS?318.1(M+H).
Embodiment 45[2-(2-oxyethyl group-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-45):
1HNMR (500MHz, DMSO-d6) δ 12.1 (s, br, 1H), 8.75 (d, J=8.3Hz, 1H), 7.97 (t, J=7.8Hz, 1H), 7.82 (d, J=8.3Hz, 1H), 7.78 (d, J=7.5Hz, 1H), 7.70 (t, J=7.8Hz, 1H), 7.56 (t, J=7.8Hz, 1H), 7.22 (d, J=8.4Hz, 1H), 7.12 (t, J=7.6Hz, 1H), 6.55 (s, 1H), 4.11 (q, J=6.9Hz, 2H), 2.16 (s, 3H), 1.22 (t, J=6.9Hz, 3H); MS 346.1 (M+H).
Embodiment 46[5-(thiophene-2-yl)-2H-pyrazole-3-yl]-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-46):
1HNMR(500MHz，DMSO-d6)δ8.04(d，J＝8.3Hz，1H)，8.05(dd，J＝7.3，8.2Hz，1H)，7.93(d，J＝6.5Hz，1H)，7.81(m，5H)，7.34(d，J＝5.0Hz，1H)，7.25(m，1H)，7.00(m，1H)，6.87(s，1H)；MS?438.1(M+H).
Embodiment 47[4-(thiophene-2-yl)-2H-pyrazole-3-yl]-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-47): prepare according to method B.
1HNMR?(500MHz，DMSO-d6)δ6.97(m，1H)，7.08(m，1H)，7.27(m，1H)，7.36(m，1H)，7.66(m，2H)，7.77(m，3H)，7.83(m，1H)，8.00(m，1H)，8.18(s，1H)，8.62(d，J＝8.2Hz，1H)，10.7(br.s，1H)；HI-MS?438.1(M+H)；HPLC-Method?A，R
t?2.97min.
Embodiment 48 (4-phenyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-48): prepare according to method B.
1HNMR?(500MHz，DMSO-d6)δ7.05(br.s，1H)，7.14(t，J＝7.8Hz，1H)，7.25(m，3H)，7.43(m，2H)，7.60(m，2H)，7.73(m，2H)，7.80(d，1H)，7.95(m，1H)，8.12(br.s，1H)，8.60(m，1H)，10.6(br.s，1H)；HI-MS?432.2(M+H)；HPLC-Method?A，R
t?3.04min.
Embodiment 49 (the 5-tertiary butyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-49):
1HNMR(500MHz，DMSO-d6)δ8.76(d，J＝8.3Hz，1H)，7.94(m，2H)，7.79(m，4H)，7.70(t，J＝7.6Hz，1H)，6.51(s，1H)，1.16(s，9H)；MS?412.2(M+H).
Embodiment 50 (5-phenyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-50):
1HNMR(500MHz，DMSO-d6)δ7.09(s，1H)，7.36(td，J＝7.8，1.1Hz，1H)，7.46(t，J＝7.8Hz，2H)，7.65(br.d，J＝8.1Hz，2H)，7.78(m，2H)，7.90(m，4H)，7.95(d，J＝7.7Hz，1H)，8.00(t，J＝7.8Hz，1H)，8.81(d，J＝8.6Hz，1H)，11.29(bt.s，1H)；EI-MS?432.1(M+H)；HPLC-Method?A，R
t?3.24min.
Embodiment 51 (4,5-phenylbenzene-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-51):
1HNMR(500MHz，DMSO-d6)δ7.13(m，1H)，7.18(m，5H)，7.36(m，5H)，7.62(m，3H)，7.73(m，2H)，7.85(m，1H)，8.48(d，J＝8.7Hz，1H)，10.02(s，1H)，13.19(s，1H)；EI-MS508.2(M+H)；HPLC-Method?A，R
t?3.39min.
Embodiment 52 (4-formamyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-52): yield 40%.
1HNMR(500MHz，DMSO-d6)：δ12.85(s，1H)，12.77(s，1H)，11.80(s，1H)，10.80(s，1H)，8.35-7.42(m，9H)；MS?399.13(M+H)HPLC-Method?A，R
t2.782min.
Embodiment 53 (2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-53): yield 38%.
1HNMR(500MHz，DMSO-d6)δ12.52(s，1H)，10.65(s，1H)，8.75(d，1H)，7.91-7.68(m，8H)，6.87(s，1H).MS：(M+H)356.17.HPLC-Method?A，R
t2.798min.
Embodiment 54 (5-hydroxyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-54): yield 36%.
1HNMR(500MHz，DMSO-d6)δ10.61(s，1H)，8.75(s，1H)，8.03-7.75(m，9H)，5.97(s，1H)；MS372.18(M+H)；HPLC-Method?A，R
t?2.766min.
Embodiment 55 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-55): yield 30%.
1HNMR(500MHz，DMSO-d6)δ12.21(s，1H)，10.45(s，1H)，8.68(s，1H)，7.89-7.45(m，8H)，6.48(s，1H)，0.89(m，2H)，0.62(s，2H).MS?396.18(M+H)；HPLC-Method?A，R
t?3.069min.
Embodiment 56 (5-methoxymethyl-2H-pyrazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-56): yield 33%.
1HNMR(500MHz，DMSO-d6)δ12.51(s，1H)，10.48(s，1H)，8.60(s，1H)，7.81-7.55(m，7H)，6.71(s，1H)，4.28(s，2H)，3.18(s，3H).MS?400.19(M+H)：HPLC-Method?A，R
t?2.881min.
Embodiment 57 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-57): obtain 51mg (yield 78%) faint yellow solid.
1HNMR(500MIIz，DMSO-d6)δ12.7(s，1H)，10.4(s，1H)，8.55(d，1H)，7.81(t，1H)，7.71(d，1H)，7.61(d，1H)，7.58(t，1H)，7.46(m，4H)，7.36(d，1H)，7.22(t，1H)，6.91(t，1H)ppm；LC-MS(ES+)406.16(M+H)，(ES-)404.19(M-H)；HPLC-Method?A，R
t?3.00min.
Embodiment 58 (4-chloro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-58): preparation (yield 70%) in DMF is faint yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.3(s，br，1H)，10.9(s，br，1H)，8.60(d，1H)，7.97(t，1H)，7.81(d，1H)，7.75(t，1H)，7.67(d，1H)，7.63(dd，1H)，7.57(m，2H)，7.43(d，1H)，7.28(dd，1H)，7.08(d，1H)ppm；LC-MS(ES+)440.10(M+H)，(ES-)438.12(M-H)；HPLC-Method?A，R
t?3.08min.
Embodiment 59 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-59): preparation (yield 34%) in DMF is faint yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.0(s，1H)，10.6(s，1H)，8.72(d，1H)，7.99(t，1H)，7.89(d，1H)，7.79(d，1H)，7.75(t，1H)，7.68(m，3H)，7.56(dd，1H)，7.39(d，1H)，7.28(t，1H)ppm；LC-MS(ES+)424.12(M+H)，(ES-)m/e＝422.13(M-H)；HPLC-Method?A，R
t?3.05min.
Embodiment 60 (7-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-60): preparation (yield 51%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.4(s，1H)，10.6(s，1H)，8.68(d，1H)，7.95(t，1H)，7.85(d，1H)，7.72(m，2H)，7.63(m，2H)，7.58(m，1H)，7.43(d，1H)，7.18(dd，1H)，7.00(m，1H)ppm；LC-MS(ES+)424.11(M+H)，(ES-)422.15(M-H)；HPLC-Method?A，R
t?3.06min.
Embodiment 61 (5-methyl isophthalic acid H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-61): preparation (yield 81%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.0(s，br，1H)，8.79(br，1H)，8.11(br，1H)，7.96(d，1H)，7.82(m，5H)，7.46(s，1H)，7.41(d，1H)，7.20(d，1H)，2.33(s，3H)ppm；MS(ES+)420.15(M+H)，(ES-)418.17(M-H)；HPLC-Method?A，R
t?3.07min.
Embodiment 62[2-(2,6-two chloro-phenyl)-quinazoline-4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-62): preparation (yield 37%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.0(s，1H)，10.8(s，1H)，8.72(d，1H)，7.97(t，1H)，7.90(d，1H)，7.75(t，1H)，7.53(m，3H)，7.43(t，1H)，7.35(d，1H)，7.23(t，1H)ppm；LCMS(ES+)424.08(M+H)(ES-)422.10(M-H)；HPLC-Method?A，R
t?3.06min.
Embodiment 63[2-(2-chloro-phenyl)-quinazoline-4-yl]-(1H-indazole-3-yl)-amine (II-63): yield 91%.
1HNMR(500MHz，DMSO-d6)δ7.06(t，1H)，7.36(t，1H)，7.39(t，1H)，7.52(m，3H)，7.62(d，1H)，7.72(d，1H)，7.82(m，1H)，7.90(d，1H)，8.05(m，1H)，8.76(d，1H)，11.5(m，1H)，13.02(s，1H)；EI-MS?372.1(M+1)；HPLC-Method?A，R
t2.93min.
Embodiment 64 (5-Trifluoromethyl-1 H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-64): preparation (yield 57%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.4(s，br，1H)，11.4(br，1H)，8.72(d，1H)，8.12(s，1H)，7.98(t，1H)，7.83(d，1H)，7.76(d，1H)，7.73(dd，1H)，7.60(m，4H)，7.52(d，1H)ppm；LC-MS(ES+)474.12(M+H)，(ES-)472.17(M-H)；HPLC-Method?A，R
t3.25min.
Embodiment 65 (4-Trifluoromethyl-1 H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-65): preparation (yield 8%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.7(s，br，1H)，11.2(br，1H)，8.70(d，1H)，8.05(s，1H)，7.85(m，3H)，7.65(m，4H)，7.51(m，2H)ppm；LC-MS (ES+)474.13(M+H)，(ES-)472.17(M-H)；HPLC-Method?A，R
t?3.15min.
Embodiment 66[2-(2,6-two chloro-phenyl)-quinazoline-4-yl]-(1H-indazole-3-yl)-amine (II-66): preparation (yield 30%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ12.9(s，1H)，11.1(s，1H)，8.69(d，1H)，7.95(t，1H)，7.82(d，1H)，7.73(t，1H)，7.56(d，1H)，7.47(s，1H)，7.45(s，1H)，7.39(m，2H)，7.26(t，1H)，6.92(t，1H)ppm；LC-MS(ES+)406.11(M+H)，(ES-)404.12(M-H)；HPLC-MethodA，R
t?3.00min.
Embodiment 67 (1H-indazole-3-yl)-[2-(2-methyl-phenyl) quinazoline-4-yl]-amine (II-67): yield 55%.
1HNMR(500MHz，DMSO-d6)δ2.15(s，3H)，7.09(t，1H)，7.26(d，1H)，7.31(t，1H)，7.39(t，1H)，7.42(m，1H)，7.55(d?1H)，7.64(d，1H)，7.74(d，1H)，7.89(m，1H)，7.96(d，1H)，8.10(m，1H)，8.81(d，1H)，12.0(m，1H)，13.18(s，1H)；EI-MS?352.2(M+1)；HPLC-Method?A，R
t2.93min.
Embodiment 68 (7-Trifluoromethyl-1 H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-68): preparation (yield 75%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.5(s，br，1H)，11.2(s，br，1H)，8.68(d，1H)，7.97(t，1H)，7.92(d，1H)，7.82(d，1H)，7.74(t，1H)，7.70(d，1H)，7.68(d，1H)，7.64(m，2H)，7.57(m，1H)，7.14(t，1H)ppm；LC-MS(ES+)474.11(M+H)，(ES-)472.14(M-H)；HPLC-Method?A，R
t?3.24min.
Embodiment 69 (6-Trifluoromethyl-1 H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-69): according to method B, preparation (yield 78%) is yellow solid in DMF.
1HNMR(500MHz，DMSO-d6)δ13.4(s，br，1H)，11.1(s，br，1H)，8.67(d，1H)，7.95(t，1H)，7.82(m，3H)，7.72(m，2H)，7.63(m，2H)，7.57(t，1H)，7.23(d，1H)ppm；LC-MS(ES+)474.12(M+H)，(ES-)472.15(M-H)；HPLC-Method?A，R
t3.28min.
Embodiment 70 (5-nitro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-70): preparation (yield 82%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.6(s，br，1H)，11.4(s，br，1H)，8.75(s，1H)，8.72(d，1H)，8.09(dd，1H)，7.98(t，1H)，7.83(d，1H)，7.75(t，1H)，7.70(m，2H)，7.61(m，3H)ppm；LC-MS(ES+)451.14(M+H)，(ES-)449.12(M-H)；HPLC-MethodA，R
t3.02min.
Embodiment 71 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-71): preparation (yield 60%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.7(s，br，1H)，11.2(s，br，1H)，8.73(d，1H)，8.03(t，1H)，7.88(d，1H)，7.80(m，2H)，7.70(m，3H)，7.32(m，2H)ppm；LC-MS(ES+)442.14(M+H)，(ES-)440.14(M-H)；HPLC-Method?A，R
t?3.11min.
Embodiment 72 (4-pyrroles-1-base-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-72): preparation (yield 33%) in DMF is yellow solid.
1HNMR (500MHz，DMSO-d6)δ13.4(s，br，1H)，11.0(s，br，1H)，8.53(d，1H)，7.98(t，1H)，7.75(m，4H)，7.62(m，2H)，7.52(d，1H)，7.43(t，1H)，7.05(d，1H)，6.80(s，2H)，5.61(s，2H)ppm；LC-MS(ES+)471.18(M+H)，(ES-)469.18(M-H)；HPLC-Method?A，R
t?3.12min.
Embodiment 73 (5-amino-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-73): with Compound I I-70 (70mg, 0.16mmol) MeOH (2ml) solution handle with Raney nickel, until solution colourless (adding about 1.5g Raney nickel).After at room temperature stirring 40min, by C salt filtering mixt, gained C salt washs (5 times) with MeOH, and evaporating solvent obtains crude product in a vacuum, passes through the HPLC purifying then, obtains title compound, is yellow solid (10mg, yield 15%).
m.p.221-223℃；
1HNMR(500MHz，DMSO-d6)δ13.2(s，br，1H)，10.7(s，br，1H)，9.80(br，2H)，8.68(d，1H)，7.97(t，1H)，7.87(d，1H)，7.75(m，2H)，7.65(m，5H)，7.30(d，1H)ppm；MS(ES+)421.16(M+H)，(ES-)419.17(M-H)；HPLC-Method?A，R
t?2.41min.
Embodiment 74[2-(2-chloro-phenyl)-quinazoline-4-yl]-(7-fluoro-1H-indazole-3-yl)-amine (II-74): preparation (yield 35%) in DMF is yellow solid.
1HNMR (500MHz，DMSO-d6)δ13.7(s，1H)，11.7(s，br，1H)，8.80(d，1H)，8.15(t，1H)，7.99(d，1H)，7.88(t，1H)，7.68(d，1H)，7.60(m，2H)，7.53(t，1H)，7.46(t，1H)，7.25(dd，1H)，7.04(m，1H)ppm；LC-MS(ES+)390.16(M+H)；HPLC-Method?A，R
t?3.00min。
Embodiment 75[2-(2-chloro-phenyl)-quinazoline-4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-75): in DMF, prepare.
1HNMR?(500MHz，DMSO-d6)δ13.2(s，1H)，11.7(s，br，1H)，8.80(d，1H)，8.10(t，1H)，7.91(m，2H)，7.70(d，1H)，7.58(m，4H)，7.50(t，1H)，7.29(t，1H)ppm；LC-MS(ES+)390.17(M+H)；HPLC-Method?A，R
t?3.00min.
Embodiment 76[2-(2-chloro-phenyl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-76): preparation (yield 55%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.8(s，1H)，11.5(s，br，1H)，8.76(d，1H)，8.08(t，1H)，7.93(d，1H)，7.84(t，1H)，7.64(d，1H)，7.55(d，1H)，7.50(t，1H)，7.44(m，2H)，7.36(t，1H)ppm；LC-MS(ES+)408.15(M+H)，(ES-)406.17(M-H)；HPLC-Method?A，R
t3.08min.
Embodiment 77[2-(2-chloro-phenyl)-quinazoline-4-yl]-(5-Trifluoromethyl-1 H-indazole-3-yl)-amine (II-77): preparation (yield 66%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.5(s，1H)，11.4(s，br，1E)，8.79(d，1H)，8.29(s，1H)，8.07(t，1H)，7.93(d，1H)，7.84(t，1H)，7.72(d，1H)，7.63(d，2H)，7.53(d，1H)，7.48(t，1H)，7.36(t，1H)ppm；LC-MS(ES+)：m/e＝440.16(M+H)；(ES-)：m/e＝438.18(M-H)；HPLC-Method?A，R
t?3.22min.
Embodiment 78[2-(2-cyano group-phenyl)-quinazoline-4-yl]-(1H-indazole-3-yl)-amine (II-78): yield 13%.
1H-NMR(500MHz，DMSO)δ12.9(br，1H)，10.8(br，1H)，8.73(br?s，1H)，7.97(m，4H)，7.74(m，1H)，7.5(m，4H)，7.42(m，1H)，7.08(m，1H)ppm；MS(FIA)363.2(M+H)；HPLC-Method?A，R
t?2.971min.
Embodiment 79 (5-bromo-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-79): preparation (yield 64%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.4(s，1H)，11.6(s，br，1H)，8.93(d，1H)，8.21(t，1H)，8.14(s，1H)，8.05(d，1H)，7.95(m，4H)，7.86(t，1H)，7.65(d，1H)，7.59(d，1H)ppm；MS(ES+)486.10(M+H)，(ES-)484.09(M-H)；HPLC-MethodA，R
t3.22min.
Embodiment 80 (6-chloro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-80): preparation (yield 94%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.1(s，1H)，11.2(s，br，1H)，8.73(d，1H)，8.03(t，1H)，7.87(d，1H)，7.79(m，2H)，7.73(m，2H)，7.67(m，2H)，7.58(s，1H)，7.04(dd，1H)ppm.LC-MS?(ES+)440.14(M+H)，(ES-)438.16(M-H)；HPLC-Method?A，R
t3.25min.
Embodiment 81 (7-fluoro-6-Trifluoromethyl-1 H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-81): preparation (yield 30%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.9(s，1H)，11.0(s，br，1H)，8.64(d，1H)，7.94(t，1H)，7.81(d，1H)，7.71(m，2H)，7.60(m，4H)，7.20(dd，1H)ppm.LC-MS(ES+)492.18(M+H)，(ES-)490.18(M-H)；HPLC-Method?A，R
t?3.44min.
Embodiment 82 (6-bromo-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-82): preparation (yield 40%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.1(s，1H)，11.2(s，br，1H)，8.73(d，1H)，8.03(t，1H)，7.87(d，1H)，7.80(m，2H)，7.73(m，3H)，7.67(m，1H)，7.61(d，1H)，7.15(dd，1H)ppm；MS(ES+)486.07(M+H)；HPLC-Method?A，R
t?3.28min.
Embodiment 83[2-(2,4-couple-trifluoromethyl-phenyl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-83): in DMF, prepare yield 28%.
1HNMR?(500MHz，MeOH-d4)δ8.81(d，J＝8.4Hz，1H)，8.35-8.20(m，3H)，8.19-7.96(m，3H)，7.40-7.34(m，1H)，7.29-7.14(m，1H)；LC-MS(ES+)510.14(M+H)；HPLC-Method?C，R
t?8.29min.
Embodiment 84 (5,7-two fluoro-1H-indazole-3-yls)-[2-(4-fluoro-2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-84): yield 48%.
1HNMR(500MHz，MeOH-d4)δ8.74-8.63(m，1H)，8.23-8.10(m，1H)，7.99-7.90(m，2H)，7.89-7.80(m，1H)，7.71-7.61(m，1H)，7.61-7.50(m，1H)，7.24-7.15(m，1H)，7.14-7.02(m，1H)；LC-MS (ES+)460.14(M+H)；HPLC-Method?C，R
t?7.59min.
Embodiment 85[2-(2-bromo-phenyl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-85): preparation (yield 21%) in THF.
1HNMR(500MHz，MeOH-d4)δ8.81(d，J＝8.4Hz，1H)，8.35-8.20(m，3H)，8.19-7.96(m，3H)，7.40-7.34(m，1H)，7.29-7.14(m，1H)；LC-MS (ES+)510.14(M+H)；HPLC-Method?C，R
t8.29min.
Embodiment 86 (5,7-two fluoro-1H-indazole-3-yls)-[2-(5-fluoro-2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (I1-86): preparation (yield 26%) in THF.
1HNMR (500MHz，MeOH-d4)δ8.62(d，J＝8.4Hz，1H)，8.16-8.02(m，1H)，7.96-.7.73(m，3H)，7.59-7.48(m，1H)，7.48-7.35(m，1H)，7.21-7.09(m，1H)，7.09-6.89(m，1H)；LC-MS (ES+)460.16(M+H)；HPLC-Method?C，R
t?7.28min.
Embodiment 87[2-(2,4-two chloro-phenyl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-87): preparation (yield 16%) in THF.
1HNMR(500MHz，MeOH-d4)δ8.81(d，J＝8.4Hz，1H)，8.35-8.20(m，3H)，8.19-7.96(m，3H)，7.40-7.34(m，1H)，7.29-7.14(m，1H)；LC-MS(ES+)510.14M+H)；HPLC-Method?C，R
t8.29min.
Embodiment 88[2-(2-chloro-5-trifluoromethyl-phenyl) quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-88): preparation (yield 33%) in THF.
1HNMR(500MHz，DMSO-d6)δ10.76(s，1H)，8.66(d，J＝8.3Hz，1H)，8.06-7.84(m，3H)，7.81-7.63(m，3H)，7.48-7.16(m，2H)；LC-MSS+)476.16(M+H)；HPLC-Method?C，R
t?19.28min.
Embodiment 89 (4-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-89): preparation (yield 79%) in NMP is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.2(e，1H)，10.8(s，br，1H)，8.63(d，1H)，7.97(t，1H)，7.85(d，1H)，7.74(m，2H)，7.64(t，1H)，7.57(m，2H)，7.32(m，2H)，6.82(m，1H)ppm；LC-MS(ES+)424.17(M+H)；HPLC-Method?A，R
t?3.14min.
Embodiment 90 (1H-indazole-3-yl)-[8-methoxyl group-2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-90): use THF to be prepared, obtain title compound, be tfa salt (yield 23%) as solvent.
1HNMR(DMSO-d6，500MHz)12.9(1H，be)，11.0-10.7(1H，bs)，8.25(1H，m)，7.75-7.50(8H，s)，7.30(1H，m)，6.90(1H，m)，4.0(3H，s)；MS(m/z)436.2(M+H).
Embodiment 91 (5-fluoro-1H-indazole-3-yl)-[8-methoxyl group-2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-91): use TFA to be prepared, obtain title compound, be tfa salt (yield 23%) as solvent.
1HNMR(DMSO-d6，500MHz)：13.0(1H，bs)，11.0-10.7(1H，bs)，8。25(1H，m)，7.75-7.50(7H，m)，7.35(1H，m)，7.25(1H，m)，4.0(3H，s)；MS(m/z)454.2(M+H).
Embodiment 92 (7-fluoro-1H-indazole-3-yl)-[8-methoxyl group-2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-92): use THF to be prepared, obtain title compound, be tfa salt (98mg, yield 58%) as solvent.
1HNMR(DMSO-d6，500MHz)δ13.45(1H，bs)，11.0-10.7(1H，bs)，8.25(1H，m)，7.75-7.60(5H，m)，7.50(1H，m)，7.40(1H，m)，7.15(1H，m)，6.95(1H，m)4.0(3H，s)；MS(m/z)454.2(M+H).
Embodiment 93 (5,7-two fluoro-1H-indazole-3-yls)-[8-methoxyl group-2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-93): use THF to be prepared, obtain title compound, be tfa salt (yield 36%) as solvent.
1HNMR?(DMSO-d6，500MHz)：13.65(1H，bs)，11.0-10.7(1H，bs)，8.22(1H，m)，7.75-7.60(5H，m)，7.40(1H，m)，7.35(1H，m)，7.19(1H，m)，4.0(3H，s)；MS(m/z)472.2(M+H).
Embodiment 94[2-(2-chloro-pyridin-3-yl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-94): in DMF, prepare.
1HNMR?(500MHz，DMSO-d6)δ13.62(br?s，1H，11.06-10.71(m，1H)，8.16-7.70(m，4H)，7.60-7.09(m，3H)；LC-MS(ES+)409.14(M+H)；HPLC-Method?A，R
t?2.89min.
Embodiment 95[2-(2-chloro-4-nitro-phenyl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-95): in THF, prepare.
1HNMR(500MHz，DMSO-d6)δ13.35(s，1H)，10.74(s，1H)，8.67(d，J＝8.4Hz，1H)，8.29(d，J＝2.05Hz，1H)，8.18-8.08(m，1H)，8.07-7.60(m，4H)，7.53-7.10(m，2H).LC-MS?(ES+)453.15(M+H)；HPLC-Method?D，R
t?3.63min.
Embodiment 96[2-(4-amino-2-chloro-phenyl)-quinazoline-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-96): with Compound I I-95 (8mg, 0.018mmol) (22mg, ethanol 0.1mmol) (2ml) solution heats 24h down at 100 ℃ with the tin chloride dihydrate.Reactant with EtOAc (10ml) dilution, with 1N NaOH solution (2x 10ml), salt water washing, through anhydrous sodium sulfate drying, is obtained crude product.(use the CH that contains 1-3%MeOH through the flash chromatography on silica gel purifying
2Cl
2Wash-out).Separate title compound, be faint yellow solid (1.2mg, 16%).LC-MS (ES+) 423.12 (M+H), HPLC-method C, R
t13.78min.
Embodiment 97 (4,5,6,7-tetrahydrochysene-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-97): yield 34%.
1HNMR(500MHz，DMSO-d6)δ1.58(m，2H)，1.66(m，2H)，2.24(m，2H)，2.54(m 2H)，7.63(m，3H)，7.71(t，1H)，7.75(d，1H)，7.78(d，1H)，7.85(t，1H)，8.53(d，1H)，9.99(s，1H)，12.09(s，1H)；EI-MS?410.2(M+1)；HPLC-Method?A，R
t?3.05min.
Embodiment 98 (1H-pyrazolo [4,3-b] pyridin-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-98): preparation (yield 37%) in DMF is yellow solid.
1HNMR(500MHz，DMSO-d6)δ13.1(s，br，1H)，11.2(s，br，1H)，8.73(d，1H)，8.54(dd，1H)，8.12(d，1H)，8.06(t，1H)，7.90(d，1H)，7.84(t，1H)，7.75(d，1H)，7.69(m，2H)，7.65(t，1H)，7.47(dd，1H)ppm；LC-MS(ES+)407.18(M+H)；HPLC-Method?A，R
t2.77min.
Embodiment 99 (1H-pyrazolo [3,4-b] pyridin-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-99): preparation (yield 45%) in DMF.
1HNMR(500MHz，DMSO-d6)δ13.5(s，br，1H)，11.3(s，br，1H)，8.78(d，1H)，8.49(d，1H)，8.17(d，1H)，8.03(t，1H)，7.89(d，1H)，7.80(m，2H)，7.74(m，2H)，7.68(m，1H)，7.08(dd，1H)ppm.MS(ES+)407.16(M+H)，(ES-)405.16(M-H)；HPLC-Method?A，R
t?2.80min.
Embodiment 100 (6-methyl isophthalic acid H-pyrazolo [3,4-b] pyridin-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-100): preparation (yield 11%) in DMF.
1HNMR(500MHz，DMSO-d6)δ13.2(s，br，1H)，10.8(s，br，1H)，8.57(d，1H)，7.95(t，1H)，7.82(d，1H)，7.72(t，1H)，7.65(m，2H)，7.58(m，2H)，2.44(s，3H，buried?by?DMSO)，2.20(s，3H)ppm.LC-MS(ES+)435.22(M+H)，(ES-)433.25(M-H)；HPLC-Method?A，R
t?2.94min.
Embodiment 101 (6-oxo-5-phenyl-5,6-dicyan-1H-pyrazolo [4,3-c] pyridazine-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-101): preparation (yield 6%) in DMF.
1HNMR(500MHz，DMSO-d6)δ12.6(s，1H)，11.0(s，br，1H)，8.60(d，1H)，7.95(t，1H)，7.88(d，1H)，7.80(d，1H)，7.68(m，4H)，7.40(s，3H)，7.22(s，2H)，6.61(s，1H)ppm.LC-MS(ES+)500.21(M+H)，(ES-)498.16(M-H)；HPLC-Method?A，R
t?3.00min.
Embodiment 103[6-methyl-2-(2-trifluoromethoxy-phenyl)-pyrimidine-4-yl]-(5-phenyl-2H-pyrazole-3-yl)-amine (II-103): MS 412.13 (M+H); HPLC-method E, R
t1.248min.
Embodiment 104 (5-furans-2-base-2H-pyrazole-3-yl)-[6-methyl-2-(2-trifluoromethoxy-phenyl)-pyrimidine-4-yl]-amine (II-104): MS 402.12 (M+H); HPLC-method E, R
t1.188min.
Embodiment 105[6-ethyl-2-(2-trifluoromethoxy-phenyl)-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-105): MS 364.14 (M+H); HPLC-method E, R
t1.112min.
Embodiment 106[2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (II-106):
1HNMR (500MHz, DMSO) δ 12.23 (s, 1H), 10.78 (s, 1H), 7.73-7.47 (m, 7H), 6.72 (s, 1H), 2.21 (s, 3H).MS：(M+H)337.02.HPLC-Method?A，R
t2.783min.
Embodiment 107 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-amine (II-107): yield 68%.
1HNMR?(500MHz，DMSO-d6)δ2.16(t，2H)，2.88(m，2H)，2.98(t，2H)，7.21(td，1H)，7.29(dd，1H)，7.50(dd，1H)，7.65(t，1H)，7.67(t，1H)，7.73(t，1H)，7.79(d，1H)，10.22(br.s，1H)，12.99(br.s，1H)；EI-MS414.2(M+H)；HPLC-Method?A，R
t?2.92min.
Embodiment 108 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-pyrido [2,3-d] pyrimidine-4-yl]-amine (II-108):
HPLC-Method?A，R
t?2.78min.(95％)；
1HNMR(DMSO-d6，500MHz)：12.95(1H，bs)，11.45δ11.15(1H，bs)，9.20(2H，m)，7.85-7.70(2H，m)，7.70-7.55(4H，m)，7.50(1H，m)，7.35(1H，m)，7.05(1H，m)；MS(m/z)407.03(M+H).
Embodiment 109 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-pyrido [2,3-d] pyrimidine-4-yl]-amine (II-109): yellow, two tfa salts (yield 25%)
HPLC
1HNMR(DMSO-d6，500MHz)：13.8-13.6(1H，bs)，11.4-11.2(1H，bs)，9.15(2H，m)，7.85-7.75(2H，m)，7.75-7.62(3H，m)，7.32(2H，m)；MS(m/z)442.98(M+H).
Embodiment 110[2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-110): from 2-amino-nicotinic acid and the preparation of 2-chloro-benzoyl chloride, obtaining title compound, is two tfa salts (yields 28%).
1HNMR(DMSO-d6，500MHz)：12.90(1H，s)，11.10-10.90(1H，bs)，9.05(2H，m)，7.75-7.60(2H，m)，7.51(1H，m)，7.45-7.25(5H，m)，6.95(1H，m)；MS(m/z)372.99(M+H).
Embodiment 111 (5-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8,9, the hot ring of 10-six hydrogen and pyrimidine-4-yl]-amine (II-111): yield 43%.
1HNMR(500MHz，DMSO-d6)δ1.46(m，2H)，1.53(m，2H)，1.77(m，4H)，2.95(m，2H)，3.04(m，2H)，7.22(m，2H)，7.50(dd，1H)，7.72(m，3H)，7.80(d，1H)，10.5(m，1H)，13.05(br?s，1H)；EI-MS?456.2(M+H)；HPLC-Method?C，R
t?11.93min.
Embodiment 112[2-(2-chloro-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-112): yield 67%.
1HNMR(500MHz，DMSO-d6)δ2.18(m，2H)，2.89(m，2H)，3.02(t，2H)，7.24(td，1H)，7.42(m，2H)，7.49(td，1H)，7.52(dd，1H)，7.54(d，1H)，7.57(dd，1H)，10.50(br.s，1H)，13.06(br.s，1H)；EI-MS?380.1(M+1)；HPLC-Method?C，R
t?9.68min.
Embodiment 113 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-amine (II-113): yield 37%.
1HNMR(500MHz，DMSO-d6)δ2.65(m，2H)，2.85(m，2H)，2.99(t，2H)，7.02(t，1H)，7.32(t，1H)，7.47(d，1H)，7.55(d，1H)，7.68(t，1H)，7.74(t，1H)，7.80(d，1H)，10.37(br.s，1H)，12.91(br.s，1H)；EI-MS?396.1(M+H)；HPLC-Method?B，R
t9.88min.
Embodiment 114 (7-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-amine (II-114): yield 40%.
1HNMR(500MHz，DMSO-d6)δ2.15(m，2H)，2.87(m，2H)，2.97(t，2H)，6.99(td，1H)，7.17(dd，1H)，7.38(d，1H)，7.65(m，2H)，7.71(t，1H)，7.78(d，1H)，10.21(br.s，1H)，13.40(br.s，1H)；EI-MS?414.1(M+H)；HPLC-MethodC，R
t?9.99min.
Embodiment 115 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-amine (II-115): according to method C preparation, yield 52%.
1HNMR(500MHz，DMSO-d6)δ2.16(m，2H)，2.89(m，2H)，2.97(t，2H)，7.19(dd，1H)，7.29(td，1H)，7.63(t，1H)，7.66(d，1H)，7.71(t，1H)，7.78(d，1H)，10.16(br.s，1H)，13.55(br.s，1H)；EI-MS432.1(M+H)；HPLC-Method?C，R
t?10.09min.
Embodiment 116[2-(2-chloro-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-116): yield 56%.
1HNMR(500MHz，DMSO-d6)δ2.16(m，2H)，2.85(m，2H)，3.01(t，2H)，7.06(t，1H)，7.34(t，1H)，7.40(t，1H)，7.48(m，2H)，7.53(d，1H)，7.56(d，1H)，7.63(d，1H)，10.39(br.s，1H)，12.91(s，1H)；EI-MS?362.1(M+H)；HPLC-Method?A，R
t?3.09min.
Embodiment 117[2-(2-chloro-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-(7-fluoro-1H-indazole-3-yl)-amine (II-117): yield 63%.
1HNMR(500MHz，DMSO-d6)δ2.15(m，2H)，2.87(m，2H)，3.00(t，2H)，7.01(td，1H)，7.19(dd，1H)，7.39(t，1H)，7.45(m，2H)，7.51(d，1H)，7.55(d，1H)，10.35(br.s，1H)，13.45(br.s，1H)；EI-MS?380.1(M+H)；HPLC-Method?A，R
t?R
t?3.15min.
Embodiment 118[2-(2-chloro-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-118): yield 60%.
1HNMR?(500MHz，DMSO-d6)δ2.18(m，2H)，2.91(m，2H)，3.01(t，2H)，7.32(t，1H)，7.33(td，1H)，7.41(t，1H)，7.48(t，1H)，7.53(d，1H)，7.55(dd，1H)，10.35(br.s，1H)，13.45(br.s，1H)；EI-MS?398.1(M+H)；HPLC-Method?A，R
t?R
t?3.24min.
Embodiment 119 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8,9, the hot ring of 10-six hydrogen and pyrimidine-4-yl]-amine (II-119): yield 36%.
1HNMR?(500MHz，DMSO-d6)δ1.47(m，2H)，1.53(m，2H)，1.78(m，4H)，2.96(m，2H)，3.06(t，2H)，7.03(t，1H)，7.47(t，1H)，7.72(d，1H)，7.73(d，1H)，7.72(m，3H)，7.81(d，1H)，10.52(m，1H)，12.97(br.s，1H)；EI-MS?438.2(M+1)；HPLC-Method?A，R
t3.37min.
Embodiment 120 (7-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8,9, the hot ring of 10-six hydrogen and pyrimidine-4-yl]-amine (II-120): yield 40%.
1HNMR(500MHz，DMSO-d6)δ1.46(m，2H)，1.52(m，2H)，1.77(m，4H)，2.94(m，2H)，3.04(m，2H)，7.00(td，1H)，7.17(dd，1H)，7.30(d，1H)，7.70(m，3H)，7.79(d，1H)，10.5(m，1H)，13.49(br?s，1H)；EI-MS?456.1(M+H)；HPLC-Method?A，R
t?3.43min.
Embodiment 121 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-5,6,7,8,9, the hot ring of 10-six hydrogen and pyrimidine-4-yl]-amine (II-121): yield 48%.
1HNMR(500MHz，DMSO-d6)δ1.46(m，2H)，1.52(m，2H)，1.77(m，4H)，2.95(m，2H)，3.03(m，2H)，7.14(d，1H)，7.30(t，1H)，7.73(m，3H)，7.80(d，1H)，10.5(m，1H)，13.62(br.s，1H)；EI-MS?475.1(M+1)；HPLC-Method?A，R
t?3.52min.
Embodiment 122[6-cyclohexyl-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-122): yield 45%.
1HNMR(500MHz，CDCl3)δ1.30(2H，m)，1.46(2H，m)，1.65(2H，m)，1.76(2H，m)，1.91(2H，m)，2.61(1H，br?m)，7.08(1H，t，J＝7.4Hz)，7.27(1H，d，J＝8.0Hz)，7.35(1H，t，J＝7.1Hz)，7.50(1H，t，J＝7.0Hz)，7.58(1H，t，J＝7.4Hz)，7.66(3H，m)，7.72(1H，d，J＝7.8Hz)，8.0(1H，br)，9.87(1H，br)ppm；HPLC-MethodD，R
t?3.57min；LC-MS?438.17(M+H)
+
Embodiment 123[6-(2-fluoro-phenyl)-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-123): yield 8%.
1HNMR(500MHz，CDCl
3)7.18(3H，m)，7.37(1H，m)，7.43(1H，t，J7.9Hz)，7.51(1H，d，J＝7.9Hz)，7.55(1H，t，J＝7.6Hz)，7.65(1H，t，J＝7.4Hz)，7.79(1H，d，J＝7.9Hz)，7.85(1H，d，J＝7.6Hz)，8.19(2H，m)，8.70(1H，d，J＝8.5Hz)ppm；HPLC-Method?D，R
t?4.93min；LC-MS?450.13(M+H)
+
Embodiment 124 (6-fluoro-1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (II-124): preparation (yield 87%) in DMF is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.0(s，1H)，11.1(s，br，1H)，8.66(d，1H)，7.95(t，1H)，7.80(d，1H)，7.72(m，2H)，7.62(m，4H)，7.21(dd，1H)，6.84(td，1H)ppm.LC-MS(ES+)424.15(M+H)；HPLC-Method?A，R
t?3.05min.
Embodiment 1253-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-base is amino]-1H-indazole-5-carboxylate methyl ester (II-125): to Compound I I-79 (100mg, 0.21mmol) DMF (2ml) solution add MeOH (1ml), DIEA (54 μ l, 0.31mmol) and PdCl
2(dppf) (4mg, 0.005mmol).Flask with CO flushing three times, is used the CO airbag aeration then.Reaction mixture is heated 14h down at 80 ℃, pour in the water then.Collection gained precipitation washes with water.Crude product at first passes through quick column purification (silica gel contains the hexane of 50% ethyl acetate) then, passes through the preparation HPLC purifying again, obtains II-125 (yield 32%), is yellow solid.
1HNMR?(500MHz，DMSO-d6)δ13.3(s，1H)，11.3(s，br，1H)，8.70(d，1H)，8.36(s，1H)，7.97(t，1H)，7.82(m，2H)，7.71(m，3H)，7.58(m，2H)，7.51(d，1H)，3.75(s，3H)ppm；LC-MS?(ES+)464.13(M+H)；HPLC-Method?A，R
t?3.12min.
Embodiment 208 (5-methyl-2H-pyrazole-3-yl)-[2-(2-naphthalene-1-yl)-quinazoline-4-yl]-amine (II-208):
1HNMR(500MHz，DMSO-d6)δ8.92(s，1H)，8.73(m，1H)，8.39(m，1H)，8.09(m，2H)，7.95(m，3H)，7.62(m，3H)，6.78(s，1H)，2.32(s，3H)；MS?352.2(M+H).
Embodiment 209[2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine 4-yl]-(7-fluoro-1H-indazole-3-yl)-amine (II-214): from 4-chloro-2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine (100mg, 0.36mmol) and 7-fluoro-1H-indazole-3-base amine (108mg, 0.72mmol) preparation.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (93mg, yield 46%).HPLC-Method?A，R
t?3.04min?；
1H?NMR(DMSO，500MHz)：δ13.67(1H，s)，11.40-11.25(1H，bs)，9.35-9.25(2H，m)，7.95(1H，m)，7.80-7.47(5H，m)，7.35(1H，m)，7.15(1H，m)；MS(m/z)，MH
+391.1.
Embodiment 210[2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine-4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-215): from 4-chloro-2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine (100mg, 0.36mmol) and 5-fluoro-1H-indazole-3-base amine (108mg, 0.72mmol) preparation.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (45mg, yield 22%).HPLC-Method?A，R
t?3.00min；
1H?NMR(DMSO，500MHz)：δ13.0(1H，s)，10.90(1H，bs)，9.15-9.05(2H，m)，7.70(1H，m)，7.60-7.30(6H，m)，7.20(1H，m)；MS(m/z)，MH
+?391.1.
Embodiment 211[2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-216): from 4-chloro-2-(2-chloro-phenyl)-pyrido [2,3-d] pyrimidine (100mg, 0.36mmol) and 5,7-two fluoro-1H-indazoles-3-base amine (112mg, 0.66mmol) preparation.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (130mg, yield 62%).HPLC-Method?A，R
t?3.12min；
1H?NMR(DMSO，500MHz)：13.80-13.60(1H，bs)，11.30-11.10(1H，bs)，9.20-9.10(2H，m)，7.80(1H，m)，7.60-7.30(6H，m)；MS(m/z)，MH
+?409.1.
Embodiment 212[2-(2-chloro-phenyl)-pyrido [3,4-d] pyrimidine-4-yl]-(1H-indazole-3-yl)-amine (II-217): from 4-chloro-2-(2-chloro-phenyl)-pyrido [3,4-d] (100mg is 0.36mmol) with 1H-indazole-3-base amine (88mg, 0.66mmol) preparation for pyrimidine.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (72mg, yield 33%).HPLC-Method?A，R
t?3.21min；
1H?NMR(DMSO，500MHz)：δ12.95(1H，s)，10.90(1H，bs)，9.25(1H，s)，8.75(1H，m)，8.55(1H，m)，7.65(1H，m)，7.55(1H，m)，7.50-7.30(5H，m)，7.00(1H，m)；MS(m/z)，MH
+373.1.
Embodiment 213[2-(2-chloro-phenyl)-pyrido [3,4-d] pyrimidine-4-yl]-(7-fluoro-1H-indazole-3-yl)-amine (II-218): from 4-chloro-2-(2-chloro-phenyl)-pyrido [3,4-d] pyrimidine (100mg, 0.36mmol) and 7-fluoro-1H-indazole-3-base amine (108mg, 0.72mmol) preparation.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (48.7mg, yield 22%).HPLC-Method?A，R
t3.35min；
1H?NMR(DMSO，500MHz)：δ12.95(1H，s)，10.90(1H，bs)，9.25(1H，s)，8.75(1H，m)，8.55(1H，m)，7.70-7.35(5H，m)，7.25(1H，m)，6.95(1H，m)，；MS(m/z)，MH
+?391.08.
Embodiment 214[2-(2-chloro-phenyl)-pyrido [3,4-d] is phonetic-the 4-yl]-(5-fluoro-1H-indazole-3-yl)-amine (II-219): from 4-chloro-2-(2-chloro-5-fluoro-1H-indazole-3-base amine (108mg, 0.72mmol) preparation.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (57.2mg, yield 26%).HPLC-Method?A，R
t?3.27min；
1H?NMR(DMSO，500MHz)：δ13.05(1H，s)，10.95(1H，s)，9.25(1H，s)，8.75(1H，m)，8.55(1H，m)，7.60(1H，m)，7.55(1H，m)，7.50-7.30(5H，m)，7.25(1H，m)；MS(m/z)，MH
+391.1.
Embodiment 215[2-(2-chloro-phenyl)-pyrido [3,4-d] pyrimidine-4-yl]-(5,7-two fluoro-1H-indazole-3-yls)-amine (II-220): from 4-chloro-2-(2-chloro-7-two fluoro-1H-indazoles-3-base amine (112mg, 0.66mmol) preparation.Through the preparation HPLC purifying, obtain title compound, be yellow, two tfa salts (57.2mg, yield 26%).
HPLC-Method?A，R
t?3.45min；
1H?NMR(DMSO，500MHz)：δ13.65(1H，s)，11.0(1H，s)，9.25(1H，s)，8.80(1H，m)，8.50(1H，m)，7.60(1H，m)，7.55(1H，m)，7.50-7.30(5H，m)；MS(m/z)，MH
+409.1.
Embodiment 2166-fluoro-1H-indazole-3-base amine (A1):
1HNMR (500MHz, DMSO-d6) δ 11.4 (s, 1H), 7.68 (dd, 1H), 6.95 (dd, 1H), 6.75 (td, 1H), 5.45 (s, 2H) ppm; LC-MS (ES+) 152.03 (M+H); HPLC-Method A, R
t2.00min.
Embodiment 2175-fluoro-1H-indazole-3-base amine (A2):
1HNMR (500MHz, DMSO-d6) δ 11.3 (s, 1H), 7.43 (d, 1H), 7.22 (m, 1H), 7.08 (m, 1H), 5.29 (s, 2H) ppm; LC-MS (ES+) 152.01 (M+H); HPLC-Method A, R
t1.93min.
Embodiment 2185,7-two fluoro-1H-indazoles-3-base-amine (A3):
1HNMR (500MHz, CD
3OD) δ 7.22 (dd, J=2.0,8.45Hz, 1H), 7.04-6.87 (m, 1H); LC-MS (ES+) 169.95 (M+H); HPLC-Method C, R
t2.94min
Embodiment 2197-fluoro-1H-indazole-3-base amine (A4):
1HNMR (500MHz, DMSO-d6) δ 11.8 (s, 1H), 7.42 (d, 1H), 6.97 (m, 1H), 6.78 (m, 1H), 5.40 (s, 2H) ppm; LCMS (ES+) 152.01 (M+H); HPLC-Method A, R
t2.00min.
Embodiment 220 7-fluoro-6-Trifluoromethyl-1 H-indazoles-3-base amine (A5):
1H-(500MHz，DMSO)δ12.5(s，1H)，7.75(d，1H)，7.25(m，1H)，5.85(m，1H)ppm；MS(FIA)220.0(M+H)；HPLC-Method?A，R
t?2.899min.
Embodiment 2216-bromo-1H-indazole-3-base amine (A6):
1H-NMR (500MHz, DMSO) δ 11.5 (s, 1H), 7.65 (d, 1H), 7.40 (s, 1H), 7.00 (d, 1H), 5.45 (br s, 1H) ppm; MS (FIA) 213.8 (M+H); HPLC-Method A, R
t2.441min.
Embodiment 2224-fluoro-1H-indazole-3-base amine (A7):
1H-NMR (500MHz, DMSO) δ 11.7 (s, 1H), 7.17 (m, 1H), 7.05 (d, 1H), 6.7 (br, 1H), 6.60 (dd, 1H), 5.20 (br s, 2H) ppm; MS (FIA) 152.0 (M+H); Method A, R
t2.256min.
Embodiment 2235-bromo-1H-indazole-3-base amine (A8):
1H-NMR (500MHz, DMSO) δ 11.55 (br s, 1H), 7.95 (s, 1H), 7.30 (d, 1H), 7.20 (d, 1H), 5.45 (br s, 2H) ppm; MS (FIA) 213.8 (M+H); Method A, R
t2.451min.
Embodiment 2245-nitro-1H-indazole-3-base amine (A9):
1H-NMR (500MHz, DMSO-d6) δ 9.00 (s, 1H), 8.20 (d, 1H), 7.45 (d, 1H), 6.15 (br s, 1H) ppm; Method A, R
t2.184min
Embodiment 2254-pyrroles-1-base-1H-indazole-3-base amine (A10):
1H-NMR (500MHz, DMSO) δ 7.20 (s, 2H), 7.00 (s, 2H), 6.75 (m, 1H), 6.25 (s, 2H), 4.30 (d, 1H) ppm; Method A, R
t2.625min.
Embodiment 2264-chloro-5,6-dimethyl-2-(2-trifluoromethyl-phenyl)-pyrimidine (B1): obtain colourless oil, yield 75%.
1H-NMR(500MHz，CDCl3)δ7.70(d，J＝7.8Hz，1H)，7.64(d，J＝7.6Hz，1H)，7.55(t，J＝7.6Hz，1H)，7.48(t，J＝7.5Hz，1H)，2.54(s，3H)，2.36(s，3H)ppm；MS(FIA)287.0(M+H)；HPLC-Method?A，R
t?3.891min.
Embodiment 2274-chloro-2-(2-chloro-phenyl)-5,6-dimethyl pyrimidine (B2): obtain yellowish-orange oil, yield 71%.
1H-NMR(500MHz，CDCl3)δ7.73(m，1H)，7.52(m，1H)，7.39(m，2H)，2.66(s，3H)，2.45(s，3H)ppm；MS(FIA)253.0(M+H)；HPLC-Method?A，R
t?R
t?4.156min.
Embodiment 2284-chloro-6-methyl-2-(2-trifluoromethyl-phenyl)-pyrimidine (B3): obtain light yellow oil, yield 68%.
1H-NMR(500MHz，CDCl3)δ7.72(d，J＝7.8Hz，1H)，7.65(d，J＝7.9Hz，1H)，7.57(t，J＝7.5Hz，1H)，7.52(t，J＝7.8Hz，1H)，7.16(s，1H)，2.54(s，3H)ppm；MS(FIA)273.0(M+H)；HPLC-Method?A，R
t?3.746min.
Embodiment 2294-chloro-6-cyclohexyl-2-(2-trifluoromethyl-phenyl)-pyrimidine (B4): obtain xanchromatic oil, yield 22%.
1H-NMR(500MHz，CDCl3)δ7.70(m，2H)，7.57(t，J＝7.5Hz，1H)，7.50(t，J＝7.5Hz，1H)，7.19(s，1H)，2.65(m，1H)，1.9(m，2H)，1.8(m，2H)，1.5(m，2H)，1.3(m，2H)，1.2(m，2H)ppm；MS(FIA)341.0(M+H).
Embodiment 2304-chloro-6-phenyl-2-(2-trifluoromethyl-phenyl)-pyrimidine (B5): obtain xanchromatic oil, yield 53%.
1H-NMR(500MHz，CDCl3)δ8.08(dd，J＝7.9，1.6Hz，2H)，7.80(d，J＝7.6Hz，1H)，7.77(d，J＝7.8Hz，1H)，7.67(s，1H)，7.61(t，J＝7.5Hz，1H)，7.54(t，J＝7.6Hz，1H)，7.47(m，3H)ppm；MS(FIA)335.0(M+H)；HPLC-Method?A，R
t?4.393min.
Embodiment 2314-chloro-2-(2,4-two chloro-phenyl)-5,6-dimethyl-pyrimidine (B6): obtain white solid, yield 91%.
1H-NMR(500MHz，CDCl3)δ7.62(d，J＝8.3Hz，1H)，7.43(d，J＝7.0Hz，1H)，7.27(dd，J＝8.3，2.0Hz，1H)，2.55(s，3H)，2.35(s，3H)ppm；MS(FIA)287，289(M+H)；HPLC-Method?A，R
t?4.140min.
Embodiment 2324-chloro-6-(2-chloro-phenyl)-2-(2-trifluoromethyl-phenyl)-pyrimidine (B7): obtain xanchromatic oil, yield 52%.
1H-NMR(500MHz，CDCl3)δ7.75(m，3H)，7.65(m，2H)，7.53(m，1H)，7.44(m，1H)，7.36(m，2H)ppm；MS(FIA)369.1(M+H)；HPLC-Method?A，R
t4.426min.
Embodiment 2334-chloro-6-(2-fluoro-phenyl)-2-(2-trifluoromethyl-phenyl)-pyrimidine (B8): obtain xanchromatic oil, yield 95%.
1H-NMR(500MHz，CDCl3)δ8.24(t，J＝7.9Hz，1H)，7.84(s，1H)，7.78(d，J＝7.7Hz，1H)，7.76(d，J＝8.0Hz，1H)，7.60(t，J＝7.5Hz，1H)，7.53(t，J＝7.6Hz，1H)，7.43(m，1H)，7.23(t，J＝7.6Hz，1H)，7.13(m，1H)ppm?；MS(FIA)353.0(M+H).
Embodiment 234 4-chloro-6-pyridines-2-base-2-(2-trifluoromethyl-phenyl)-pyrimidine (B9): obtain faint yellow solid, yield 50%.
1H-NMR(500MHz，CDCl3)δ8.68(m，1H)，8.48(dd，J＝7.9，0.8Hz，1H)，8.38(d，J＝2.3Hz，1H)，7.84(m，3H)，7.62(t，J＝7.6Hz，1H)，7.55(t，J＝7.6Hz，1H)，7.38(m，1H)ppm；MS(FIA)336.0(M+H)；HPLC-Method?A，R
t?4.575min.
Embodiment 2356-benzyl-4-chloro-2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydrochysene-pyrido [4,3-d] pyrimidines (B10):
1HNMR?(500MHz，CDCl
3)δ7.70(d，1H)，7.62(d，1H)；7.55(t，1H)，7.48(t，1H)，7.32(m，4H)，7.25(m，1H)，3.74(s，2H)，3.66(s，2H)，2.99(t，2H)，2.80(t，2H)ppm；LCMS(ES+)404.17(M+H)；HPLC-Method?A，R
t?3.18min.
Embodiment 2367-benzyl-4-chloro-2-(2-trifluoromethyl-phenyl)-5,6,7,8-tetrahydrochysene-pyrido [3,4-d] pyrimidines (B11):
1HNMR(500MHz，CDCl
3)δ7.69(d，1H)，7.60(d，1H)，7.54(t，1H)，7.47(t，1H)，7.28(m，4H)，7.20(m，1H)，3.68(s，2H)，3.67(s，2H)，2.86(t，2H)，2.79(t，2H)ppm.MS(ES+)404.18(M+H)；HPLC-Method?A，R
t?3.12min.
Embodiment 237 4-chloro-2-(4-fluoro-2-trifluoromethyl-phenyl)-quinazoline (B12):
1HNMR?(500MHz，CD
3OD)δ8.43(d，J＝8.1Hz，1H)，8.20-8.05(m，2H)，8.05-7.82(m，2H)，7.71-7.51(m，2H).LC-MS (ES+)327.09(M+H).HPLC-MethodD，R
t?4.56min.
Embodiment 2384-chloro-2-(2-chloro-5-trifluoromethyl-phenyl)-quinazoline (B13): LC-MS (ES+) 342.97 (M+H) .HPLC-method D, R
t4.91min.
Embodiment 239 4-chloro-2-(2-chloro-4-nitro-phenyl)-quinazoline (B14): LC-MS (ES+) 319.98 (M+H) .HPLC-method D, R
t4.45min.
Embodiment 240 4-chloro-2-(2-trifluoromethyl-phenyl)-quinazolines (B15): yield 57%.White solid.
1HNMR?(500MHz，DMSO-d6)δ7.79(t，1H)，7.86(t，1H)，7.94(m，3H)，8.15(dd，1H)，8.20(td，1H)，8.37(m，1H)；EI-MS?308.9(M).
Embodiment 2414-chloro-2-(2-trifluoromethyl-phenyl)-6,7-dihydro-5H-penta ring and pyrimidine (B16): yield 22%.
1HNMR(500MHz，DMSO-d6)δ2.19(m，H)，3.01(t，2H)，3.08(t，2H)，7.49(t，1H)，7.55(t，1H)，7.62(d，1H)，7.71(d，1H).EI-MS?299.0(M+H).
Embodiment 242 4-chloro-2-(2-chloro-phenyl)-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine (B17) heptan: according to method C preparation, yield 82% obtains white solid.
1HNMR(500MHz，CDCl
3)δ1.67(m?4H)，1.87(m 2H)，3.02(m?4H)，7.28(m，2H)，7.40(m，1H)，7.65(m，1H)；EI-MS?293.0(M+1).
Embodiment 243 4-chloro-2-(2-trifluoromethyl-phenyl)-5,6,7,8,9,10-six hydrogen-Xin ring and pyrimidine (B18): yield 38% obtains the oil of brown.
1HNMR(500MHz，CDCl
3)δ1.35(m?2H)；1.41(m?2H)，1.76(m?4H)，2.96(m，4H)，7.48(t，1H)，7.56(t，1H)，7.66(d，1H)，7.70(d，1H)；EI-MS?341.0(M+1).
Embodiment 244 4-chloro-8-methoxyl group-2-(2-trifluoromethyl-phenyl)-quinazolines (B19): from 8-methoxyl group-2-(2-trifluoromethyl-phenyl)-3H-quinazoline-4-one (1.0g, 3.12mmol), Triethylammonium chloride (472mg, 3.43mmol) and POCl
3Preparation.Through purification by flash chromatography, obtain white solid (89%).HPLC-method A, R
t4.10min, (98%), MS (m/z) 258.08 (M+H).
Embodiment 245 2-(4-chloro-quinazoline-2-yl)-benzonitrile (B20): obtain yellow solid, yield 1.5%.
1H-NMR(500MHz，CDCl3)δ8.47(d，1H)，8.24(d，1H)，8.16(d，1H)，8.07(impurity)，7.94(t，1H)，7.92(impurity)，7.86(d，1H)，7.68(m，2H)，7.65(impurity)，7.54(impurity)，7.49(t，1H)，4.2(impurity)，1.05(impurity)ppm；MS(LC/MS)266.05(M+H)；HPLC-Method?A，R
t?3.88min.
Embodiment 246 6-methyl-2-(2-trifluoromethyl-phenyl)-3H-pyrimidin-4-one (D3): obtain yellow solid, yield 50%.
1H-NMR(500MHz，DMSO-d6)δ12.7(brs，1H)，7.9(m，1H)，7.8(m，2H)，7.7(m，1H)，6.3(s，1H)，2.21(s，3H)ppm；MS(FIA)255.0(M+H)；HPLC-Method?A，R
t2.578min.
Embodiment 247 6-cyclohexyl-2-(2-trifluoromethyl-phenyl)-3H-pyrimidin-4-one (D4): obtain pale solid, yield 54%.
1H-NMR(500MHz，DMSO-d6)δ12.9(brs，1H)，7.9(m，4H)，6.3(s，1H)，2.5(m，1H)，1.9(m，5H)，1.4(m，5H)ppm；MS(FIA)323.1(M+H)；HPLC-MethodA，R
t?3.842min.
Embodiment 248 2-(2-chloro-5-trifluoromethyl-phenyl)-3H-quinazoline-4-one (D10):
1HNMR?(500MHz，CD
3OD)δ8.32-8.25(m，1H)，8.01(s，1H)，7.91-7.72(m，1H)，7.66-7.55(m，1H).LC-MS (ES+)325.01(M+H).HPLC-Method?D，R
t?3.29min.
Embodiment 249 2-(4-fluoro-2-trifluoromethyl-phenyl)-3H-quinazoline-4-one (D14):
1HNMR(500MHz，CD
3OD)δ8.28(d，8.0Hz，1H)，7.94-7.84(m，1H)，7.84-7.77(m，1H)，7.76-7.67(m，2H)，7.65-7.53(m，2H).LC-MS(ES+)309.06(M+H).HPLC-Method?D，R
t?2.88min.
Embodiment 2502-(4-nitro-2-chloro-phenyl)-3H-quinazoline-4-one (D15): LC-MS (ES+) 302.03 (M+H) .HPLC-method D, R
t2.81min.
Embodiment 2512-(5-fluoro-2-trifluoromethyl-phenyl)-3H-quinazoline-4-one (D17):
1HNMR(500MHz，CD
3OD)δ8.28(d，R
t?J＝8.05Hz，1H)，7.96(dd，J＝5.05，8.55Hz，1H)，7.89(t，J＝7.9Hz，1H)，7.78-7.69(m，1H)，7.66-7.46(m，3H).LC-MS(ES+)309.14(M+H).HPLC-Method?D，R
t?2.90min.
Embodiment 252 (1H-indazole-3 base)-(2-phenyl-quinazoline-4-yl)-amine (III-1): A prepares in DMF according to method, obtains 70mg (50%), is faint yellow solid.
1H?NMR(500MHz，DMSO-d6)δ13.1(s，br，1H)，8.48(d，1H)，7.91(d，2H)，7.76(br，2H)，7.45(m，2H)，7.36(d，1H)，7.20(m，4H)，6.86(t，1H)ppm.MS (ES+)338.07(M+H)；(ES-)336.11(M-H)；HPLC-Method?A，R
t2.88min.
Embodiment 253 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-5,6,7,8-tetrahydro quinazoline-4-yl)-amine (III-7): prepare according to method A.
1H?NMR(500MHz，DMSO-d6)δ12.1(s，br，1H)，8.70(s，br，1H)，8.37(d，J?＝6.7Hz，2H)，7.54(m，3H)，6.67(s，1H)，2.82(m，2H)，2.68(m，2H)，2.37(s，3H)，1.90(s，br，4H)；MS?306.1(M+H).
Embodiment 254 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-6,7,8,9-tetrahydrochysene-5H-encircles and pyrimidine-4-yl heptan)-amine (III-8): MS 320.48 (M+H); HPLC-method E, R
t1.124min.
Embodiment 255 (5-methyl-2H-pyrazole-3-yl)-(2-pyridin-4-yl-quinazoline-4-yl)-amine (I II-9): yellow solid, mp 286-289 ℃,
1H NMR (DMSO) δ 2.35 (3H, s), 6.76 (1H, s), 7.61 (1H, m), 7.89 (2H, m), 8.32 (2H, d), 8.70 (1H, d), 8.78 (2H, d), 10.56 (1H, br s), 12.30 (1H, br s); IR (solid) 1620,1598,1571,1554,1483,1413,1370,1328; MS 303.2 (M+H)
+
Embodiment 256 (7-chloro-2-pyridin-4-yl-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (III-28):
1H NMR (DMSO-d6) δ 2.35 (3H, s), 6.75 (1H, s), 7.65 (1H, d), 7.93 (1H, s), 8.30 (2H, d), 8.73 (1H, d), 8.79 (2H, d), 10.69 (1H, s), 12.33 (1H, s); MS m/z 337.2 (M+H)
+.
Embodiment 257 (6-chloro-2-pyridin-4-yl-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (III-29):
1H NMR (DMSO-d6) δ 2.31 (3H, s), 6.74 (1H, s), 7.89 (1H, s), 8.30 (2H, d), 8.80 (2H, d), 8.91 (1H, s), 10.63 (1H, s), 12.29 (1H, s); MS 337.2 (M+H)
+.
Embodiment 258 (2-cyclohexyl-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (III-30):
1H NMR (DMSO) δ 2.35 (3H, s), 1.70 (3H, m), 1.87 (2H, d), 1.99 (2H, d), 2.95 (1H, t), 6.72 (1H, s), 7.75 (1H, d), 7.88 (1H, s), 7.96 (1H, s), 8.83 (1H, s), 11.95 (1H, s), 12.70 (1H, s); MS 308.4 (M+H)
+.
246 ℃ of embodiment 259 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-31): mp;
1H NMR (400MHz) δ 2.35 (3H, s), 6.70 (1H, br s), 7.51-7.57 (4H, m), 7.83-7.84 (2H, d), 8.47-8.50 (2H, d), 8.65 (1H, d), 10.4 (1H, s), 12.2 (1H, bs); IR (solid) 3696,3680,2972,2922,2865; MS 302.1 (M+H)+.
Embodiment 260[2-(4-iodo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-32):
1H?NMR(DMSO-d6)δ2.34(3H，s)，6.72(1H，s)，7.56(1H，d)，7.84(2H，d)，7.93(2H，d)，8.23(2H，d)，8.65(1H，s)，10.44(1H，s)，12.24(1H，s)；MS?428.5(M+H)+.
Embodiment 261[2-(3,4-two chloro-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-33): with 2-(3,4-two chloro-phenyl)-(1g, phosphoryl chloride 3.43mmol) (4ml) suspension stirs 3h down at 110 ℃ to the 3H-quinazoline-4-one.Evaporation removes and desolvates, and resistates is used cold saturated NaHCO carefully
3The aqueous solution is handled.Filter and collect the gained solid,, obtain 4-chloro-2-(3,5-two chloro-phenyl)-quinazoline, be white solid (993mg, 93%) with the ether washing.To above-claimed cpd (400mg, THF 1.29mmol) (30ml) solution add the 3-amino-5-methylpyrazole (396mg, 2.58mmol), with the gained mixture 65 ℃ of following heated overnight.Evaporating solvent is developed resistates with ethyl acetate, filter, and with the small amount of ethanol washing, obtains compound III-33, is white solid (311mg, 65%):
mp?274℃；
1H?NMR(DMSO)δ2.34(3H，s)，6.69(1H，s)，7.60(1H，m)，7.84(1H，d)，7.96(2H，d)，8.39(1H，dd)，8.60(1H，d)，8.65(1H，d)，10.51(1H，s)，12.30(1H，s)；IR(solid)1619，1600，1559，1528，1476，1449，1376，1352，797，764，738；MS370.5(M+H)
+.
Embodiment 262[2-(4-bromo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-34):
mp?262-265℃；
1HNMR(DMSO)δ2.34(3S，s)，6.73(1H，s)，7.55(1H，m)，7.74(2H，d)，7.83(2H，m)，8.40(2H，d)，8.65(1H，d)，10.44(1H，s)，12.25(1H，s)；IR(solid)1603，1579，1546，1484，1408，1365；MS?380.1/382.1(M+H)+.
Embodiment 263[2-(4-chloro-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-35):
mp＞300℃；
1H?NMR(DMSO)δ2.34(3H，s)，6.74(1H，s)，7.53-7.62(3H，m)，7.84(2H，d)，8.47(2H，d)，8.65(1H，d)，10.44(1H，s)，12.26(1H，s)；IR(solid)1628，1608，1584，1546，1489，1408，1369，1169；MS?336.2(M+H)+.
Embodiment 264[2-(3,5-two chloro-phenyl)-quinazoline-4-yl]-228 ℃ of (5-methyl-2H-pyrazole-3-yl)-amine (III-36): mp;
1H NMR (DMSO) δ 2.34 (3H, s), 6.69 (1H, s), 7.96 (1H, d), 8.21 (3H, m), 8.56 (1H, d), 8.60 (2H, d), 10.51 (1H, s), 12.30 (1H, s); IR (solid) 1546,1331,802,763,729,658,652; MS 370.5 (M+H)+.
Embodiment 265[2-(4-cyano group-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-37):
mp?263℃；
1H?NMR(DMSO)δ2.34(3H，s)，6.72(1H，s)，7.61(1H，d)，7.88(2H，s)，8.04(2H，d)，8.63(2H，d)，8.67(1H，s)，10.52(1H，s)，12.27(1H，s)；IR(solid)1739，1436，1366，1229，1217；MS?327.2(M+H)+.
Embodiment 266[2-(3-iodo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-38): mp 234-235 ℃;
1H NMR (DMSO) δ 2.35 (3H, s), 6.73 (1H, s), 7.35 (1H, m), 7.56 (1H, m), 7.85 (3H, m), 8.47 (1H, m), 8.65 (1H, m), 8.86 (1H, s), 10.49 (1H, s), 12.28 (1H, br s); IR (solid) 1560,1541,1469,1360; MS 428.1 (M+H)+.
Embodiment 267[2-(4-ethylmercapto group-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-39): mp229-231 ℃;
1H NMR (DMSO) δ 1.29 (3H, t), 2.35 (3H, s), 3.07 (2H, q), 6.76 (1H, s), 7.43 (2H, d), 7.51 (1H, m), 7.81 (2H, m), 8.41 (2H, d), 8.64 (1H, d), 10.38 (1H, s), 12.24 (1H, brs); IR (solid) 1587,1574,1555,1531,1484,1412,1369; MS 362.1 (M+H)+.
Embodiment 268 (5-cyclopropyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-40):
mp?218-219℃；
1H?NMR(DMSO-d6)δ0.70-0.80(2H，m)，0.90-1.00(2H，m)，6.70(1H，s)，7.45-7.55(4H，m)，7.80-7.85(2H，m)，8.45-8.55(2H，m)，8.65(1H，d)，10.40(1H，s)，12.27(1H，s)；IR(solid)1624，1605，1591，1572，1561，1533，1479，1439，1419，1361，1327，997，828，803，780，762，710；MS?328.2(M+H)
+.
Embodiment 269[2-(the 4-tertiary butyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-41):
mp＞300℃；
1H?NMR(DMSO-d6)δ1.35(9H，s)，2.34(3H，s)，6.79(1H，s)，7.55(3H，d)，7.85(2H，d)，8.39(2H，d)，8.62(1H，d)，10.35(1H，s)，12.22(1H，s)；IR(solid)1603，1599，1577，1561，1535，1481，1409，1371，1359，998，841，825，766，757；MS?358.3(M+H)
+.
Embodiment 270[2-(4-chloro-phenyl)-quinazoline-4-yl]-(5-cyclopropyl-2H-pyrazole-3-yl)-amine (III-42):
1H NMR (DMSO-d6) δ 0.77 (4H, br m), 2.05 (1H, m), 6.59 (1H, s), 7.60 (1H, d), 7.85 (2H, d), 7.91 (2H, d), 8.22 (2H, d), 8.65 (1H, s), 10.51 (1H, s), 12.33 (1H, s); MS 362.1 (M+H)
+.
Embodiment 271 (2-benzo [1,3] dioxolane-5-base-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (III-43):
1H NMR (DMSO) δ 2.33 (3H, s), 6.13 (2H, s), 6.78 (1H, s), 7.11 (1H, d), 7.80 (1H, t), 7.94 (1H, s), 8.09 (3H, m), 8.25 (1H, d), 10.34 (1H, s), 12.21 (1H, s); MS 346.5 (M+H)
+.
Embodiment 272[2-(4-dimethylamino-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-44):
1H NMR (DMSO-d6) δ 2.02 (6H, s), 2.39 (3H, s), 6.83 (1H, s), 7.71 (1H, d), 7.98 (2H, s), 8.04 (2H, d), 8.33 (2H, d), 8.67 (1H, s), 11.82 (1H, s), 12.72 (1H, s); MS 345.3 (M+H)
+.
Embodiment 273[2-(3-methoxyl group-phenyl)-quinazoline-4-yl]-226 ℃ of (5-methyl-2H-pyrazole-3-yl)-amine (III-45): mp;
1H NMR (DMSO) δ 2.34 (3H, s), 3.92 (3H, s), 6.72 (1H, s), 7.21 (1H, d), 7.57 (1H, t), 7.79 (1H, t), 8.02 (3H, m), 8.14 (1H, s), 8.79 (1H, d), 10.39 (1H, s), 12.22 (1H, s); IR (solid) 1599,1572,1538,1478,1427,1359,833,761,661; MS 332.2 (M+H)
+.
Embodiment 275 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(3,4-two chloro-phenyl)-quinazoline-4-yl]-amine (III-46):
1H?NMR(DMSO-d6)δ0.86(2H，d)，1.02(2H，d)，1.69(1H，m)，6.56(1H，s)，7.57(1H，d)，7.84(4H，m)，8.40(1H，d)，8.58(1H，s)，8.64(1H，s)，10.53(1H，s)，12.36(1H，s)；MS?396.0(M+H)
+.
Embodiment 276 (2-biphenyl-4-base-quinazoline-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (III-47): to [2-(4-bromo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (I II-34) (196mg, 0.51mmol) with phenyl for boric acid (75mg, 0.62mmol) at THF: (1: 1,4ml) mixture in added Na to water
2CO
3(219mg, 2.06mmol), triphenyl phosphine (9mg, 1/15mol%) and acid chloride (1mg, 1: 135mol%).With the gained mixture 80 ℃ of following heated overnight, evaporating solvent, resistates through purification by flash chromatography (methylene dichloride: the MeOH gradient), obtain III-21, be yellow solid (99mg, 51%):
1H?NMR(DMSO)δ2.37(3H，s)，6.82(1H，s)，7.39-7.57(4H，m)，7.73-7.87(6H，m)，8.57(2H，d)，8.67(1H，d)，10.42(1H，s)，12.27(1H，s)；MS?378.2(M+H)
+.
Embodiment 277[2-(4-ethynyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-48): to [2-(4-bromo-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-34) (114mg, 0.3mmol) and trimethylsilyl acetylene (147mg, 1.5mmol) mixture in DMF (2ml) adds CuI (1.1mg, 1: 50mol%), Pd (PPh
3)
2Cl
2(4.2mg, 1: 50mol%) and triethylamine (121mg, 0.36mmol).With the gained mixture at 120 ℃ of following heated overnight, evaporating solvent.In ethyl acetate, develop resistates, filter and collect the gained precipitation.With collected solid suspension in THF (3ml), add TBAF (1M THF solution, 1.1eq).Reaction mixture is at room temperature stirred 2h, evaporating solvent.Resistates obtains III-48 through purification by flash chromatography (silica gel, DCM:MeOH gradient), is white solid (68mg, 70%):
1H NMR (DMSO) δ 2.34 (3H, s), 4.36 (1H, s), 6.74 (1H, s), 7.55 (1H, m), 7.65 (2H, d), 7.84 (2H, m), 8.47 (2H, d), 8.65 (1H, d), 10.43 (1H, s), 12.24 (1H, s); MS 326.1 (M+H)
+.
Embodiment 278[2-(3-ethynyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-49):
mp?204-207℃；
1HNMR(DMSO)δ2.34(3H，s)，4.28(1H，s)，6.74(1H，s)，7.55-7.63(3H，m)，7.83-7.87(2H，m)，8.49(1H，d)，8.57(1H，s)，8.65(1H，d)，10.46(1H，s)，12.27(1H，s)；IR (solid)1598，1574，1541，1489，1474，1422，1365；MS326.1(M+H)+.
Embodiment 279[2-(3-methyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-50): with 1H-quinazoline-2,4-diketone (10.0g, POCl 61.7mmol)
3(60ml, 644mmol) and N, (8ml, 63.1mmol) suspension heats 2h to accelerine under refluxing.Remove excessive POCl in a vacuum
3, resistates is poured in the ice, filter and collect the gained precipitation.With thick solid product 2,4-two chloro-quinazolines (6.5g, 53%) wash with water, and are dry under vacuum, need not to be further purified promptly to can be used for next step.To 2, (3.3g, dehydrated alcohol 16.6mmol) (150ml) solution add 5-methyl isophthalic acid H-pyrazole-3-yl amine, and (3.2g 32.9mmol), at room temperature stirred the gained mixture 4 hours 4-two chloro-quinazolines.Filter and collect the gained precipitation, use washing with alcohol, drying obtains 4.0g (93%) (2-chloro-quinazoline-4-yl)-(5-methyl isophthalic acid H-pyrazole-3-yl)-amine under vacuum, need not to be further purified promptly to can be used for next step.(50mg, tolyl was for boric acid (0.38mmol), 2MNa between DMF 0.19mmol) (1.0ml) solution added to (2-chloro-quinazoline-4-yl)-(5-methyl isophthalic acid H-pyrazole-3-yl)-amine
2CO
3(0.96mmol) and tri-butyl phosphine (0.19mmol).Wash flask with nitrogen, disposable adding catalyst P dCl
2(dppf) (0.011mmol).Then reaction mixture is heated 10h down at 80 ℃, be cooled to room temperature, pour in the water (2ml).Filter and collect the gained precipitation, wash with water,, obtain III-50, be faint yellow solid (61mg, 75%) through the HPLC purifying:
1H?NMR(500MHz，DMSO-d6)δ12.3(brs，1H)，10.4(br?s，1H)，8.75(d，1H)，8.30(s，1H)，8.25(d，1H)，7.78(s，2H)，7.55(m，1H)，7.45(m，1H)，7.35(m，1H)，6.80(s，1H)，2.47(s，3H)，2.30(s，3H)；MS?316.1(M+H).
Embodiment 280[2-(3,5-two fluoro-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-51):
1H NMR (500MHz, DMSO-d6) δ 12.3 (br s, 1H), 10.8 (br s, 1H), 8.63 (d, 1H), 7.95 (d, 2H), 7.85 (m, 2H), 7.58 (t, 1H), 7.41 (t, 1H), 6.59 (s, 1H), 2.27 (s, 3H); MS 338.1 (M+H).
Embodiment 281[2-(3-chloro-4-fluoro-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-52):
1H NMR (500MHz, DMSO-d6) δ 12.4 (br s, 1H), 10.8 (br s, 1H), 8.65 (d, 1H), 8.50 (d, 1H), 8.36 (m, 1H), 7.85 (m, 1H), 7.60 (m, 1H), 6.62 (s, 1H), 2.30 (s, 3H); MS 354.1 (M+H).
Embodiment 282 (5-methyl-2H-pyrazole-3-yl)-[2-(3-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (III-53):
1HNMR (500MHz, DMSO-d6) δ 12.2 (br, 1H), 10.45 (br, 1H), 7.53 (s, 1H), 7.43 (d, J=7.2Hz, 1H), 7.06 (d, J=8.2Hz, 1H), 6.65 (d, J=8.3Hz, 1H), 6.57 (t, J=7.6Hz, 1H), 6.51 (d, J=7.8Hz, 1H), 6.43 (t, J=7.8Hz, 1H), 6.32 (t, J=7.6Hz, 1H), 5.51 (s, 1H), 2.03 (s, 3H); MS370.2 (M+H).
Embodiment 283[2-(3-cyano group-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-54):
1H NMR (500MHz, DMSO-d6) δ 9.01 (s, 1H), 8.96 (m, 2H), 8.28 (d, J=7.3Hz, 1H), 8.16 (s, br, 2H), 8.06 (t, J=7.8Hz, 1H), 7.88 (m, 1H), 6.96 (S, 1H), 2.58 (s, 3H); MS 327.1 (M+H).
Embodiment 284[2-(3-sec.-propyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-55):
1H NMR (500MHz, DMSO-d6) δ 8.89 (d, J=7.5Hz, 1H), 8.37 (s, 1H), 8.26 (s, 1H), 8.08 (m, 2H), 7.81 (t, br, 1H), 7.67 (m, 2H), 6.88 (s, 1H), 3.12 (m, 1H), 2.40 (s, 3H), 1.38 (d, J=6.9Hz, 6H); MS 344.2 (M+H).
Embodiment 285 (5-methyl-2H-pyrazole-3-yl)-(2-pyridin-3-yl-quinazoline-4-yl)-amine (III-56):
1H(500MHz，DMSO-d6)δ9.50(s，1H)，8.84(d，J＝7.3Hz，1H)，8.80(d，J＝4.4Hz，1H)，8.66(d，J＝8.2Hz，1H)，7.87(m，2H)，7.77(m，1H)，7.60(t，J＝7.2Hz，1H)，6.67(s，1H)，2.28(s，3H)；MS?303.1(M+H).
Embodiment 286[2-(3-ethanoyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-57):
1H NMR (500MHz, DMSO-d6) δ 8.80 (s, 1H), 8.55 (d, J=7.7Hz, 1H), 8.42 (d, J=7.6Hz, 1H), 8.00 (d, J=7.0Hz, 1H), 7.76 (m, 2H), 7.58 (t, J=7.7Hz, 1H), 7.48 (s, br, 1H), 6.60 (s, 1H), 2.49 (s, 3H), 2.03 (s, 3H); MS 344.1 (M+H).
Embodiment 287[2-(3,5-di-trifluoromethyl-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-58):
1H?NMR(500MHz，DMSO-d6)δ10.7(s，br，1H)，8.95(s，2H)，8.63(d，J＝8.2Hz，1H)，8.25(s，1H)，7.86(m，2H)，7.58(t，J＝6.9Hz，1H)，6.62(s，1H)，2.26(s，3H)；MS?438.1(M+H).
Embodiment 288[2-(3-methylol-phenyl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-59):
1H NMR (500MHz, DMSO-d6) δ 8.74 (d, J=7.9Hz, 1H), 8.33 (s, 1H), 8.17 (s, br, 1H), 7.95 (s, br, 1H), 7.89 (s, br, 1H), 7.62 (m, 3H), 6.72 (s, 1H), 5.53 (s, 1H), 4.60 (s, 2H), 2.28 (s, 3H); MS 332.1 (M+H).
Embodiment 289 (5-methyl-2H-pyrazole-3-yl)-[2-(3-phenoxy group-phenyl)-quinazoline-4-yl]-amine (III-60): mp 231-232 ℃;
1H?NMR(DMSO-d6)δ2.21(3H，s)，6.59(1H，s)，7.10-7.22(4H，m)，7.41-7.45(2H，m)，7.54-7.59(2H，m)，7.81(2H，s)，8.09(1H，s)，8.27(1H，m)，8.64(1H，m)，10.40(1H，s)，12.20(1H，s)；IR(solid)；IR(solid)1589，1560，1541，1536，1484，1360，1227；MS?394.7(M+H)
+.
Embodiment 290 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(3-phenoxy group-phenyl)-quinazoline-4-yl]-amine (III-61):
1H?NMR(DMSO-d6)δ0.67(2H，m)，0.93(2H，m)，1.87(1H，m)，6.56(1H，s)，7.06-7.20(4H，m)，7.40-7.43(2H，m)，7.55-7.59(2H，m)，7.81(2H，s)，8.11(1H，s)，8.27(1H，m)，8.63(1H，m)，10.43(1H，s)，12.26(1H，s)；IR(solid)；IR(solid)1589，1574，1527，1483，1369，1226；MS?420.7(M+H)
+.
Embodiment 291 (5-methyl-2H-pyrazole-3-yl)-(2-thiene-3-yl--quinazoline-4-yl)-amine (III-62):
1H NMR (500MHz, DMSO-d6) δ 11.78 (s, br, 1H), 8.75 (d, J=8.1Hz, 1H), 8.68 (s, 1H), 7.98 (dd, J=7.9,7.5Hz, 1H), 7.89 (m, 2H), 7.81 (m, 1H), 7.68 (t, J=7.5Hz, 1H), 6.69 (s, 1H), 2.30 (s, 3H); MS 308.1 (M+H).
Embodiment 292 (2-phenyl-quinazoline-4-yl)-(2H-pyrazole-3-yl)-amine (III-63): mp 247-249 ℃;
1H NMR (DMSO) δ 6.99 (1H, brs), 7.49-7.58 (5H, m), 7.81 (1H, br s), 7.83 (2H, m), 8.47-8.49 (2H, m), 8.66 (1H, d), 10.54 (1H, s), 12.59 (1H, s); IR (solid) 3145,2922,1622,1597; MS 288.2 (M+H)
+.
Embodiment 293 (2H-pyrazole-3-yl)-(2-pyridin-4-yl-quinazoline-4-yl)-amine (III-64): mp 285-286 ℃;
1H NMR (DMSO) δ 6.99 (1H, br s), 7.65 (1H, m), 7.81-7.94 (3H, m), 8.3-8.35 (2H, m), 8.73 (1H, d), 8.84-8.90 (2H, m), 10.76 (1H, s), 12.6 (1H, s); IR (solid) 3180,2972,1600,1574; MS 289.2 (M+H)
+.
Embodiment 294 (5-ethyl-2H-pyrazole-3-yl)-(2-phenylquinazoline-4-yl)-amine (III-65):
mp?221-222℃；
1H?NMR(DMSO)δ1.31(3H，t)，2.68(2H，d)，6.80(1H，s)，7.50-7.60(4H，m)，8.45-8.55(2H，m)，8.65-8.75(1H，m)，10.44(1H，s)，12.27(1H，s)；IR(solid)3190，1622，1595，1575，1533，1482，1441，1420，1403，1361，758，711；MS?316.2(M+H)
+.
Embodiment 295 (2-phenyl-quinazoline-4-yl)-(5-propyl group-2H-pyrazole-3-yl)-amine (III-66): mp 204-205 ℃;
1H NMR (DMSO-d6) δ 1.02 (3H, t), 1.66-1.75 (2H, m), 2.69 (2H, t), 6.80 (1H, s), and 7.45-7.60 (4H, m), 7.80-7.88 (2H, m), 8.45-8.50 (2H, m), 8.65 (1H, d), 10.39 (1H, s), 12.25 (1H, s); IR (solid) 1621,1560,1572,1533,1479,1441,1421,1363,1328,999,827,808,763,709,697; MS 330.2 (M+H)
+.
Embodiment 296 (5-sec.-propyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (II-67): mp 218-219 ℃;
1H NMR (DMSO-d6) δ 1.36 (6H, d), 3.05 (1H, m), 6.86 (1H, s), 7.48-7.59 (4H, m), 7.80-7.88 (2H, m), 8.49-8.58 (2H, m), 8.66 (1H, d), 10.47 (1H, s), 12.30 (1H, s); IR (solid) 3173,2968,1619,1593,1573,1533,1478,1438,1413,1398,1363,1329,995,822,798,761,707,666,659; MS330.2 (M+H)
+.
Embodiment 297 (the 5-tertiary butyl-2H-pyrazole-3-yl)-(2-phenylquinazoline-4-yl)-amine (III-68):
mp?136-137℃；
1HNMR(DMSO-d6)δ1.38(9H，s)，6.87(1H，br?s)，7.51-7.57(4H，m)，7.84-7.85(2H，m)，8.49-8.51(2H，m)，8.65(1H，d)，10.43(1H，s)，12.21(1H，br?s)；IR(solid)3162，2963，1621，1590，1572；MS?344.2(M+H)
+.
Embodiment 298 (the 5-tertiary butyl-2H-pyrazole-3-yl)-(2-pyridin-4-yl-quinazoline-4-yl)-amine (III-69):
mp＞300℃；
1H?NMR(DMSO)δ1.38(9H，s)，6.82(1H，br?s)，7.63(1H，m)，7.86-7.91(2H，m)，8.32-8.33(2H，d)，8.69(1H，d)，8.75-8.76(2H，d)，10.60(1H，s)，12.31(1H，br?s)；IR(solid)3683，3149，2963，1621；MS?345.2(M+H)
+.
Embodiment 299 (5-cyclopentyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-70):
mp?240-241℃；
1H?NMR(DMSO-d6)δ1.68-1.89(6H，m)，2.03-2.17(2H，m)，3.14-3.22(1H，m)，6.80(1H，s)，7.50-7.60(4H，m)，7.80-7.89(2H，m)，8.45-8.52(2H，m)，8.67(1H，d)，10.52(1H，s)，12.26(1H，s)；IR(solid)2957，1621，1591，1571，1531，1476，1438，1405，1370，1325，999，951，801，775，761，747，710695，668，654；MS?356.2(M+H)+.
Embodiment 300 (5-phenyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-71):
mp?207-209℃；
1H?NMR(DMSO)δ7.38-7.40(1H，m)，7.50-7.58(6H，m)，7.82-7.88(4H，m)，8.51(2H，m)，8.67(1H，s)，10.58(1H，s)，13.11(1H，br?s)；IR(solid)3345，3108，1627，1612；MS?364.2(M+H)
+.
Embodiment 301 (5-carboxyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (II I-72): with (5-methoxycarbonyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-73) (345mg, 1mmol THF solution, 6ml) with NaOH (1M, 4.0ml) handle, stir 5h down at 50 ℃, be cooled to room temperature, with 1M HCl neutralization.Enriched mixture is removed THF in a vacuum, and dilute with water filters the gained precipitation then.Residual solid is dry under 80 ℃ of vacuum, obtain III-72, be pale solid (312mg, 94%):
Mp 289-291 ℃ (decomposition);
1H?NMR(DMSO)δ7.45(1H，br?s)，7.50-7.60(5H，m)，7.80-7.88(2H，m)，7.40-7.50(2H，m)，8.60-8.70(1H，d)，10.70(1H，s)，13.00-13.80(2H，br?s)；IR(solid)1699，1624，1607，1570，1539，1506，1486，1398，1333，1256，1177，1004，827，764，705；MS?332.3(M+H)
+.
Embodiment 302 (5-methoxycarbonyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-73):
mp?271-273℃；
1HNMR(DMSO)δ3.95(3H，s)，7.50-7.65(5H，m)，7.80-7.98(2H，m)，8.40-8.50(2H，m)，8.65-8.73(1H，m)，10.80(1H，s)，13.80(1H，s)；IR(solid)3359，1720，1624，1597，1561，1538，1500，1475，1435，1410，1358，1329，1283，1261，1146，1125，1018，1010，944，827，806，780，763，703，690，670；MS?346.3(M+H)
+.
Embodiment 303 (5-methylol-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-74): under 65 ℃, with (5-methoxycarbonyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-73) (345mg, (125mg 5.75mmol) handles 5h to anhydrous THF (10ml) solution 1mmol) with lithium borohydride.Mixture is cooled to room temperature, merges with 2M HCl and ethyl acetate then.Add solid sodium bicarbonate, reach pH 8, gained mixture ethyl acetate extraction.Extraction liquid concentrates through dried over mgso.Through purification by flash chromatography (SiO
2, methyl alcohol-dichloromethane gradient), obtain III-74 (95mg, 30%), be pale solid: mp238-239 ℃;
1H NMR (DMSO) δ 4.58 (2H, d, CH2), 5.35 (1H, s, OH), 6.94 (1H, s), 7.50-7.60 (4H, m), 7.85-7.90 (2H, m), 8.48-8.54 (2H, m), 8.69 (1H, 1H), 10.40 (1H, s), 12.48 (1H, s); IR (solid) 1652,1621,1603,1575,1558,1539,1532,1480,1373,1320,1276,1175,1057,1037,1007,951,865,843,793,780,7124; MS 318.2 (M+H)
+.
Embodiment 304 (5-methoxymethyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-75): mp 190-191 ℃;
1H NMR (DMSO) δ 3.34 (3H, s), 4.45 (2H, s), 7.00 (1H, s), 7.50-7.62 (4H, m), 7.82-7.90 (2H, m), 8.45-8.52 (2H, m), 8.65 (1H, brs), 10.50 (1H, s), 12.30 (1H, s); IR (solid) 3177,1606,1589,1530,1479,1441,1406,1374,1363,1329,1152,1099,999,954,834,813,766,707,691; MS332.3 (M+H)
+.
Embodiment 305[5-(3-hydroxyl third-1-yl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-76): with (5-benzyloxy propyl group-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-78) (200mg, 0.46mmol) toluene (4ml) and acetonitrile (8ml) solution and trimethylsilyl iodine (0.64ml, 4.6mmol) stir 3h down at 55 ℃, obtain amber solution.This mixture is diluted with ethyl acetate and sodium bicarbonate aqueous solution.Separating obtained each layer, organic layer concentrate in a vacuum through dried over mgso.Through purification by flash chromatography (SiO
2, methyl alcohol-dichloromethane gradient), obtain xanchromatic oil (115mg).With the methylene dichloride development, obtain III-76, be pale solid, under 75 ℃ of vacuum dry (83mg, 52%):
mp?164-165℃；
1H?NMR(DMSO)δ1.80-1.90(2H，m)，2.70-2.80(2H，m)，3.50-3.60(2H，m)，4.59(1H，s)，6.80(1H，s)，7.50-7.60(4H，m)，7.82-7.90(2H，m)，8.48-8.53(2H，m)，8.63(1H，s)，10.40(1H，s)，12.25(1H，s)；IR(solid)1622，1587，1574，1562，1528，1480，1440，1421，1368，1329，1173，1052，1030，1006，952，833，762，734，706，690，671，665；MS?346.0(M+H)
+.
Embodiment 306[5-(3-methoxy propyl-1-yl)-2N-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-77): mp 169-170 ℃;
1HNMR (DMSO-d6) δ 1.86-1.97 (2H, m), 2.75 (2H, t), 3.30 (3H, s), 3.45 (2H, t), 6.80 (1H, s), 7.50-7.60 (4H, m), 7.80-7.90 (2H, m), 8.45-8.55 (2H, m), 8.67 (1H, d), 10.30 (1H, s), 12.25 (1H, s); IR (solid) 1620,1591,1572,1532,1476,1425,1408,1373,1326,1117,1003,831,764,714,695; MS360.3 (M+H)
+.
Embodiment 307[5-(3-benzyloxy third-1-yl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-78): mp 177-178 ℃;
1H NMR (DMSO) δ 1.92-2.03 (2H, m), 3.76-3.85 (2H, m), 3.52-3.62 (2H, m), 4.51 (2H, s), 6.82 (1H, s), 7.28-7.40 (5H, m), 7.46-7.58 (4H, m), 7.80-7.85 (2H, m), 8.47-8.52 (2H, m), 8.66 (1H, d), 10.45 (1H, s); IR (solid) 1621,1591,1562,1532,1479,1454,1426,1408,1374,1101,1006,835,766,738,712,696; MS 436.3 (M+H)
+.
Embodiment 308[5-(3-amino third-1-yl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-79): under 0 ℃, (250mg, methylene dichloride 0.56mmol) (3ml) solution is handled with TFA (2ml) with [5-(3-tert butoxy carbonyl amino third-1-yl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-80).Make mixture be warmed to room temperature, concentrate in a vacuum then.With resistates development, from methylene dichloride (3 * 5ml) and ether concentrate, with the methylene dichloride development, tfa salt is crystallized out then.Filter and collect the gained solid, be dissolved in the mixture of ethanol (3ml) and water (3ml).Add salt of wormwood in batches, reach pH 8, make crystalline mixture then.Filter and collect product, dry under 80 ℃ of vacuum, obtain III-79, be pale powder (122mg, 63%): mp 205-207 ℃;
1H NMR (DMSO) δ 1.68-1.83 (2H, m), 2.65-2.80 (4H, m), 6.80 (1H, s), 7.50-7.60 (4H, m), 7.80-7.90 (2H, m), 8.45-8.53 (2H, m), 8.65 (1H, d), 10.45 (1H, br s); IR (solid) 1621,1598,1568,1533,1484,1414,1364,1327,1169,1030,951,830,776,764,705,677; MS 345.3 (M+H)
+.
Embodiment 309[5-(3-tert butoxy carbonyl amino third-1-yl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-80):
mp?199-200℃；
1H?NMR(DMSO)δ1.37(9H，s)，1.71-1.82(2H，m)，2.67(2H，t)，3.00-3.11(2H，m)，7.81(1H，s)，7.99(1H，s)，7.50-7.60(4H，m)，7.80-7.85(2H，m)，8.48-8.52(2H，m)，8.63(1H，d)，10.40(1H，s)，12.26(1H，m)；IR(solid)2953，1687，1622，1594，1573，1535，1481，1441，1419，1364，1327，1281，1252，1166，1070，1028，998，951，848，807，768，740，728，710，693；MS?445.3(M+H)
+.
Embodiment 310 (5-sec.-propyl formamyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-81):
1H?NMR(500MHz，DMSO-d6)δ1.20(d，J＝6.6Hz，6H)，4.13(m，1H)，7.42(br.s，1H)，7.61(dd，J＝7.0，7.7Hz，2H)，7.66(t，J＝7.1Hz，1H)，7.71(m，1H)，7.99(m，2H)，8.39(m，1H)，8.42(d，J＝7.1Hz，2H)，8.74(d，J＝8.2Hz，1H)，11.41(br.s，1H)；EI-MS?373.2(M+H)；HPLC-Method?C，R
t?14.09min.
Embodiment 311 (5-allyl amino formyl radical-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-82):
1H NMR (500MHz, DMSO-d6) δ 4.02 (m, 2H), 5.15 (m, 1H), 5.23 (m, 1H), 5.94 (m, 1H), 7.45 (br.s, 1H), 7.60 (t, J=6.9Hz, 2H), 7.64 (m, 1H), 7.72 (m, 1H), 7.98 (m, 2H), (8.43 m 2H), 8.72 (d, J=8.2Hz, 1H), 8.84 (br.s, 1H), 11.34 (br.s, 1H); EI-MS 371.2 (M+H); HPLC-Method C, R
t13.67min.
Embodiment 312[5-(2-methoxy ethyl formamyl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-83):
1HNMR (500MHz, DMSO-d6) δ 3.32 (s, 3H), 3.48 (m, 4H), 7.36 (br.s, 1H), 7.62 (m, 2H), 7.63 (m, 1H), 7.71 (m, 1H), 7.98 (m, 2H), 8.41 (dd, J=1.4,7.0,2H), 8.70 (m, 2H), 11.30 (br.s, 1H); EI-MS 389.2 (M+H); HPLC-Method C, R
t12.37min.
Embodiment 313 (5-benzylamino formyl radical-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-84):
1H NMR (500MHz, DMSO-d6) δ 4.52 (d, J=6.0Hz, 2H), 7.29 (m, 1H), 7.38 (d, J=4.2Hz, 4H), 7.58 (t, J=7.5Hz, 2H), 7.63 (m, 1H), 7.72 (m, 1H), 7.98 (m, 2H), 8.43 (d, J=7.7Hz, 2H), 8.72 (d, J=7.5Hz, 1H), 9.23 (br.s, 2H), 11.34 (br.s, 1H); EI-MS 421.2 (M+H); HPLC-Method C, R
t16.76min.
Embodiment 314 (5-cyclohexyl carboxyamide base-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-85):
1H?NMR(500MHz，DMSO-d6)δ1.16(m，1H)，1.34(m，4H)，1.62(d，J＝2.6Hz，1H)，1.76(m，2H)，1.85(m，2H)，3.79(m，1H)，7.43(m，1H)，7.60(t，J＝7.2Hz，2H)，7.65(t，J＝7.1Hz，1H)，7.71(ddd，J＝2.2，5.4，8.2Hz，1H)，7.98(m，2H)；8.35(m，1H)，8.43(dd，J＝1.4，7.2Hz，2H)，8.72(d，J＝8.2Hz，1H)，11.34(br.s，1H)；EI-MS?413.5(M+H)；HPLC-Method?C，R
t?17.18min.
Embodiment 315 (5-diethylamino formyl radical-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-86):
1H NMR (500MHz, DMSO-d6) δ 1.18 (br.s, 3H), 1.25 (br.s, 3H), 3.49 (br.s, 2H), 3.69 (b.s, 2H), 7.21 (s, 1H), 7.59 (t, J=6.9Hz, 2H), 7.62 (m, 1H), 7.70 (m, 1H), 7.96 (m, 2H), 8.39 (d, J=7.1Hz, 2H), 8.74 (d, J=8.4Hz, 1H), 11.37 (br.s, 1H); EI-MS 387.2 (M+H); HPLC-Method C, R
t14.50min.
Embodiment 316[5-(benzyl-methyl-formamyl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-87):
1H NMR (500MHz, DMSO-d6) δ 3.33 (s, 3H), 4.75 (s, 2H), 7.26 (m, 1H), 7.31 (m, 1H), 7.38 (m, 4H), 7.58 (m, 2H), 7.70 (m, 1H), 7.95 (m, 3H), 8.26 (m, 1H), 8.40 (d, J=7.8Hz, 2H), 8.75 (m, 1H), 11.2 (br.s, 1H); EI-MS 435.2 (M+H); HPLC-Method C, R
t16.77min.
Embodiment 317 (2-phenyl-quinazoline-4-yl)-(5-propyl group formamyl-2H-pyrazole-3-yl)-amine (III-88):
1H NMR (500MHz, DMSO-d6) δ 0.94 (t, J=7.3Hz, 3H), 1.57 (m, 2H), 3.24 (q, J=6.5Hz, 2H), 7.39 (br.s, 1H), 7.60 (t, J=7.3Hz, 2H), 7.64 (m, 1H), 7.71 (br.t, J=6.5Hz, 1H), 7.98 (m, 2H), 8.42 (d, J=7.2Hz, 2H), 8.61 (br.s, 1H), 8.72 (d, J=8.5Hz, 1H), 11.34 (br.s, 1H); EI-MS373.3 (M+H); HPLC-Method C, R
t13.51min.
Embodiment 318[5-(ethyl-sec.-propyl-formamyl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-89):
1H?NMR(500MHz，DMSO-d6)δ0.92(t，J＝7.4Hz，6H)，1.52(m，2H)，1.59(m，1H)，3.79(m，2H)，7.53(br.s，1H)，7.57(t，J＝7.5Hz，2H)，7.65(t，J＝7.2Hz，1H)，7.71(m，1H)，7.99(m，2H)，8.23(br.d，J＝8.8Hz，1H)，8.46(d，J＝7.5Hz，2H)，8.74(d，J＝8.4Hz，1H)，11.34(br.s，1H)；EI-MS?401.2(M+H)；HPLC-Method?C，R
t?15.51min.
Embodiment 319 (5-cyclopropyl formamyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-90):
1H NMR (500MHz, DMSO-d6) δ 0.60 (m, 2H), 0.74 (m, 2H), 2.86 (m, 1H), 7.34 (br.s, 1H), 7.62 (m, 3H), 7.70 (m, 1H), 7.97 (m, 2H), 8.41 (d, J=7.9Hz, 2H), 8.63 (br.s, 1H), 8.72 (d, J=7.8Hz, 1H), 11.35 (br.s, 1H); EI-MS 371.2 (M+H); HPLC-Method C, R
t12.64min.
Embodiment 320 (5-isobutylamino formyl radical-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-91):
1H NMR (500MHz, DMSO-d6) δ 0.94 (d, J=6.7Hz, 6H), 1.88 (m, 1H), 3.12 (t, J=6.4Hz, 2H), 7.45 (br.s, 1H), 7.58 (t, J=7.2Hz, 3H), 7.64 (t, J=7.1Hz, 1H), 7.71 (m, 1H), 7.98 (m, 2H), 8.44 (dd, J=1.3,7.9Hz, 2H), 8.62 (br.s, 1H), 8.72 (d, J=8.3Hz, 1H), 11.33 (br.s, 1H); EI-MS 387.2 (M+H); HPLC-Method C, R
t14.70 min.
Embodiment 321{5-[(3S)-3-methoxymethyl-tetramethyleneimine-1-carbonyl]-the 2H-pyrazole-3-yl }-(2-phenyl-quinazoline-4-yl)-amine (II1-93):
1H?NMR(500MHz，DMSO-d6)δ2.00(m，2H)，2.12(m，1H)，3.29(s，3H)，3.45(t，J＝8.7Hz，1H)，3.57(dd，J＝3.2，9.3Hz，1H)，3.86(m，1H)，3.92(m，1H)，4.36(m，2H)，7.45(br.s，1H)，7.59(t，J＝7.2Hz，2H)，7.63(m，1H)，7.69(m，1H)，7.97(m，2H)，8.40(d，J＝7.5Hz，2H)，8.74(d，J＝7.6Hz，1H)，11.38(br.s，1H)；EI-MS?429.2(M+H)；HPLC-Method?C，R
t?13.84min.
Embodiment 322 (2-phenyl-quinazoline-4-yl)-(tolyl formamyl-2H-pyrazole-3-yl between 5-)-amine (III-94):
1H?NMR(500MHz，DMSO-d6)δ2.33(s，3H)，6.97(d，J＝7.5Hz，1H)，7.27(t，J?＝7.8Hz，1H)，7.62(m，7H)，7.72(m，1H)，7.98(m，2H)，8.46(dd，J＝2.0，7.9Hz，2H)，8.71(m，1H)，10.29(s，1H)，11.31(br.s，1H)；EI-MS?421.2(M+H)；HPLC-Method?C，R
t?17.11min.
Embodiment 323 (2-phenyl-quinazoline-4-yl)-(5-p-methylphenyl formamyl-2H-pyrazole-3-yl)-amine (III-95):
1H NMR (500MHz, DMSO-d6) δ 2.30 (s, 3H), 7.20 (d, J=8.3Hz, 2H), 7.62 (m, 5H), 7.68 (d, J=8.3Hz, 2H), 7.72 (m, 1H), 7.98 (m, 2H), 8.46 (dd, J=1.8,7.0Hz, 2H), 8.72 (m, 1H), 10.31 (s, 1H), 11.36 (br.s, 1H); EI-MS 421.2 (M+H); HPLC-Method C, R
t16.95min.
Embodiment 324 (5-methylamino formyl radical-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-96):
1H NMR (500MHz, DMSO-d6) δ 2.82 (d, J=4.6Hz, 3H), 7.31 (br.s, 1H), 7.62 (m, 3H), 7.69 (m, 1H), 7.97 (m, 2H), 8.42 (d, J=7.1Hz, 2H), 8.59 (br.s, 1H), 8.71 (d, J=8.0Hz, 1H), 11.30 (br.s, 1H); EI-MS 345.1 (M+H); HPLC-Method C, R
t11.02min.
Embodiment 325[5-(morpholine-4-carbonyl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-97):
1H NMR (500MHz, DMSO-d6) δ 3.33 (m, 4H), 3.83 (m 4H), 7.34 (br.s, 1H), 7.53 (m, 4H), 7.86 (m, 2H), 8.43 (m, 2H), 8.67 (d, J=8.6Hz, 1H), 10.70 (s, 1H), 13.56 (s, 1H); EI-MS 401.2 (M+H); HPLC-Method A, R
t2.68min.
Embodiment 326[5-(1-methylpiperazine-4-carbonyl)-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-98):
1H?NMR(500MHz，DMSO-d6)δ2.25(s，3H)，2.43(m，4H)，3.87(m?4H)，7.33(br.s，1H)，7.53(m，4H)，7.87(m，2H)，8.45(m，2H)，8.67(d，J＝7.6Hz，1H)，10.70(s，1H)，13.30(s，1H)；EI-MS?414.2(M+H)；HPLC-Method?A，R
t2.38min.
Embodiment 327[5-(2-hydroxyethylamino formyl radical-2H-pyrazole-3-yl]-(2-phenyl-quinazoline-4-yl)-amine (III-99):
1H NMR (500MHz, DMSO-d6) δ 3.36 (m, 2H), 3.52 (m, 2H), 4.79 (m, 1H), 7.50 (m, 5H), 7.83 (m, 2H), 8.50 (m, 4H), 10.52 (br.s, 1H), 13.25 (s, 1H); EI-MS375.1 (M+H); HPLC-Method A, R
t2.51min.
Embodiment 328 (5-formamyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-100): to 5-(2-phenyl-quinazoline-4-base is amino)-1H-pyrazoles-3-carboxylic acid 2; 5-dioxo-tetramethyleneimine-1-base ester (270mg; 0.63mmol) DMF (20ml) solution add 1 of ammonia; the 4-dioxane solution (0.5M, 10ml).The gained mixture is at room temperature stirred 24h.Behind the concentrated solvent, resistates is added to the water (20ml).Collection gained precipitation obtains III-100 (168mg, 80%), is yellow solid.
1H?NMR(500MHz，DMSO-d6)δ7.77-7.51(m，6H)，7.86(br?s，2H)，8.11(m，1H)，8.50(m，2H)，8.63(m，1H)，10.52(s，1H)，11.25(s，1H)；EI-MS?331.1(M+H)；HPLC-Method?A，R
t?2.52min.
Embodiment 329 (4-bromo-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-101): according to method A preparation, obtain yellow solid,
mp?189℃；
1H?NMR(DMSO-d6)δ7.44-7.46(3H，m)，7.58(1H，m)，7.87(2H，d)，8.15(1H，s)，8.31-8.34(2H，m)，8.49(1H，d)，10.08(1H，s)，13.13(1H，s)；IR(solid)3286，2969，1738，1632；MS366.2/368.2(M+H)
+.
Embodiment 330 (4-bromo-5-methyl-2H-pyrazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-102):
mp?183-185℃；
1H?NMR(DMSO)δ2.33(3H，br?s)，7.44-7.46(3H，m)，7.57(1H，m)，7.84-7.87(2H，m)，8.31-8.34(2H，m)，8.48(1H，d)，10.05(1H，s)，12.91(1H，br?s)；IR(solid)3362，3065，2831，1619，1578；MS?380.2/382.2(M+H)
+.
Embodiment 331 (4-cyano group-2H-pyrazole-3-yl)-(2-phenylquinazoline-4-yl)-amine (III-103):
mp＞250℃；
1H?NMR(DMSO)δ7.47-7.49(3H，m)，7.64(1H，m)，7.91(2H，m)，8.40-8.43(2H，m)，8.53(1H，d)，8.71(1H，d)，10.61(1H，s)，13.60(1H，s)；IR(solid)3277，3069，2855，2231，1625；MS?313.2(M+H)
+.
Embodiment 332 (5-methyl-2H-pyrazole-3-yl)-(2-morpholine-4-base quinazoline-4-yl)-amine (III-104): mp 223-224 ℃;
1H NMR (DMSO) δ 2.26 (3H, s), 3.65 (4H, m), 3.75 (4H, m), 6.44 (1H, s), 7.12 (1H, d), 7.33 (1H, d), 7.56 (1H, t), 8.37 (1H, d), 10.01 (1H, s), 12.13 (1H, brs); IR (solid) 1621,1578,1537,1475,1434,1385; MS311.0 (M+H)
+.
Embodiment 333 (5-methyl-2H-pyrazole-3-yl)-(2-piperazine-1-base-quinazoline-4-yl)-amine (III-105): mp 179-181 ℃;
1H NMR (DMSO) δ 2.26 (3H, s), 2.74 (4H, br s), 3.71 (4H, br s), 6.43 (1H, s), 7.08 (1H, t), 7.30 (1H, d), 7.53 (1H, t), 8.34 (1H, d), 9.50 (1H, s), 12.08 (1H, br s); IR (solid) 2853,1619,1603,1566,1549,1539; MS 310.0 (M+H)
+
Embodiment 334[2-(4-methyl piperidine-1-yl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-106):
mp?148-150℃；
1H?NMR(DMSO)δ1.06(3H，d)，1.03(2H，m)，1.51-1.70(3H，m)，2.26(3H，s)，2.86(2H，m)，4.73(2H，d)，6.44(1H，s)，7.06(1H，d)，7.29(1H，d)，7.52(1H，t)，8.32(1H，d)，9.92(1H，s)，12.09(1H，br?s)；IR(solid)2917，2840，1629，1593，1562，1546，1486；MS?323.0(M+H)
+.
Embodiment 335[2-(4-methylpiperazine-1-yl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-107): mp 105-107 ℃;
1H?NMR(DMSO)δ2.21(3H，s)，2.26(3H，s)，2.34(4H，m)，3.75(4H，m)，6.45(1H，s)，7.09(1H，t)，7.31(1H，d)，7.54(1H，t)，8.34(1H，d)，9.96(1H，s)，12.12(1H，br?s)；IR(solid)2934，2844，2804，1620，1593，1572，1536，1476；MS?324.0(M+H)
+.
294 ℃ of embodiment 336 (5-methyl-2H-pyrazole-3-yl)-(2-piperidines-1-base-quinazoline-4-yl)-amine (III-108): mp;
1H NMR (DNSO) δ 1.45-1.58 (4H, m), 1.63 (2H, m), 2.26 (3H, s), 3.79 (4H, m), 6.45 (1H, br s), 7.06 (1H, t), 7.29 (1H, d), 7.52 (1H, t), 8.33 (1H, d), 9.92 (1H, s), 12.11 (1H, brs); IR (solid) 2929,2847,1632,1591,1500,1482,1437,1382; MS 309.3 (M+H)
+.
Embodiment 337 (2-azepan-1-yl)-quinazoline-4-yl]-269 ℃ of (5-methyl-2H-pyrazole-3-yl)-amine (III-109): mp;
1H NMR (DMSO) δ 1.50 (4H, br s), 1.76 (4H, br s), 2.25 (3H, s), 3.78 (4H, t), 6.55 (1H, br s), 7.03 (1H, t), 7.28 (1H, d), 7.50 (1H, t), 8.33 (1H, d), 9.92 (1H, s), 12.09 (1H, brs); IR (solid) 3427,2963,2927,2909,2872,2850,1623,1595,1586,1568,1504,1486,1468,1386,1427; MS 323.3 (M+H)
+.
Embodiment 338[2-(4-(2-hydroxyethyl piperidine-1-yl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-110):
mp?175℃；
1H?NMR(DMSO)δ1.08(2H，m)，1.38(2H，m)，1.57-1.83(3H，m)，2.26(3H，s)，2.85(2H，t)，3.47(2H，m)，4.38(1H，t)，4.75(2H，d)，6.45(1H，brs)，7.06(1H，t)，7.29(1H，d)，7.52(1H，t)，8.32(1H，d)，9.93(1H，s)，12.12(1H，br?s)；IR(solid)3365，3073，2972，2868，1622，1604，1586，1568，1486，1463，1440，1394；MS?353.2(M+H)
+.
Embodiment 339 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(4-methyl piperidine-1-yl)-quinazoline-4-yl]-amine (III-111): to (5-cyclopropyl-1H-pyrazole-3-yl)-(2-chloro-quinazoline-4-yl)-amine (118mg, 0.41mmol) the trimethyl carbinol (3.0ml) solution add 4-methyl piperidine (0.49ml, 4.1mmol), with reaction mixture heated overnight under refluxing.Concentrated reaction mixture in a vacuum is dissolved in EtOH with resistates: and water mixture (1: 3,4ml).(57mg 0.41mmol), at room temperature stirred mixture 2 hours to add salt of wormwood.The gained suspension is filtered, wash (x2) with water, use Et
2O washes (x2), obtains III-111, is white solid (123mg, 85%):
mp?190℃；
1H?NMR(DMSO)δ0.66(2H，s)，0.93(5H，br?s)，1.07(2H，d)，1.66(3H，s)，1.91(1H，s)，2.85(2H，t)，4.72(2H，d)，6.33(1H，s)，7.06(1H，t)，7.29(1H，d)，7.52(1H，t)，8.31(1H，d)，9.95(1H，s)，12.18(1H，br?s)；IR(solid)2925，2852，1622，1590，1581，1558，1494，1481，1453，1435，1394；MS?349.2(M+H)
+.
Embodiment 340[2-(1,4-two oxa-s-8-azepine-spiral shell [4,5] last of the ten Heavenly stems-8-yl) quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-112):
mp?191℃；
1H?NMR(DMSO)δ1.65(4H，s)，2.26(3H，s)，3.90(4H，s)，3.93(4H，s)，6.43(1H，br?s)，7.09(1H，t)，7.32(1H，d)，7.54(1H，t)，8.35(1H，d)，9.99(1H，br?s)，12.13(1H，br?s)；IR(solid)3069，2964，2927，2868，1618，1581，1568，1540，1495，1481，1435，1390；MS?367.3(M+H)
+.
Embodiment 341[2-(4-cyclopentyl amino-piperadine-1-yl)-quinazoline-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (III-113):
mp?191℃；
1H?NMR(DMSO)δ1.33(2H，d)，1.65(4H，s)，1.87(2H，d)，2.20(1H，s)，2.26(3H，s)，2.49(2H，s)，3.00(2H，t)，3.36(2H，s)，4.61(2H，d)，6.45(1H，br?s)，7.07(1H，s)，7.31(1H，d)，7.52(1H，s)，8.33(1H，d)，9.94(1H，br?s)，12.12(1H，br?s)；IR(solid)3371，2943，1622，1600，1581，1545，1509，1463，1440，1390；MS?378.2(M+H)
+.
Embodiment 342[2-(4-hydroxy piperidine-1-yl)-quinazoline-4-yl]-123 ℃ of (5-methyl-2H-pyrazole-3-yl)-amine (III-114): mp;
1H NMR (DMSO) δ 1.34 (2H, d), 1.80 (2H, d), 2.26 (3H, s), 3.24 (2H, t), 3.72 (1H, br s), 4.39 (2H, d), 4.70 (1H, d), 6.44 (1H, br s), 7.07 (1H, t), 7.30 (1H, d), 7.53 (1H, t), 8.33 (1H, d), 9.94 (1H, brs), 12.11 (1H, br s); IR (solid) 3265,3151,2927,2863,1622,1600,1572,1540,1504,1476,1440,1390,1349,1066,1098; MS 325.3 (M+H)
+.
Embodiment 343 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(4-hydroxy-4-phenyl piperidine-1-yl)-quinazoline-4-yl]-amine (III-115):
mp?131℃；
1H?NMR(DMSO)δ0.64(2H，q)，0.93(2H，q)，1.68(2H，d)，1.83-1.97(3H，m)，3.20-3.45(2H，m)，4.69(2H，d)，5.11(1H，s)，6.37(1H，brs)，7.08(1H，t)，7.20(1H，t)，7.31(3H，t)，7.49(2H，d)，7.53(1H，t)，8.33(1H，d)，9.98(1H，br?s)，12.18(1H，br?s)；IR(solid)3362，2952，2934，2911，2870，2825，1618，1584，1570，1559，1536，1481，1459，1431，1372，1336，1213，994；MS?427.6(M+H)
+.
Embodiment 344 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(1,3-dihydro-isoindole-2-yl)-quinazoline-4-yl]-amine (III-116): according to method E-I preparation, obtain pale solid,
mp?237℃；
1H?NMR(DMSO-d6)δ0.79(2H，s)，1.00(2H，d)，1.99(1H，m)，4.92(4H，d)，6.72(1H，br?s)，7.13(1H，t)，7.33(2H，s)，7.30-7.48(3H，m)，7.58(1H，t)，8.40(1H，d)，10.12(1H，s)，12.17(1H，s)；IR(solid)3449，3318，2850，1623，1595，1577，1541，1509，1482，1432，1391，1359，1141，1027，877，814；MS369.4(M+H)
+.
Embodiment 345 (2-azepan-1-yl)-quinazoline-4-yl]-(5-cyclopropyl-2H-pyrazole-3-yl)-amine (III-117): mp 199-200 ℃;
1H NMR (DMSO-d6) δ 0.60-0.70 (2H, m), 0.90-1.002H, m), 1.45-1.57 (4H, m), and 1.70-1.85 (4H, m), 1.88-1.97 (1H, m), 3.75-3.87 (4H, m), 6.42 (1H, s), 7.02 (1H, t), 7.27 (1H, d), 7.49 (1H, t), 8.29 (1H, d), 9.91 (1H, s), 12.19 (1H, br s); IR (solid) 2929,1624,1595,1581,1563,1542,1498,1482,1440,1426,1397,1356,1305,1000,825,754; MS349.2 (M+H)
+.
Embodiment 346 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(3,4-dihydro-1H-isoquinoline 99.9-2-yl)-quinazoline-4-yl]-amine (III-118):
mp?182-184℃；
1H?NMR(DMSO)δ0.75(2H，d)，1.02(2H，d)，1.96(1H，m)，2.89(2H，m)，4.05(2H，m)，4.94(2H，s)，6.46(1H，s)，7.10(1H，t)，7.21(4H，d)，7.37(1H，d)，7.55(1H，d)，8.36(1H，d)，10.05(1H，s)，12.23(1H，br?s)；IR(solid)1621，1581，1560，1337，1479，1456，1426，1396，1374，1341，1222；MS383.3(M+H)
+.
Embodiment 347 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(2,3-dihydro-indoles-1-yl)-quinazoline-4-yl]-amine (III-119): mp150-153 ℃;
1H NMR (DMSO) δ 0.74 (2H, d), 0.98 (2H, d), 1.96 (1H, m), 3.15 (2H, t), 4.25 (2H, t), 6.45 (1H, brs), 6.88 (1H, t), 7.09 (1H, t), 7.20 (2H, m), 7.53 (1H, d), 7.65 (1H, t), 8.43 (2H, br s), 10.09 (1H, s), 12.28 (1H, br s); IR (solid) 1621,1588,1577,1564,1537,1487,1455,1425,1386,1259; MS369.3 (M+H)
+.
Embodiment 348 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(4-hydroxymethyl piperidine-1-yl)-quinazoline-4-yl]-amine (III-120):
mp?142℃；
1H?NMR(DMSO)δ0.67(2H，d)，0.96(2H，d)，1.10(2H，q)，1.55-1.70(3H，m)，1.91(1H，m)，2.85(2H，t)，3.28(2H，s)，4.48(1H，s)，4.76(2H，d)，6.34(1H，s)，7.06(1H，t)，7.30(1H，d)，7.52(1H，t)，8.31(1H，d)，9.96(1H，s)，12.19(1H，s)；IR(solid)3363，3000，2927，2854，1618，1604，1573，1536，1509，1477，1436，1395，1354，1314，1241，1186，1091，995，941，823；MS?365.8(M+H)
+.
Embodiment 349 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(3,4-dihydro-2H-quinoline-1-yl)-quinazoline-4-yl]-amine (III-121):
mp?137-145℃；
1H?NMR(DMSO-d6)δ0.55(2H，d)，0.88(2H，d)，1.78(1H，m)，1.92(2H，t)，2.75(2H，t)，4.04(2H，t)，6.20(1H，br?s)，6.97(1H，t)，7.14(1H，m)，7.19(1H，t)，7.42(1H，d)，7.61(1H，t)，7.67(1H，d)，8.43(1H，d)，10.04(1H，s)，12.21(1H，br?s)；IR?(solid)1622，1572，1539，1493，1454，1420，1373，1249；MS?383.3(M+H)
+.
Embodiment 350 (5-methoxycarbonyl-2H-pyrazole-3-yl)-[2-(piperidines-1-yl)-quinazoline-4-yl]-amine (III-122):
1H NMR (500MHz, CDCl
3) (6H, m), (4H, m), (3H, s), (1H, s), (1H, t), (1H, d), (1H, t), (1H, d) .HPLC-Method B (starts from 95%H to δ 8.0 to δ 7.6 to δ 7.4 to δ 7.15 to δ 5.5 to δ 3.9 to δ 3.8 to δ 1.7-1.8
2O) R
t7.4min; MS (ES+) 353.24 (M+H).
Embodiment 351[5-(piperidines-1-carbonyl)-2H-pyrazole-3-yl]-[2-(piperidines-1-yl)-quinazoline-4-yl]-amine (III-123): HPLC-method B, (from 95%H
2O:0.1%TFA begins) R
t8.0min; MS (ES+) 406.30, (ES-) 404.30.
Embodiment 352 (5-methylol-2H-pyrazole-3-yl)-[2-(piperidines-1-yl)-quinazoline-4-yl]-amine (III-124): at ambient temperature, (10.0mg, THF 0.028mmol) (6ml) solution slowly adds 1M LiAlH to III-122
4THF solution (0.05ml, 0.05mmol).After 15 minutes, with solution with water and 1N HCl quencher.From the waterbearing stratum, extract product with EtOAc.Organic layer is through MgSO
4Drying is filtered, and concentrates in a vacuum.Resistates obtains III-124 (4.0mg, 44%) through the preparation HPLC purifying.HPLC-method B is (from 95%H
2O:0.1%TFA begins) R
t6.1min; MS (ES+) 325.13 (M+H), (ES-) 323.13 (M-H).
Embodiment 353 (5-formamyl-2H-pyrazole-3-yl)-[2-(piperidines-1-yl)-quinazoline-4-yl]-amine (III-125): with III-122 (1.5g, 2.0MNH 4.3mmol)
3/ MeOH (100ml) solution heated 2 days down at 110 ℃.Concentrate the Vandyke brown reaction mixture in a vacuum, obtain the oil of viscosity,, obtain 0.7g (50%) III-125 through the column chromatography purifying.
1H NMR (500MHz, CD3OD-d
3) δ 1.6 (4H, m), δ 1.7 (2H, m), δ 3.3 (1H, s), δ 3.8 (4H, m), δ 5.5 (1H, s), δ 7.15 (1H, t), δ 7.45 (1H, d), δ 7.55 (1H, t), δ 8.0 (1H, d); HPLC-Method B (starts from 95%H
2O:0.1%TFA) R
t5.9min; MS (ES+) 338.13, (ES-) 336.15.
Embodiment 354 (5-formamyl-2H-pyrazole-3-yl)-[2-(4-methyl piperidine-1-yl)-quinazoline-4-yl]-amine (III-126): HPLC-method B, (from 95%H
2O:0.1%TFA begins) R
t6.4min; MS (ES+) 352.19, (ES-) 350.20.
Embodiment 355 (5,7-two fluoro-1H-indazole-3-yls)-(2-phenyl-5,6,7,8-tetrahydro quinazoline-4-yl)-amine (III-127):
1H NMR (500MHz, DMSO-d6) δ 13.7 (s, 1H), 10.3 (s, br, 1H), 7.90 (d, 2H), 7.52 (t, 1H), 7.45 (m, 3H), 7.26 (d, 1H), 2.99 (m, 2H), 2.75 (m, 2H), 1.95 (br, 4H) ppm; MS (ES+) 378.24 (M+H); (ES-) 376.23 (M-H); HPLC-Method A, R
t3.04min.
Embodiment 356 (2-phenyl-5,6,7,8-tetrahydro quinazoline-4-yl)-(5-Trifluoromethyl-1 H-indazole-3-yl)-amine (III-128):
1HNMR(500MHz，DMSO-d6)δ13.4(s，1H)，10.2(s，br，1H)，8.13(s，1H)，7.86(d，2H)，7.78(d，1H)，7.69(d，1H)，7.50(t，1H)，7.35(dd，2H)，2.89(m，2H)，2.72(m，2H)，1.90(s，br，4H)ppm；MS(ES+)410.24(M+H)；(ES-)408.23(M-H)；HPLC-Method?A，R
t?3.19min.
Embodiment 357 (7-fluoro-1H-indazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-129):
1H NMR (500MHz, DMSO-d6) δ 13.6 (s, 1H), 11.1 (s, br, 1H), 8.65 (d, 1H), 8.03 (d, 2H), 7.95 (s, 2H), 7.67 (m, 1H), 7.45 (m, 2H), 7.33 (t, 2H), 7.22 (dd, 1H), 6.99 (td, 1H) ppm.MS (ES+): m/e=356.20 (M+H); HPLC-Method A R
t3.00min.
Embodiment 358 (5-fluoro-1H-indazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (III-130):
1H NMR (500MHz, DMSO-d6) δ 13.2 (s, 1H), 11.3 (s, br, 1H), 8.67 (d, 1H), 8.04 (d, 2H), 7.96 (s, 2H), 7.70 (m, 1H), 7.58 (dd, 1H), 7.43 (m, 4H), 7.28 (td, 1H) ppm.MS (ES+) 356.20 (M+H); HPLC-Method A, R
t3.00min.
Embodiment 359 (5,7-two fluoro-1H-indazole-3-yls)-(2-phenylquinazoline-4-yl)-amine (III-131):
1H NMR (500MHz, DMSO-d6) δ 13.7 (s, 1H), 8.65 (d, 1H), 8.04 (d, 2H), 7.95 (s, 2H), 7.68 (m, 1H), 7.45 (m, 1H), 7.35 (m, 4H) ppm.MS (ES+): m/e=374.17 (M+H); HPLC-MethodA, R
t3.07min.
Embodiment 360 (1H-indazole-3-yl)-[2-(3-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (III-132):
1H NMR (500MHz, DMSO-d6) δ 7.06 (t, 1H), 7.42 (t, 1H), 7.59 (d, 1H), 7.63 (t, 1H), 7.66 (d, 1H), 7.71 (m, 1H), 7.80 (d, 1H), 7.98 (m, 2H), 8.33 (s, 1H), 8.46 (d, 1H), 8.71 (d, 1H), 11.04 (br.s, and 1H) 12.97 (s, 1H); EI-MS 406.1 (M+1); HPLC-Method A, R
t3.15min.
Embodiment 361 (2-phenyl-quinazoline-4-yl)-(1H-pyrazolo [4,3-b] pyridin-3-yl)-amine (III-133):
1H NMR (500MHz, DMSO-d6) δ 13.3 (s, br, 1H), 11.4 (s, br, 1H), 8.78 (d, 1H), 8.58 (dd, 1H), 8.24 (d, 1H), 8.10 (m, 2H), 7.95 (d, 2H), 7.86 (t, 1H), 7.56 (m, 2H), 7.44 (t, 2H) ppm.MS (ES+) 339.11 (M+H); HPLC-Method A, R
t2.63min.
Embodiment 362[5-(3-methoxyl group-phenyl)-6-oxo-5,6-dihydro-1 h-pyrazole be [4,3-c] pyridazine-3-yl also]-(2-phenyl-quinazoline-4-yl)-amine (III-134):
1H?NMR(500MHz，MeOH-d4)δ8.65(d，1H)，8.17(m，3H)，8.10(d，1H)，7.90(t，1H)，7.75(t，1H)，7.58(m，2H)，7.25(t，1H)，6.95(m，2H)，6.85(d，1H)，6.80(s，1H)，3.64(s，3H)ppm.MS (ES+)：m/e＝462.2(M+H).
Embodiment 363 (6-oxo-5-phenyl-5,6-dihydro-1 h-pyrazole be [4,3-c] pyridazine-3-yl also)-(2-phenyl-quinazoline-4-yl)-amine (III-135):
1H?NMR(500MHz，MeOH-d4)δ8.61(d，1H)，8.13(m，3H)，8.05(d，1H)，7.85(t，1H)，7.70(t，1H)，7.58(m，2H)，7.32(m，5H)，6.79(s，1H)ppm.MS(ES+)：m/e＝432.2(M+H).
Embodiment 364[5-(4-methoxyl group-phenyl)-6-oxo-5,6--dihydro-1 h-pyrazole be [4,3-c] pyridazine-3-yl also]-(2-phenyl-quinazoline-4-yl)-amine (III-136): MS (ES+) 462.2 (M+H).
Embodiment 365[5-(2,4-two chloro-phenyl)-6-oxo-5, the 6-dihydro-1 h-pyrazole is [4,3-c] pyridazine-3-yl also]-(2-phenyl-quinazoline-4-yl)-amine (III-137):
1H?NMR(500MHz，MeOH-d4)δ8.63(d，1H)，8.17(m，4H)，7.89(t，1H)，7.73(t，1H)，7.61(t，2H)，7.57(d，1H)，7.32(m，1H)，7.21(d，1H)，6.84(s，1H)ppm.MS (ES+)：m/e＝500.1(M+H).
Embodiment 366[6-oxo-5-(3-trifluoromethyl-phenyl)-5,6-dihydro-1 h-pyrazole be [4,3-c] pyridazine-3-yl also]-(2-phenylquinazoline-4-yl)-amine (III-138):
1H?NMR(500MHz，MeOH-d4)δ8.55(d，1H)，8.19(d，2H)，7.92(m，2H)，7.65(m，3H)，7.45(t，2H)，7.25(t，1H)，7.13(t，1H)，7.05(t，1H)，6.75(s，1H)ppm.MS (ES+)：m/e＝500.2(M+H).
Embodiment 367[6-oxo-5-(4-phenoxy group-phenyl)-5,6-dihydro-1 h-pyrazole be [4,3-c] pyridazine-3-yl also]-(2-phenyl-quinazoline-4-yl)-amine (III-139): MS (ES+) 524.3 (M+H).
Embodiment 368[5-(4-chloro-phenyl)-6-oxo-5, the 6-dihydro-1 h-pyrazole is [4,3-c] pyridazine-3-yl also]-(2-phenyl-quinazoline-4-yl)-amine (III-140): MS (ES+) 466.2 (M+H).
Embodiment 369 (2-imidazoles-1-base-quinazoline-4-yl)-(1H-indazole-3-yl)-amine (III-141):
1H NMR (500MHz, DMSO-d6) δ 7.10 (t, 1H), 7.44 (t, 1H), 7.50 (br.s, 1H), 7.60 (d, 1H), 7.72 (m, 2H), 7.77 (m, 1H), 7.88 (d, 1H), 7.98 (t, 1H), 8.73 (d, 1H), 8.96 (s, 1H), 11.23 (s, 1H), 13.06 (s, 1H); EI-MS 328.1 (M+1); .HPLC-Method A, R
t2.93min.
Embodiment 370 (1H-indazole-3-yl)-[2-(2-methyl-imidazoles-1-base quinazoline-4-yl]-amine (III-142):
1H NMR (500MHz, DMSO-d6) δ 2.48 (s, 3H), 7.10 (t, 1H), 7.43 (t, 1H), 7.57 (d, 1H), 7.60 (d, 1H), 7.67 (d, 1H), 7.76 (td, 1H), 7.86 (d, 1H), 7.91 (d, 1H), 8.01 (td, 1H), 8.72 (d, 1H), 11.15 (s, 1H), 13.10 (s, 1H); EI-MS 342.1 (M+1); HPLC-Method A, R
t3.06min.
Embodiment 371 (1H-indazole-3-yl)-(2-piperidines-1-base-quinazoline-4-yl)-amine (III-143):
1H NMR (500MHz, DMSO-d6) δ 1.48 (m, 6H), 3.60 (m, 4H), 7.11 (t, 1H), 7.52 (t, 1H), 7.55 (d, 1H), 7.64 (d, 1H), 7.69 (d, 1H), 7.75 (d, 1H), 7.90 (t, 1H), 8.58 (d, 1H), 11.82 (br.s, 1H), 13.25 (s, 1H); EI-MS 345.1 (M+1); HPLC-Method A, R
t3.03min.
Embodiment 372 (1H-indazole-3-yl)-[2-(octahydro-quinoline-1-yl)-quinazoline-4-yl]-amine (III-144):
1H?NMR(500MHz，DMSO-d6)δ0.6-1.9(m，13H)，3.15(m，1H)，3.25(m，1H)，4.0(m，1H)，7.10(t，0.5H)，7.12(t，0.5H)，7.55(m，2H)，7.66(d，0.5H)，7.69(d，0.5H)，7.77(d，1H)，7.91(t，1H)，8.55(d，0.5H)，8.59(d，0.5H)，11.46(s，0.5H)，11.54(s，0.5H)，11.78(s，0.5H)，11.84(s，0.5H)，13.10(s，0.5H)，13.12(s，0.5H)；EI-MS?399.3(M+1)；HPLC-Method?A，R
t?3.37min.
Embodiment 373 (1H-indazole-3-yl)-[2-(2,6-dimethyl-morpholine-4-yl)-quinazoline-4-yl]-amine (III-145):
1H NMR (500MHz, DMSO-d6) δ 1.0 (m, 6H), 4.0 (m, 6H), 7.12 (t, 1H), 7.41 (td, 1H), 7.56 (t, 1H), 7.58 (d, 1H), 7.68 (dd, 1H), 7.77 (t, 1H), 7.93 (t, 1H), 8.60 (d, 1H), 11.69 (s, 1H), 13.16 (s, 1H); EI-MS 375.3 (M+1); HPLC-Method A, R
t2.93min.
Embodiment 374 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-pyrimidine-4-yl)-amine (IV-1):
mp?245-246℃；
1H?NMR(DMSO)δ2.26(3H，s)，6.32(1H，brs)，7.07(1H，brs)，7.48-7.54(3H，m)，8.33-8.39(3H，m)，9.87(1H，s)，12.03(1H，s)；IR (solid)1628，1589，1579，1522，1479，1441，1393，1336；MS?252.2(M+H)
+.
Embodiment 375[6-(4-acetylaminohydroxyphenylarsonic acid thiophenyl)-2-phenyl-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-3): with Fenclorim (4,6-two chloro-2-phenyl pyrimidines) (0.1g, 0.44mmol), 3-amino-5-methylpyrazole (0.045g, 0.47mmol), N, N-diisopropylethylamine (0.08ml, 0.47mmol) (0.067g, propyl carbinol 0.44mmol) (5ml) suspension heats 18h down at 117 ℃ with sodium iodide.Remove in a vacuum and desolvate, crude product is through purification by flash chromatography (silica gel, 3: 2 sherwood oils: EtOAc), obtain 0.037g (29%) (6-chloro-2-phenyl-pyrimidine-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine, be pale solid.(0.037g, 0.13mmol) (0.108g, trimethyl carbinol suspension 0.64mmol) heated 2 days under 85 ℃ of nitrogen with the amino thiophenol of thioacetyl with above-mentioned pyrimidine.Reaction mixture is cooled to room temperature, removes in a vacuum and desolvate.Enriched material is dissolved in EtOAc, uses NaHCO
3(saturated aqueous solution) washing.Concentrate organic layer in a vacuum, crude product is through the preparation HPLC purifying.Still the disulphide that remains in behind the HPLC in the mixture can and filter and be removed by precipitation from EtOAc.Concentrated mother liquor obtains IV-3 (7mg, 13%), is pale solid:
Mp 235-236 ℃;
1H NMR (DMSO) δ 2.10 (3H, s), 2.21 (3H, s), 6.33 (1H, brs), 7.50 (3H, m), 7.7-7.59 (2H, m), 7.76-7.78 (2H, m), 8.25 (2H, m), 9.72,10.26 and 11.93 (3H, 3x brs); IR (solid) 1669,1585,1551,1492,1392,1372,1312,1289,1259,1174,1102,1089,1027,1015,984; MS 417.3 (M+H)
+.
Embodiment 376[2-(4-methyl piperidine-1-yl)-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-4): mp 215-216 ℃;
1HNMR (CD
3OD) δ 0.96 (3H, d), 1.16 (2H, m), 1.66 (3H, m), 2.27 (3H, s), 2.86 (2H, t), 4.58 (2H, m), 4.78 (2H, exch.protons), 6.13 (2H, m), 7.83 (1H, d); IR (solid) 1593,1550,1489,1436,1331,1246,1231; MS 273.1 (M+H)
+.
Embodiment 377[2-(4-methyl piperidine-1-yl)-5-nitro-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-5): mp 185-187 ℃;
1H NMR (DMSO) δ 0.93 (3H, d), 1.06-1.18 (2H, m), 1.68-1.80 (3H, m), 2.26 (3H, s), 3.01-3.12 (2H, m), 4.63 (1H, d), 4.80 (1H, d), 6.39 (1H, s), 9.00 (1H, s), 10.41 (1H, s), 12.36 (1H, s); IR (solid) 1589,1517,1479,1446,1346,1317,1246,1222,1055; MS 318.2 (M+H)
+.
Embodiment 378[5-amino-2-(4-methyl piperidine-1-yl)-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-6): to IV-5 (48mg, 0.151mmol) ethanol (2.0ml) solution add tindichloride dihydrate (171mg, 0.756mmol), the gained mixture is heated 3h under refluxing.Reactant is cooled to room temperature, is poured on 1M NaOH: methylene dichloride: propanol mixture (18: 8: 4ml), stir 15min.Separate each layer, twice of dichloromethane extraction in waterbearing stratum.Merge organic layer, concentrate in a vacuum, resistates process purification by flash chromatography (silica gel, methylene dichloride: the MeOH gradient), obtain IV-6, be gray solid (27mg, 63%):
1H?NMR(DMSO)δ0.88-1.04(5H，m)，1.55-1.62(3H，m)，2.21(3H，s)，2.70(2H，m)，3.36(2H，m)，4.40(2H，m)，6.37(1H，s)，7.49(1H，s)，8.40(1H，s)，11.92(1H，br?s)；MS?288.2(M+H)
+.
Embodiment 379[5-amino-6-methyl-2-(4-methyl piperidine-1-yl)-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-7):
mp?172-175℃；
1H?NMR(DMSO)δ0.90(3H，d)，1.03(2H，m)，1.52-1.62(3H，m).2.13(3H，s)，2.20(3H，s)，2.69(2H，m)，3.92(2H，br?s)，4.44(2H，d)，6.35(1H，s)，8.41(1H，s)，11.85(1H，br?s)；IR(solid)1612，1589，1489，1446，1317；MS?302.5(M+H)
+.
Embodiment 380[6-methyl-2-(4-methyl-phenyl)-pyrimidine-4-yl]-(5-phenyl-2H-pyrazole-3-yl)-amine (IV-10): MS 342.34 (M+H); HPLC-method E, R
t1.334min.
Embodiment 381[2-(4-chloro-phenyl)-6-methyl-pyrimidine-4-yl]-(5-furans-2-base-2H-pyrazole-3-yl)-amine (IV-11): MS 352.11 (M+H); HPLC-method E, R
t1.194min.
Embodiment 382 (5-furans-2-base-2H-pyrazole-3-yl)-(6-methyl-2-phenyl-pyrimidine-4-yl)-amine (IV-12): MS 318.21 (M+H); HPLC-method E, R
t1.192min.
Embodiment 383[6-methyl-2-(4-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(5-phenyl-2-base-2H-pyrazole-3-yl)-amine (IV-13): MS 396.24 (M+H); HPLC-method E, R
t1.419min.
Embodiment 384 (5-furans-2-base-2H-pyrazole-3-yl)-[6-methyl-2-(4-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (IV-14): MS 386.08 (M+H); HPLC-method E R
t1.347min.
Embodiment 385[2-(2,3-dihydro-benzo [1,4] dioxin-2-yl)-6-methyl-pyrimidine-4-yl]-(5-furans-2-base-2H-pyrazole-3-yl)-amine (IV-15): MS 376.18 (M+H); HPLC-method E, R
t1.181min.
Embodiment 386[2-(2,3-dihydro-benzo [1,4] dioxin-2-yl)-6-ethyl-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-16): MS 338.17 (M+H); HPLC-method E, R
t1.082min.
Embodiment 387 (6-ethyl-2-phenyl-pyrimidine-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (IV-17): MS 280.18 (M+H); HPLC-method E, R
t1.024min.
Embodiment 388 (6-methyl-2-phenyl-pyrimidine-4-yl)-(5-phenyl-2H-pyrazole-3-yl)-amine (IV-19): MS 328.51 (M+H); HPLC-method E, R
t1.192min.
Embodiment 389[6-ethyl-2-(4-trifluoromethyl-phenyl)-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-20): MS 348.5 (M+H); HPLC-method E, R
t1.224min.
Embodiment 390 (5-furans-2-base-2H-pyrazole-3-yl)-[6-methyl-2-(4-methyl-phenyl)-pyrimidine-4-yl]-amine (IV-21): MS 332.23 (M+H); HPLC-method E, R
t1.139min.
Embodiment 391 (6-methoxymethyl-2-phenyl-pyrimidine-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (IV-22): MS 296.31 (M+H); HPLC-method E, R
t0.971min.
Embodiment 392 (5,6-dimethyl-2-phenyl-pyrimidine-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (IV-23): MS 280.2 (M+H); HPLC-method E, R
t0.927m in.
Embodiment 393 (6-methyl-2-phenyl-pyrimidine-4-yl)-(5-methyl-2H-pyrazole-3-yl)-amine (IV-24): MS 266.18 (M+H); HPLC-method E, R
t0.925min.
Embodiment 394[6-ethyl-2-(4-methyl-phenyl)-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-25): MS 294.46 (M+H); HPLC-method E, R
t1.174min.
Embodiment 395[2-(4-chloro-phenyl)-6-ethyl-pyrimidine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-26): MS 314.42 (M+H); HPLC-method E R
t1.213min.
Embodiment 396 (5-methyl isophthalic acid H-pyrazole-3-yl)-(6-methyl-2-p-methylphenyl-pyrimidine-4-yl)-amine (IV-27): MS 280.45 (M+H); HPLC-method E, R
t1.135min.
Embodiment 397 (1H-indazole-3-yl)-(6-methoxymethyl-2-phenyl-pyrimidine-4-yl)-amine (IV-28):
1H NMR (500MHz, DMSO) δ 3.57 (3H, s), 4.65 (2H, s), 7.23 (1H, J=7.5Hz, t), 7.52 (1H, J=7.6Hz, t), 7.63 (4H, m), 7.75 (1H, br), 8.13 (1H, J=5.5Hz, br d), 8.44 (1H, J=5.7Hz, br d), 10.6 (1H, br), 12.8 (1H, br s) ppm; HPLC-Method A, R
t2.944min; MSFIA) 332.1 (M+H)
+
Embodiment 398 (5-methyl-2H-pyrazole-3-yl)-(2-pyridin-4-yl-thieno-[3,2-d] pyrimidine-4-yl)-amine (IV-29):
1H NMR (DMSO) δ 2.34 (3H, s), 6.66 (1H, s), 7.53 (1H, d), 7.84 (1H, d), 8.32 (2H, d), 8.70 (2H, d); MS 309.6 (M+H)
+.
Embodiment 399 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-pyrido [3,4-d] pyrimidine-4-yl)-amine (IV-30):
mp?225℃；
1HNMR(DMSO)δ2.35(3H，s)，6.81(1H，s)，7.50-7.63(3H，m)，8.45-8.52(2H，m)，8.54(1H，d)，8.62(1H，d)，9.20(1H，s)，10.79(1H，s)，12.38(1H，br?s)；IR(solid)2958，2917，2852，1593，1565，1524，1467，1450；MS?303.2(M+H)
+.
Embodiment 400 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-pyrido [2,3-d] pyrimidine-4-yl)-amine (IV-31): to 4-chloro-2-phenyl-pyrido [2,3-d] pyrimidine (J.Pharm.Belg., 29,1974,145-148) (109mg, THF 0.45mmol) (15ml) solution add 3-amino-5-methylpyrazole (48mg, 0.5mmol), with the gained mixture 65 ℃ of following heated overnight.Mixture is cooled to room temperature, filters the gained suspension, use Et
2The O washing.Solid is dissolved in EtOH: water mixture, regulate pH to pH 7.The waterbearing stratum merges organic layer with ethyl acetate extraction twice, dry (MgSO
4), filter, concentrate in a vacuum.Resistates is through purification by flash chromatography (SiO
2, the DCM-MeOH gradient), obtain IV-31, be pale solid (69mg, 50%): 234 ℃ of mp;
1H NMR (DMSO) δ 2.14 (3H, s), 5.99 (1H, s), 7.20-7.40 (3H, m), 7.40-7.50 (3H, m), 8.60 (1H, d), 8.79 (1H, d), 12.82 (1H, br s); IR (solid) 2957,2921,2857,1644,1560,1459,1427; MS 303.2 (M+H)
+.
Embodiment 401 (5-cyclopropyl-2H-pyrazole-3-yl)-(2-phenyl-pyrido [3,4-d] pyrimidine-4-yl)-amine (IV-32): pale solid,
mp?232-233℃；
1H?NMR(DMSO)δ0.70-0.85(2H，m)，0.90-1.05(2H，m)，1.05-2.07(1H，m)，6.75(1H，s)，7.50-7.75(3H，m)，8.40-8.70(4H，m)，9.20(1H，s)，10.80(1H，s)，12.41(1H)；IR(solid)3178，1601，1573，1532，1484，1452，1409，1367，1328，802，781，667；MS?329.2(M+H)
+.
Embodiment 402[2-(4-methyl piperidine-1-yl)-purine-4-yl]-(5-methyl-2H-pyrazole-3-yl)-amine (IV-33): to 2,4-dichloropurine (2.0g, 10.6mmol) dehydrated alcohol (10ml) solution add 5-methyl isophthalic acid H-pyrazole-3-yl amine (2.05g, 21.2mmol).The gained mixture is at room temperature stirred 48h.Filter and collect the gained precipitation, use washing with alcohol, drying obtains 1.524g (58%) (2-chloro-purine-4-yl)-(5-methyl isophthalic acid H-pyrazole-3-yl) amine under vacuum, need not to be further purified promptly to can be used for next step.To (2-chloro-purine-4-yl)-(5-methyl isophthalic acid H-pyrazole-3-yl) amine (200mg, 0.80mmol) solution add the 4-methyl piperidine (4ml, 8.01mmol), with reaction mixture heated overnight under refluxing.Evaporating solvent is dissolved in EtOH with resistates: and water mixture (1: 3,4ml).(57mg 0.41mmol), at room temperature stirred mixture 2 hours to add salt of wormwood.Filter the gained suspension, wash (x2) with water, use Et
2O washes (x2), obtains IV-33, is white solid (225mg, 90%): mp＞300 ℃;
1H?NMR(DMSO)δ0.91(3H，d)，1.10(2H，m)，1.65(3H，m)，2.24(3H，s)，2.84(2H，m)，4.60(2H，m)，6.40(1H，s)，7.87(1H，m)，9.37-9.59(1H，m)，12.03-12.39(2H，m)；IR(solid)1651，1612，1574，1484，1446，1327，1317，1255，1203；MS?313.3(M+H)
+.
Embodiment 403 (5-cyclopropyl-2H-pyrazole-3-yl)-[2-(4-methyl piperidine-1-yl)-pyrrolo-[3,2-d] pyrimidine-4-yl]-amine (IV-34): white solid;
1H?NMR(DMSO)δ0.65(2H，m)，0.91-0.96(5H，m)，1.08(2H，m)，1.58-1.64(3H，m)，1.89(1H，m)，2.77(2H，t)，4.57(2H，d)，6.09(1H，s)，6.38(1H，s)，7.33(1H，s)，9.42(1H，s)，10.65(1H，s)，12.02(1H，br?s)；MS?338.3(M+H)
+
Embodiment 404[6-benzyl-2-phenyl-5,6,7,8-tetrahydropyridine be [4,3-d] pyrimidine-4-yl also]-(5-fluoro-1H-indazole-3-yl)-amine (IV-35):
1H?NMR(500MHz，DMSO-d6)δ13.0(s，1H)，10.4(s，br，1H)，9.73(s，1H，TFA-OH)，8.00(d，2H)，7.64(m，2H)，7.59(dd，1H)，7.52(m，3H)，7.41(t，1H)，7.31(m，3H)，7.14(dd，1H)，4.58(s，2H)，4.35(br，2H)，3.74(m，2H)，3.17(s，2H)ppm.MS(ES+)：m/e＝451.30M+H)；HPLC-Method?A，T
ret?2.96min.
Embodiment 405 (5-fluoro-1H-indazole-3-yl)-(2-phenyl-5,6,7,8-tetrahydrochysene-pyrido [4,3-d] pyrimidine-4-yl)-amine (IV-36): from IV-35 (0.13mmol) preparation, at room temperature, the Pd/C (10%) of weight such as in containing the MeOH of 4.4%HCOOH, use to handle 12h.By C salt filtering mixt, evaporated filtrate, crude product obtains IV-36 through the HPLC purifying, is yellow solid, yield 35%.
1H?NMR(500MHz，DMSO-d6)δ12.9(s，1H)，9.06(s，1H)，7.99(d，2H)，7.57(dd，1H)，7.34(m，1H)，7.28(m，3H)，7.22(d，1H)，3.83(s，2H)，3.05(m，2H)，2.72(m，2H)ppm.MS (ES+)：m/e＝361.20(M+H)；HPLC-Method?A，T
ret?2.68min.
Embodiment 406 (5-methyl-2H-pyrazole-3-yl)-(3-phenyl-isoquinolyl-1)-amine (V-1): to 1-chloro-3-phenyl isoquinolin quinoline (J.Het.Chem., 20,1983,121-128) (0.33g, 1.37mmol) DMF (anhydrous, 5ml) solution add the 3-amino-5-methylpyrazole (0.27g, 2.74mmol) and salt of wormwood (0.57g, 4.13mmol), the gained mixture is heated 6h under refluxing.With the reaction mixture cooling, remove in a vacuum and desolvate then.Resistates merges organic layer with ethyl acetate extraction twice, uses the salt water washing, dry (MgSO
4), filter, concentrate in a vacuum.Crude product is through purification by flash chromatography (SiO
2, the DCM-MeOH gradient), obtain V-1, be colourless oil;
1H NMR (MeOD) δ 2.23 (3H, s), 5.61 (1H, s), 7.41 (1H, m), 7.52 (2H, m), 7.62 (1H, m), 7.81 (1H, m), 8.07 (1H, d), 8.19 (2H, m), 8.29 (1H, s), 8.54 (1H, d); MS 301.2 (M+H)
+.
Embodiment 407 (1H-indazole-3-yl)-[3-(2-trifluoromethyl-phenyl)-isoquinolyl-1]-amine (V-2): with 1-chloro-3-(2-trifluoromethyl-phenyl)-isoquinoline 99.9 (100mg, 0.326mmol) and 1H-indazole-3-base amine (86mg, 0.651mmol) ethanol (3ml) solution 160 ℃ of down heating, with the nitrogen gas stream evaporating solvent.Then remaining oil is heated 18h under 160 ℃ of nitrogen.The gained melt is dissolved in 5% methyl alcohol: methylene dichloride (50ml), with saturated sodium bicarbonate aqueous solution washing (1 * 25ml), then through dried over mgso.Through silica gel chromatography purifying (25% to 50% hexane: ethyl acetate), obtain V-2, be yellow solid (35mg, 27%).
1H?NMR(500MHz，d
6-DMSO)δ9.78(br?s，1H)，8.62(d，1H)，7.9-7.85(m，1H)，7.78-7.72(m，1H)，7.70-7.68(m，1H)，7.65-7.62(m，1H)，7.60-7.55(m，1H)，7.52-7.45(m，3H)，7.41-7.38(m，1H)，7.28-7.25(m，1H)，7.18(s，1H)，6.95-6.92(m，1H)，5.76(s，1H)；LC-MS(ES+)m/e＝405.18(M+H)；HPLC-Method?D?R
t2.74min.
Embodiment 408 (5,7-two fluoro-1H-indazole-3-yls)-[3-(2-trifluoromethyl-phenyl)-isoquinolyl-1]-amine (V-3): from 5,7-two fluoro-1H-indazoles-3-base amine preparation obtain compound V-3, are yellow solid (90mg, 63%).
1H?NMR(500MHz，d
6-DMSO)δ13.25(s，1H)，9.92(br?s，1H)，8.61(d，1H)，7.9(d，1H)，7.81-7.49(m，6H)，7.26-7.2(m，2H)，7.12-7.10(m，1H)；LC-MS(ES+)m/e＝441.16(M+H)；HPLC-Method?D，R
t?3.58min.
Embodiment 409 (5-methyl-2H-pyrazole-3-yl)-(2-phenyl-quinolyl-4)-amine (V-4): to 4-chloro-2-phenylquinoline (J.Het.Chem., 20,1983,121-128) (0.53g, 2.21mmol) mixture in phenyl ether (5ml) adds 3-amino-5-methylpyrazole (0.43g, 4.42mmol), the gained mixture 200 ℃ of following heated overnight, is stirred simultaneously.Reaction mixture is cooled to envrionment temperature, adds sherwood oil (20ml) then, filtering separation gained precipitation.Thick solid is through purification by flash chromatography (SiO
2, the DCM-MeOH gradient), obtain V-4, be white solid: mp 242-244 ℃;
1H NMR (DMSO) δ 2.27 (3H, s), 6.02 (1H, s), 7.47 (2H, d), 7.53-7.40 (2H, br m), 7.67 (1H, m), 7.92 (1H, m), 8.09 (2H, d), 8.48 (2H, m), 9.20 (1H, s), 12.17 (1H, br s); IR (solid) 1584,1559,1554,1483,1447,1430,1389; MS 301.2 (M+H)
+.
Embodiment 410 (1H-indazole-3-yl)-(2-phenyl-quinolyl-4)-amine (V-5):
1H?NMR(500MHz，d
6-DMSO)δ12.78(s，1H)，9.50(s，1H)，8.65(d，1H)，8.15(s，1H)，8.04-7.98(m，3H)，7.94(s，1H)，7.78-7.75(m，1H)，7.60-7.40(m，6H)，7.15-7.10(m，1H).LC-MS?(ES+)m/e＝337.11(M+H)；HPLC-Method?D，R
t?2.10min.
Embodiment 411 (2-phenyl-quinolyl-4)-(1H-pyrazolo [4,3-b] pyridin-3-yl)-amine (V-6):
1H?NMR(500MHz，DMSO-d6)δ13.6(s，1H)，11.4(s，1H)，8.94(d，1H)，8.61(dd，1H)，8.23(d，1H)，8.16(dd，1H)，8.12(t，1H)，7.89(t，1H)，7.86(d，1H)，7.65(m，4H)，7.54(s，1H)，7.52(dd，1H)ppm.MS?(ES+)：m/e＝338.11(M+H)；HPLC-Method?A，HPLC-Method?D，R
t2.91min.
Embodiment 412 (1H-indazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinolyl-4]-amine (V-7):
1H?NMR(500MHz，d
6-DMSO)δ12.68(s，1H)，9.51(s，1H)，8.7(d，1H)，7.95-7.89(m，2H)，7.83-7.70(m，3H)，7.68-7.62(m，2H)，7.60(s，1H)，7.55-7.52(m，1H)，7.49-7.45(m，1H)，7.40-7.37(m，1H)，7.12-7.09(m，1H)；LC-MS (ES+)m/e＝405.15(M+H)；HPLC-Method?D?R
t?2.25min.
Embodiment 413 (5,7-two fluoro-1H-indazole-3-yls)-[2-(2-trifluoromethyl-phenyl)-quinolyl-4]-amine (V-8):
1H?NMR(500MHz，d
6-DMSO)δ13.31(s，1H)，9.49(s，1H)，8.70-8.67(m，1H)，7.96-7.92(m，1H)，7.85-7.66(m，7H)，7.63-7.60(m，1H)，7.42-7.40(m，1H).LC-MS(ES+)m/e＝441.18(M+H)；HPLC-Method?D?R
t2.39min.
Embodiment 414[2-(2-trifluoromethyl-phenyl)-quinolyl-4]-(1H-pyrazolo [4,3-b] pyridin-3-yl)-amine (V-9):
1H?NMR(500MHz，DMSO-d6)δ13.6(s，1H)，11.6(s，br，1H)，8.98(d，1H)，8.57(dd，1H)，8.12(m，3H)，7.97(m，2H)，7.86(m，3H)，7.49(dd，1H)，7.23(s，1H)ppm.MS(ES+)：m/e＝406.20(M+H)；HPLC-Method?A?R
t?2.91min.
Embodiment 415 (2-phenyl-quinazoline-4-yl)-(2H-[1,2,4] triazole-3-yl)-amine (IX-154): pale solid,
mp266-267℃；
1H?NMR(DMSO)δ7.50-7.70(4H，m)，7.85-8.00(2H，m)，8.15-8.25(2H，m)，8.37-8.45(2H，m)，8.58(1H，d)，13.90(1H，br?s)；IR(solid)3344，3059，1630，1609，1570，1557，1543，1501，1495，1445，1411，1355，1326，1267，1182，1053，1038，760，676，667，654；MS?289.2(M+H)
+.
Embodiment 416 (5-methyl-2H-[1,2,4] triazole-3-yl)-(2-phenyl-quinazoline-4-yl)-amine (IX-155):
1H NMR (500MHz, DMSO-d6) δ 8.59 (s, 1H), 8.42 (d, J=6.7Hz, 2H), 7.79 (m, 4H), 8.03 (m, 2H), 7.74 (m, 4H), 2.51 (s, 3H) ppm.MS (ES+): m/e=303.08 (M+H); HPLC-Method A, R
t2.64min.
Embodiment 417 (2H-[1,2,4] triazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (IX-47): faint yellow solid (yield 52%).
1H?NMR(500MHz，DMSO-d6)δ8.54(s，1H)，8.15(s，br，1H)，7.91(t，1H)，7.85(m，2H)，7.76(m，3H)，7.66(t，1H)ppm.MS (ES+)：m/e＝357.13(M+H)；(ES-)：m/e＝355.15(M-H)；HPLC-Method?A，R
t2.81min.
Embodiment 418 (5-methyl-2H-[1,2,4] triazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (IX-38): faint yellow solid (yield 54%).
1H?NMR(500MHz，DMSO-d6)δ8.44(s，br，1H)，7.92(m，3H)，7.84(m，1H)，7.77(m，2H)，7.68(t，1H)，2.28(s，3H)ppm.MS(ES+)：m/e＝371.14(M+H)；(ES-)：m/e＝369.18(M-H)；HPLC-Method?A，R
t2.89min.
Embodiment 419 (5-methylthio group-2H-[1,2,4] triazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinazoline-4-yl]-amine (IX-156): faint yellow solid (yield 65%).
1H?NMR(500MHz，DMSO-d6)δ8.56(br，1H)，7.90(t，1H)，7.84(m，2H)，7.78(m，2H)，7.67(m，2H)，2.51(s，3H，buried?by?DSO)ppm.MS(ES+)：m/e＝403.12(M+H)；(ES-)：m/e＝401.16(M-H)；HPLC-Method?A，R
t?3.20min.
Embodiment 420 (1H-[1,2,4] triazole-3-yl)-[3-(2-trifluoromethyl-phenyl)-isoquinolyl-1]-amine (IX-175): with 1-chloro-3-(2-trifluoromethyl-phenyl)-isoquinoline 99.9 (0.326mmol) and 1H-[1,2,4] ethanol (3ml) solution of triazole-3-base amine (0.651mmol) is 160 ℃ of heating down, with the nitrogen gas stream evaporating solvent.Then remaining oil is heated 18h under 160 ℃ of nitrogen.The gained melt is dissolved in 5% ethanol/methylene (50ml), with saturated sodium bicarbonate aqueous solution washing (1 * 25ml), then through dried over mgso.Through the silica gel chromatography purifying, obtain IX-175, be colourless oil (yield 4%).
1H?NMR(500MHz，CDCl
3)δ9.18(d，1H)，8.82(s，1H)，7.90(d，1H)，7.85-7.75(m，3H)，7.71-7.62(m，3H)，7.60-7.55(m，2H)，4.42-4.35(m，1H).LC-MS (ES+)356.16(M+H)HPLC-Method?D，R
t?3.55min.
Embodiment 421 (2-phenyl-quinolyl-4)-(1H-[1,2,4] triazole-3-yl)-amine (IX-176): faint yellow solid (yield 30%).
1HNMR(500MHz，d
6-DMSO)δ13.82(s，1H)，9.91(s，1H)，8.80(s，1H)，8.70-8.65(m，1H)，8.55(s，1H)，8.15-8.12(m，2H)，8.03-7.98(m，1H)，7.75-7.72(m，1H)，7.57-7.49(m，3H).LC-MS(ES+)m/e＝288.11(M+H)；HPLC-Method?D，R
t1.55min.
Embodiment 422 (1H-[1,2,4] triazole-3-yl)-[2-(2-trifluoromethyl-phenyl)-quinolyl-4]-amine (IX-177): faint yellow solid (yield 46%).
1H?NMR(500MHz，d
6-DMSO)δ13.70(s，1H)，9.98(s，1H)，8.70(d，1H)，8.49(s，1H)，8.30(s，1H)，7.94-7.88(m，2H)，7.80-7.68(m，3H)，7.64-7.56(m，2H).LC-MS?(ES+)m/e＝356.18(M+H)；HPLC-Method?D，R
t?1.68min.
Embodiment 423 (1H-indazole-3-yl)-[5-methyl-6-morpholine-4-base-2-(2-trifluoromethyl-phenyl)-pyrimidine-4-yl]-amine (II-251): colorless film; Yield 2%;
1H-NMR(500MHz，CD
3OD)δ7.84(m，2H)，7.71(m，3H)，7.41(t，2H)，7.14(m，1H)，3.74(m，4H)，3.69(m，4H)，1.24(s，3H)ppm；HPLC-Method?A?R
t?3.26min；MS(FIA)455.1(M+H).
Biological test
Can measure the activity of compound in external, body or in the clone as kinases inhibitor.The external test method comprises that mensuration is to the restraining effect of phosphorylation activity or the atpase activity of activated protein kinase.Can quantize inhibitor and protein kinase bonded ability for alternate external test method.The inhibitor keying action can be measured like this, and radio-labeling inhibitor before combination separates inhibitor/protein kinase title complex, measures the radiolabeled amount of institute's bonded again.Select as an alternative, the inhibitor keying action can be measured like this, and the experiment that is at war with is wherein cultivated with the inhibitor of novelty with known radioligand bonded protein kinase.
Biological test example 1
To the inhibiting K of GSK-3
iMeasure
Utilize standard conjugate enzyme system, according to suppressing the active ability SCREENED COMPOUND of GSK-3 β (AA 1-420) (Fox etc., (1998) Protein Sci.7,2249).Reaction is to contain 100mM HEPES (pH 7.5), 10mM MgCl
2, 25mM NaCl, 300 μ M NADH, 1mMDTT and 1.5%DMSO solution in carry out.Final concentration of substrate is that (Sigma Chemicals, St Louis is MO) with 300 μ M peptide (HSSPHQS (PO for 20 μ MATP in this assay method
3H
2) EDEEE, American Peptide, Sunnyvale, CA).Reaction is carried out under 30 ℃ and 20nMGSK-3 β.The ultimate density of each component of conjugate enzyme system is 2.5mM phosphoenolpyruvic acid, 300 μ M NADH, 30 μ g/ml pyruvate kinases and 10 μ g/ml serum lactic dehydrogenases.
Formation determination deposit buffered soln wherein contains above-named whole reagent and relevant test compound except that ATP.Cultivate 10min down at 30 ℃ with measuring deposit buffered soln (175 μ l) together with the relevant test compound of 5 μ l in 96 hole flat boards, the ultimate density of test compound does not wait from 0.002 μ M to 30 μ M.Usually, in daughter board, utilize the serial dilutions of DMSO (from 10mM compound storing solution) preparation test compound, carry out 12 titration.Add 20 μ lATP initiation reactions (ultimate density 20 μ M).(Sunnyvale CA) obtains 30 ℃ of speed of reaction results in following 10 minutes to utilize Molecular Devices Spectramax plate reader.
From speed data determination K
iValue is as the function of inhibitor concentration.
Following compounds shows that GSK-3 is had K less than 0.1 μ M
iValue: Compound I I-1, II-105, II-33, II-34, II-36, II-39, II-38, II-39, II-40, II-41, II-42, II-46, II-57, II-59, II-60, II-61, II-62, II-63, II-64, II-66, II-67, II-69, II-70, II-53, II-71, II-99, II-73, II-74, II-75, II-76, II-77, II-7, II-8, II-9, II-10, II-24, II-19, II-78, II-54, II-79, II-80, II-81, II-82, II-83, II-84, II-56, II-86, II-20, II-25, II-26, II-85, II-21, II-27, II-28, II-87, II-88, II-29, II-11, II-12, II-30, II-31, II-13, II-14, II-15, II-16, II-17, II-18, II-79, II-23, II-2, II-90, II-91, II-92, II-93, II-3, II-4, II-5, II-6, II-94, II-95, II-96, II-107, II-108, II-109, II-110, II-124, II-125, II-111, II-112, II-113, II-114, II-115, II-116, II-117, II-118, II-119, II-120, II-121, II-208, III-8, III-7, III-9, III-37, III-38, III-39, III-40, III-42, III-45, III-46, III-47, III-48, III-49, III-51, III-52, III-53, III-54, III-55, III-56, III-57, III-58, III-59, III-60, III-61, III-62, III-63, III-30, III-65, III-66, III-67, III-70, III-73, III-31, III-75, III-76, III-77, III-33, III-34, III-106, III-108, III-109, III-1, III-35, III-116, III-117, III-118, III-119, III-120, III-121, III-127, III-128, III-141, III130, III-131, IV-15, IV-16, IV-17, IV-20, IV-25, IV-26, IV-30, IV-34, V-3 and IX-47.
Following compounds shows that GSK-3 is had K between 0.1 and 1.0 μ M
iValue: Compound I I-103, II-104, II-35, II-44, II-45, II-49, II-50, II-97, II-101, II-22, II-32, III-41, III-43, III-44, III-28, III-50, III-29, III-64, III-71, III-74, III-78, III-82, III-88, III-90, III-102, III-105, III-107, III-110, III112, III-114, III-115, III-122, III-124, III-124, IV-1, III-1, III-138, III-140, III-142, III-129, III-132, III134, III-135, III-136, IV-1, IV-10, IV-11, IV-12, IV-13, IV-14, IV-19, IV-21, IV-22, IV-23, IV-24, IV-3, IV-4, IV6, IV-7, IV-8, IV-29, IV-31, IV-32, IV-33, IV-36, V-2, V7, IX-38, IX-154 and IX-177.
Following compounds shows that GSK-3 is had K between 1.0 and 20 μ M
iValue: Compound I I-43, II-65, II-48, II-47, II-51, II-68, II-52, II-72, II-100, II-98, II-89, III-68, III-81, III-83, III-91, III-94, III-95, III-96, III-97, III-98, III-99, III-100, III-101, III-103, III-123, III-137, III-139, III-143, III-145, III-146, V-4, V-8, IX-156 and IX-176.
Biological test example 2
To the inhibiting K of Aurora-2
iMeasure
Utilize the analysis of standard conjugate enzyme, according to the ability SCREENED COMPOUND (Fox etc., (1998) Protein Sci.7,2249) of following manner according to inhibition Aurora-2.
To containing 0.1M HEPES (pH 7.5), 10mM MgCl
2, 1mM DTT, 25mM NaCl, 2.5mM phosphoenolpyruvic acid, 300mM NADH, 30mg/ml pyruvate kinase, 10mg/ml serum lactic dehydrogenase, 40mM ATP and 800 μ M peptide (LRRASLG, American Peptide, Sunnyvale, CA) mensuration deposit buffered soln adds the DMSO solution of The compounds of this invention, to ultimate density be 30 μ M.The gained mixture is cultivated 10min down at 30 ℃.Add 10 μ lAurora-2 stock solution initiation reactions, the ultimate density that obtains in this assay method is 70nM.(Hercules, CA) absorbancy under the monitoring 340nm in 30 ℃ of following 5min obtains the speed of reaction result to utilize BioRad Ultramark plate reader.From speed data determination K
iValue is as the function of inhibitor concentration.
Following compounds shows that Aurora-2 is had K less than 0.1 μ M
iValue: Compound I I-33, III-34, II-36, II-37, II-40, II-41, II-55, III-7, III-9, III-37, III-38, III-39, III-40, III-41, III-42, III-44, III-45, III-46, III-47, III-48, III-49, III-50, III-51, III-52, III-53, III-54, III-55, III-56, III-57, III-59, III-60, III-61, III-63, III-30, III-65, III-66, III-67, III-70, III-31, III-76, III-77, III-78, III-80, III-32, III-33, III-34, III-106, III-108, III-109, III-110, III-111, III-112, III-114, III-35, III-115, III-116, III-117, III-118, III-119, III-120, III-121, IV-7, IV-30, IV-32 and IV-34.
Following compounds shows that Aurora-2 is had K between 0.1 and 1.0 μ M
iValue: Compound I I-1, II-105, II-35, II-38, II-39, II-42, II-64, II-70, II-53, II-99, II-77, II-79, II-86, II-20, II-93, II-94, III-28, III-58, III-64, III-71, III-73, III-74, III-75, III-102, III-105, III-107, III-113, III-124, III-1, III-130, IV-1, IV-3, IV-4, IV-6, IV-29, IV-33 and V-4.
Following compounds shows that Aurora-2 is had K between 1.0 and 20 μ M
iValue: Compound I I-103, II-104, II-57, II-59, II-61, II-63, II-67, II-69, II-75, II-76, II-10, II-19, II-78, II-54, II-80, II-82, II-21, II-90, II-91, II-96, II-107, III-68, III-79, III82, III-101, III-103, III-127, III-141, III-129, III-132, IV-31, V-2, IX-47, IX-154 and IX-177.
Biological test example 3
CDK-2 restraining effect assay method
Utilize the analysis of standard conjugate enzyme, according to the ability SCREENED COMPOUND (Fox etc., (1998) Protein Sci.7,2249) of following manner according to inhibition CDK-2.
To containing 0.1M HEPES (pH7.5), 10mM MgCl
2, 1mM DTT, 25mM NaCl, 2.5mM phosphoenolpyruvic acid, 300mM NADH, 30mg/ml pyruvate kinase, 10mg/ml serum lactic dehydrogenase, 100mM ATP and 100 μ M peptide (MAHHHRSPRKRAKKK, AmericanPeptide, Sunnyvale, CA) mensuration deposit buffered soln adds the DMSO solution of The compounds of this invention, to ultimate density be 30 μ M.The gained mixture is cultivated 10min down at 30 ℃.
Add 10 μ l CDK-2/ cyclin A stock solution initiation reactions, the ultimate density that obtains in this assay method is 25nM.(Hercules, CA) absorbancy under the monitoring 340nm in 30 ℃ of following 5min obtains the speed of reaction result to utilize BioRad Ultramark plate reader.From speed data determination K
iValue is as the function of inhibitor concentration.
Biological test example 4
ERK restraining effect assay method
Measure the ERK2 restraining effect (Fox etc., (1998) Protein Sci 7,2249) of compound by spectrophotometric conjugate enzyme assay method.In this assay method, containing 10mM MgCl
2, 2.5mM phosphoenolpyruvic acid, 200 μ M NADH, 150 μ g/ml pyruvate kinases, 50 μ g/ml serum lactic dehydrogenases and 200mM ERK peptide 0.1M HEPES damping fluid (pH7.5) in, the activation ERK2 (10nM) of fixed concentration is cultivated 10min with the solution of compound in 2.5%DMSO of various concentration down at 30 ℃.Add 65 μ M ATP initiation reactions.Absorbancy decrement under the monitoring 340nm.From speed data evaluation IC
50, as the function of inhibitor concentration.
Following compounds shows that ERK-2 is had＜the Ki value of 1 μ M: III-109, III-111, III-115, III-117, III-118, III-120 and IV-4.
Following compounds shows that ERK-2 is had Ki value between 1 μ M and the 12 μ M: III-63, III-40 and III-108.
Biological test example 5
AKT restraining effect assay method
Utilize standard conjugate enzyme assay method, according to the ability SCREENED COMPOUND (Fox etc., (1998) Protein Sci.7,2249) that suppresses AKT.Mensuration is at 100mM HEPES (pH 7.5), 10mM MgCl
2, 25mM NaCl, 1mM DTT and 1.5%DMSO mixture in carry out.In this assay method final concentration of substrate be 170 μ M ATP (Sigma Chemicals) and 200 μ M peptides (RPRAATF, American Peptide, Sunnyvale, CA).Mensuration is carried out under 30 ℃ and 45nM AKT.The ultimate density of each component of conjugate enzyme system is 2.5mM phosphoenolpyruvic acid, 300 μ M NADH, 30 μ g/ml pyruvate kinases and 10 μ g/ml serum lactic dehydrogenases.
Formation determination deposit buffered soln wherein contains except that above-named whole reagent and relevant test compound AKT and the DTT.56 μ l stock solutions are placed 384 hole flat boards, add the 2mM DMSO stock solution (final compound concentration is 30 μ M) that 1 μ l contains test compound then.Flat board at 30 ℃ of pre-down 10min that cultivate, is added 10 μ l enzymes (ultimate density is 45nM) and 1mM DTT initiation reaction.(Hercules CA) obtains the interior speed of reaction result of 30 ℃ of following 5min to utilize BioRad Ultramark plate reader.The standard orifice that will not contain test compound than containing mensuration mixture and DMSO shows that surpassing 50% inhibiting compound carries out titration, measures IC
50Value.
Biological test example 6
SRC restraining effect assay method
Utilization is based on radioactive assay method or the spectrophotometry evaluation compound as people Src kinase inhibitor.
Src restraining effect assay method A: based on radioactive assay method
Measure as total length recombinant human Src kinases (Upstate Biotechnology, cat.no.14-117) compound of inhibitor from baculovirus cell expressing and purifying.To composition Glu: Tyr=4: 1 (Sigma, the tyrosine of poly-Glu-Tyr polymeric substrates at random cat.no.P-0275) mixes from ATP's
33After the P, monitoring Src kinase activity.Be the ultimate density of measuring component below: 0.05M HEPES, pH7.6,10mM MgCl
2, 2mMDTT, 0.25mg/ml BSA, 10 μ M ATP (1-2 μ Ci
33P-ATP reacts at every turn), poly-Glu-Tyr of 5mg/ml and the recombinant human Src of 1-2 unit kinases.In typical assay method, total overall reaction component pre-mixing that will be except that ATP, five equilibrium is in the assay plate aperture.To the DMSO solution of aperture adding inhibitor, obtaining final DMSO concentration is 2.5%.Assay plate is cultivated 10min down at 30 ℃, use then
33The P-ATP initiation reaction.Behind the reaction 20min, contain 20mM Na with 150 μ l
3PO
410% trichoroacetic acid(TCA) (TCA) quencher reaction.Then with quencher sample be transferred in the 96 hole filter plates (Whatman, UNI-Filter GF/F Glass Fiber Filter, cat no.7700-3310), the latter is installed on the filter plate vacuum manifold.With filter plate with containing 20mM Na
3PO
410%TCA washing four times, use methanol wash again four times.Add 200 μ l flicker fluid to every hole then.With the flat board sealing, at the exit dose that quantizes on the TopCount scintillometer on the filter.Institute's bonded radioactivity is mapped to inhibitor concentration.Adjust data according to the competitive inhibition kinetic model, obtain the K of compound
i
Src restraining effect assay method B: spectrophotometry
People's kinase catalytic poly-Glu-Tyr substrate phosphorylation effect of Src of recombinating makes ATP generate ADP, utilizes the conjugate enzyme assay method to quantize the ADP (Fox etc., (1998) ProteinSci 7,2249) that is generated.In this assay method, about the per molecule ADP that kinase reaction generated, a part NADH is oxidized to NAD.The suitable disappearance of observing NADH under 340nm.
Be the ultimate density of measuring component below: 0.025M HEPES, pH7.6,10mM MgCl
2, 2mM DTT, poly-Glu-Tyr of 0.25mg/ml and 25nM recombinant human Src kinases.The ultimate density of each component of conjugate enzyme system is 2.5mM phosphoenolpyruvic acid, 200 μ M NADH, 30 μ g/ml pyruvate kinases and 10 μ g/ml serum lactic dehydrogenases.
In typical assay method, total overall reaction component pre-mixing that will be except that ATP, five equilibrium is in the assay plate aperture.To the DMSO solution of aperture adding inhibitor, obtaining final DMSO concentration is 2.5%.Assay plate is cultivated 10min down at 30 ℃, use 100 μ M ATP initiation reactions then.Monitoring on the molecular device plate reader under 340nm absorbancy over time, i.e. Fan Ying speed.According to the speed data of competitive inhibition kinetic model adjustment, obtain the K of compound as the inhibitor concentration function
i
Following compounds shows that SRC is had＜K of 100nM
iValue: III-31, III-32, III-33, III-34, III-35, III-47, III-65, III-66, III-37, III-38, III-39, III-40, III-42, III-44, III-48, III-49, III-70, III-45, III-78, III-76 and IV-32.
Following compounds shows that SRC is had K between 100nM and the 1 μ M
iValue: III-63, III-71, III-75, III-73, III-72, III-74, III-80, III-50 and IV-30.
Following compounds shows that SRC is had K between 1 μ M and the 6 μ M
iValue: III-79, IV-1 and IV-31.
Although we have enumerated a large amount of embodiments of the present invention hereinbefore, but obviously our essential structure can change, so that other embodiments that adopt The compounds of this invention and method to be provided.Therefore, what will be figured out is that scope of the present invention is subjected to claims but not the qualification of embodiment, and the latter only supplies illustration.
Claims (41)
1. formula II compound:
Or its pharmacy acceptable salt, wherein:
Ring C is selected from phenyl or pyridyl ring, and wherein said ring C has one or two and independently is selected from-R
1Ortho-substituent, ring C goes up arbitrarily commutable non-ortho position carbon independently and optionally by-R
5Replace, last two the adjacent substituting groups of ring C constitute condensed, unsaturated or part is undersaturated, have 0-1 heteroatomic 5-6 unit ring that is selected from oxygen, sulphur or nitrogen with intervenient atom alternatively;
R
1Be selected from-halogen ,-CN, OH-,-O (C
1-4Aliphatic group) ,-O (halo C
1-4Aliphatic group), C (=O) C
1-4Aliphatic group, phenyl or C
1-6Aliphatic group, described C
1-4Aliphatic group and C
1-6Aliphatic group is optionally replaced by halogen, perhaps R
1Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group;
R
xBe H or C
1-6Aliphatic group;
R
yBe C
1-6Aliphatic group or the phenyl that is optionally replaced, or 5-6 unit heterocyclic radical by halogen;
Perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 0-3 is selected from the ring hetero atom of oxygen, sulphur or nitrogen, wherein by R with intervenient atom
xAnd R
yAny commutable carbon selectivity ground is by C on the described fused rings that constitutes
1-6Aliphatic group or O (C
1-6Aliphatic group) replaces, by R
xAnd R
yAny commutable nitrogen selectivity ground is by CH on the described ring that constitutes
2-phenyl replaces;
R
2And R
2' be independently selected from C
1-6Aliphatic group, phenyl, thienyl, C (O) NH
2, C (O) NH (C
1-6Aliphatic group), C (O) N (C
1-6Aliphatic group)
2, or furyl; Perhaps R
2And R
2' with intervenient atom constitute condensed, 6 yuan, unsaturated or part is undersaturated, have the ring that 0-2 is selected from the ring hetero atom of nitrogen, wherein said ring is optionally by halogen, C
1-6Aliphatic group, halo C
1-6Aliphatic group, NO
2, pyrroles, CO
2(C
1-6Aliphatic group), NH
2, NH (C
1-4Aliphatic group) or N (C
1-4Aliphatic group)
2Replace; When the pyrazoles ring system of formula II is monocycle, R
2Can be CH
2OCH
3
Each R
5Be independently selected from-halogen ,-CN, C
1-6Aliphatic group, O (C
1-6Aliphatic group), halo C
1-6Aliphatic group ,-NO
2, NH
2, NH (C
1-6Aliphatic group) or N (C
1-6Aliphatic group)
2, perhaps R
5Constitute and the described ring of ring C condensed with intervenient atom with adjacent substituting group.
2. according to the compound of claim 1, wherein encircling C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring.
3. according to the compound of claim 1, R wherein
xBe hydrogen or C
1-4Aliphatic group, perhaps R
xAnd R
yConstitute optionally substituted, as to have 0-3 ring the nitrogen unsaturated or undersaturated ring of part of 5-7 unit with intervenient atom.
4. according to the compound of claim 1, R wherein
1The C that is-halogen, is optionally replaced by halogen
1-6Aliphatic group, phenyl ,-O (C
1-4Aliphatic group) ,-O (halo C
1-4Aliphatic group), C (=O) C
1-4Aliphatic group or-CN.
5. according to the compound of claim 1, R wherein
2' be hydrogen, R
2Be hydrogen, C
1-6Aliphatic group, phenyl, thienyl, C (O) NH
2, or furyl, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
6. according to the compound of claim 1, wherein:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from naphthyl, quinolyl or isoquinoline 99.9 basic ring;
(b) R
xBe hydrogen or C
1-4Aliphatic group, perhaps R
xAnd R
yConstitute optionally substituted, as to have 0-3 ring the nitrogen unsaturated or undersaturated ring of part of 5-7 unit with intervenient atom;
(c) R
1The C that is-halogen, is optionally replaced by halogen
1-6Aliphatic group, phenyl ,-O (C
1-4Aliphatic group) ,-O (halo C
1-4Aliphatic group), C (=O) C
1-4Aliphatic group or-CN; And
(d) R
2' be hydrogen, R
2Be hydrogen, C
1-6Aliphatic group, phenyl, thienyl, C (O) NH
2, or furyl, perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom.
7. according to the compound of claim 1, wherein encircling C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from optionally substituted naphthyl ring.
8. according to the compound of claim 1, R wherein
xBe hydrogen or methyl, R
yBe C
1-6Aliphatic group, the phenyl or the pyridyl that are optionally replaced, perhaps R by halogen
xAnd R
yConstitute 5-7 unit unsaturated or undersaturated carbocyclic ring of part and ring with intervenient atom, optionally by C
1-6Aliphatic group or O (C
1-6Aliphatic group) replaces.
9. according to the compound of claim 1, R wherein
1Be-halogen, C
1-6Halogenated aliphatic group, the C that is optionally replaced by halogen
1-6Aliphatic group, phenyl or-CN.
10. according to the compound of claim 1, each R wherein
5Be independently selected from-halogen ,-CN ,-NO
2,-NH
2, C
1-6Aliphatic group, halo C
1-6Aliphatic group ,-OC
1-6Aliphatic group.
11. according to the compound of claim 1, wherein:
(a) ring C is phenyl or pyridyl ring, optionally by-R
5Replace, when wherein two adjacent substituting groups formation bicyclic rings were as ring C with on it, this bicyclic ring system was selected from optionally substituted naphthyl ring;
(b) R
xBe hydrogen or methyl, R
yBe C
1-6Aliphatic group, the phenyl or the pyridyl that are optionally replaced, perhaps R by halogen
xAnd R
yConstitute 5-7 unit unsaturated or undersaturated carbocyclic ring of part and ring with intervenient atom, optionally by C
1-6Aliphatic group or O (C
1-6Aliphatic group) replaces;
(c) R
1Be-halogen, C
1-6Halogenated aliphatic group, the C that is optionally replaced by halogen
1-6Aliphatic group, phenyl or-CN;
(d) R
2' be hydrogen, R
2Be hydrogen, C
1-6Aliphatic group, phenyl, thienyl, C (O) NH
2, or furyl; Perhaps R
2And R
2' constitute replacement or undersaturated 6-unit's carbocyclic ring of unsubstituted benzo, pyrido, Mi Dingbing or part and ring with intervenient atom;
(e) each R
5Be independently selected from-halogen ,-NO
2, C
1-6Aliphatic group or O (C
1-6Aliphatic group).
12. according to the compound of claim 1, wherein R
xBe hydrogen or methyl, R
yBe methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl or the optionally substituted 2-of being selected from pyridyl, 4-pyridyl or phenyl groups, perhaps R
xAnd R
yConstitute optionally substituted undersaturated or undersaturated 6-unit's carbocyclic ring of part and ring with intervenient atom, described substituting group is C
1-6Aliphatic group or O (C
1-6Aliphatic group).
13. according to the compound of claim 1, wherein R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN.
14. according to the compound of claim 1, wherein R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-NH
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2Replace, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl.
15. according to the compound of claim 1, each R wherein
5Be independently selected from-Cl ,-F ,-CF
3,-NH
2,-O (C
1-4Aliphatic group) or C
1-4Aliphatic group.
16. according to the compound of claim 1, wherein:
(a) R
xBe hydrogen or methyl, R
yBe methyl, ethyl, cyclopropyl, sec.-propyl, the tertiary butyl or optionally substituted following groups, be selected from 2-pyridyl, 4-pyridyl or phenyl, perhaps R
xAnd R
yConstitute optionally substituted benzo ring or undersaturated carbocyclic ring of part and ring with intervenient atom, described substituting group is C
1-6Aliphatic group or O (C
1-6Aliphatic group);
(b) R
1Be-halogen, the optional C that is replaced by halogen
1-4Aliphatic group or-CN;
(c) R
2And R
2' constitute the undersaturated 6-of benzo, pyrido, Mi Dingbing or part unit's carbocyclic ring and ring with intervenient atom, optionally by-halogen ,-NH
2,-C
1-4Alkyl ,-C
1-4Haloalkyl ,-NO
2Replace, wherein (C
1-4Alkyl) is straight chain, side chain or cyclic alkyl;
(d) each R
5Be independently selected from-Cl ,-F ,-CF
3,-NH
2,-O (C
1-4Aliphatic group) or C
1-4Aliphatic group.
17. according to the compound of claim 16, wherein R
xAnd R
yEach is methyl, perhaps R naturally
xAnd R
yConstitute the optionally substituted ring that is selected from quinazoline or tetrahydro quinazoline with pyrimidine ring, and R
2And R
2' constitute optionally substituted indazole ring with the pyrazoles ring.
18. compound that is selected from down group:
19. a composition, it comprises each compound and the pharmaceutically acceptable carrier according to claim 1-18.
20. according to the composition of claim 19, itself and second kind of therapeutical agent are linked together.
21. be used for suppressing the purposes of patient's GSK-3 or the active medicine of Aurora in preparation according to each compound of claim 1-18.
22. according to the purposes of claim 21, wherein said medicine suppresses patient's GSK-3 activity.
23. be used for suppressing the GSK-3 of biological specimen or the purposes in the active reagent of Aurora in preparation according to each compound of claim 1-18.
24. be used for the treatment of purposes in the medicine of the disease that is alleviated by the GSK-3 inhibitor for treating in preparation according to each compound of claim 1-18.
25. according to the purposes of claim 24, wherein said medicine and second kind of therapeutical agent are linked together.
26. according to the purposes of claim 24, wherein said disease is diabetes.
27. according to the purposes of claim 24, wherein said disease is an Alzheimer.
28. according to the purposes of claim 24, wherein said disease is a schizophrenia.
29. be used for strengthening the purposes of patient's glycogen synthetic medicine in preparation according to each compound of claim 1-18.
30. be used for reducing the purposes of medicine of patient's glucose blood levels in preparation according to each compound of claim 1-18.
31. be used for suppressing the purposes of the medicine that patient's excessive phosphorylation tau protein produces in preparation according to each compound of claim 1-18.
32. be used for suppressing the purposes of patient's beta-catenin white phosphorus acidifying medicine in preparation according to each compound of claim 1-18.
33. be used for the treatment of purposes in the medicine of the disease that is alleviated by the Aurora inhibitor for treating in preparation according to each compound of claim 1-18.
34. according to the purposes of claim 33, wherein said medicine and second kind of therapeutical agent are linked together.
35. according to the purposes of claim 33, wherein said disease is a cancer.
36. formula A compound:
R wherein
10Be selected from
37. formula C compound:
Wherein:
R
2And R
2' be independently selected from C
1-6Aliphatic group, phenyl, thienyl, C (O) NH
2, or furyl, perhaps R
2And R
2' with intervenient atom constitute condensed, 6 yuan, unsaturated or part is undersaturated, have the ring that 0-2 is selected from the ring hetero atom of nitrogen, wherein said ring is optionally by halogen, C
1-6Aliphatic group, halo C
1-6Aliphatic group, NO
2, pyrroles or NH
2Replace;
R
xBe H or C
1-6Aliphatic group;
R
yBe C
1-6Aliphatic group, the optionally phenyl that is replaced by halogen, or 5-6 unit heterocyclic radical; Perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 0-1 is selected from the ring hetero atom of oxygen, sulphur or nitrogen, wherein by R with intervenient atom
xAnd R
yAny commutable carbon is optionally and independently by C on the described fused rings that constitutes
1-6Aliphatic group or O (C
1-6Aliphatic group) replaces, by R
xAnd R
yAny commutable nitrogen is by CH on the described ring that constitutes
2-phenyl replaces.
38. according to the compound of claim 37, wherein R
xAnd R
yEach is methyl, perhaps R naturally
xAnd R
yConstitute quinazoline or tetrahydro quinazoline ring with pyrimidine ring.
39. according to the compound of claim 38, wherein R
2And R
2' constitute the indazole ring with the pyrazoles ring.
40. formula D compound:
Wherein:
R
xBe H or C
1-6Aliphatic group;
R
yBe C
1-6Aliphatic group or the phenyl that is optionally replaced, or 5-6 unit heterocyclic radical by halogen; Perhaps R
xAnd R
yConstitute condensed, unsaturated or part is undersaturated, have the 5-8 unit ring that 0-1 is selected from the ring hetero atom of oxygen, sulphur or nitrogen, wherein by R with intervenient atom
xAnd R
yAny commutable carbon is optionally and independently by C on the described fused rings that constitutes
1-6Aliphatic group or O (C
1-6Aliphatic group) replaces, by R
xAnd R
yAny commutable nitrogen is by CH on the described ring that constitutes
2-phenyl replaces;
Each R
5Be independently selected from halogen, C
1-6Aliphatic group, O (C
1-6Aliphatic group), halo C
1-6Aliphatic group ,-NO
2, NH
2
41. according to the compound of claim 40, wherein R
xAnd R
yEach is methyl, perhaps R naturally
xAnd R
yConstitute quinazoline or tetrahydro quinazoline ring with pyrimidine ring.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23279500P | 2000-09-15 | 2000-09-15 | |
| US60/232,795 | 2000-09-15 | ||
| US25788700P | 2000-12-21 | 2000-12-21 | |
| US60/257,887 | 2000-12-21 | ||
| US28694901P | 2001-04-27 | 2001-04-27 | |
| US60/286,949 | 2001-04-27 | ||
| PCT/US2001/028940 WO2002022607A1 (en) | 2000-09-15 | 2001-09-14 | Pyrazole compounds useful as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1926132A CN1926132A (en) | 2007-03-07 |
| CN1926132B true CN1926132B (en) | 2010-12-29 |
Family
ID=32849357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN018174345A Expired - Fee Related CN1926132B (en) | 2000-09-15 | 2001-09-14 | Pyrazole compounds useful as protein kinase inhibitors |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1926132B (en) |
| EC (1) | ECSP034516A (en) |
| ZA (8) | ZA200301701B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| US4051252A (en) * | 1974-12-13 | 1977-09-27 | Bayer Aktiengesellschaft | 3-aminoindazole-1 and 2-carboxylic acid derivatives |
| US4493726A (en) * | 1980-12-23 | 1985-01-15 | Ciba Geigy Corporation | Phenylpyrimidines as antidotes for protecting cultivated plants against phytotoxic damage caused by herbicides |
| WO1993022681A1 (en) * | 1992-04-30 | 1993-11-11 | Neurogen Corporation | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES |
| US5972946A (en) * | 1995-04-13 | 1999-10-26 | Dainippon Pharmaceutical Co., Ltd. | Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same |
| WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| CN1429222A (en) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | Kinase inhibitors |
-
2001
- 2001-09-14 ZA ZA200301701A patent/ZA200301701B/en unknown
- 2001-09-14 CN CN018174345A patent/CN1926132B/en not_active Expired - Fee Related
- 2001-09-14 ZA ZA200301703A patent/ZA200301703B/en unknown
-
2003
- 2003-02-28 ZA ZA200301699A patent/ZA200301699B/en unknown
- 2003-02-28 ZA ZA200301702A patent/ZA200301702B/en unknown
- 2003-02-28 ZA ZA200301697A patent/ZA200301697B/en unknown
- 2003-02-28 ZA ZA200301698A patent/ZA200301698B/en unknown
- 2003-02-28 ZA ZA200301704A patent/ZA200301704B/en unknown
- 2003-02-28 ZA ZA200301700A patent/ZA200301700B/en unknown
- 2003-03-14 EC ECSP034516 patent/ECSP034516A/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| US4051252A (en) * | 1974-12-13 | 1977-09-27 | Bayer Aktiengesellschaft | 3-aminoindazole-1 and 2-carboxylic acid derivatives |
| US4493726A (en) * | 1980-12-23 | 1985-01-15 | Ciba Geigy Corporation | Phenylpyrimidines as antidotes for protecting cultivated plants against phytotoxic damage caused by herbicides |
| WO1993022681A1 (en) * | 1992-04-30 | 1993-11-11 | Neurogen Corporation | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES |
| US5972946A (en) * | 1995-04-13 | 1999-10-26 | Dainippon Pharmaceutical Co., Ltd. | Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same |
| WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| CN1429222A (en) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | Kinase inhibitors |
Non-Patent Citations (7)
| Title |
|---|
| Baig, Ghouse Unissa et al.Triazines and Related Products. Part 27.1 Thermolysisof4-Anilino-1,2,3-benzotriazines.J.Chem,Soc., Perkin Trans 1.1984,999-1003. * |
| E.W.Parnell.2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroindazole.Journal of The Chemical Society.1959,2363-2365. * |
| JP特开2000-26421A 2000.01.25 |
| M.W.Partridge et al.Cyclic Amidines. Part XXII.1 Novel Isomerism ofDisubstitutedTricycloquinazolines and Molecular OrientationsinCarcinogenesis.Journal of The Chemical Society C 19.1970,(19),2641-2647. |
| M.W.Partridge et al.Cyclic Amidines. Part XXII.1 Novel Isomerism ofDisubstitutedTricycloquinazolines and Molecular OrientationsinCarcinogenesis.Journal of The Chemical Society C 19.1970,(19),2641-2647. * |
| Medwid Jeffrey B et al.Preparation of Triazolo[1,5-c]pyrimidines asPotentialAntiasthma Agents.J Med Chem33 4.1990,33(4),1230-1241. * |
| MedwidJeffreyBetal.PreparationofTriazolo[1 5-c]pyrimidines asPotentialAntiasthma Agents.J Med Chem33 4.1990 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200301702B (en) | 2004-03-01 |
| ZA200301698B (en) | 2004-03-02 |
| ECSP034516A (en) | 2003-04-25 |
| ZA200301699B (en) | 2004-03-01 |
| ZA200301701B (en) | 2004-03-01 |
| ZA200301703B (en) | 2004-03-02 |
| ZA200301700B (en) | 2004-03-01 |
| CN1926132A (en) | 2007-03-07 |
| ZA200301697B (en) | 2004-03-01 |
| ZA200301704B (en) | 2004-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100355750C (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| US6660731B2 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| US6610677B2 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| US6613776B2 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| US7473691B2 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| RU2340611C2 (en) | Pyrazole derivatives applied as protein kinase inhibitors | |
| CN1926132B (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| EP1698627A1 (en) | Pyrazole compounds useful as protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101229 Termination date: 20130914 |